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5The Medical Card Scheme (GMS) and Community Drug 
Schemes are at the centre of the Primary Care Infrastructure 
of the Irish Health System. The net cost of the Schemes has 
more than doubled in just seven years, from €1.024 billion 
in 2001 to more than €2.289 billion in 2007. The volume of 
claims processed has also increased commensurately. This 
expenditure represents 20% of total current public health 
budget, a very significant element of total health spending. 
The Primary Care Reimbursement Service (PCRS), which 
is part of the Health Service Executive (HSE) Finance 
Directorate, has a national operational role in relation to 
making payments to Primary Care Contractors for services 
provided by them under the Community Drug Schemes. 
The objectives of the PCRS are to deliver an efficient 
shared reimbursement service and support the delivery 
of enhanced accountability and value for money against a 
standardised Financial Management Framework.
The core business of PCRS, as a National Shared Service, 
is the processing and payment of claims, verification of 
the accuracy and reasonableness of these claims and the 
publication of statistical information in relation to all claims 
paid. This service is delivered nationally to key external 
customers including General Practitioners, Pharmacists, 
Dentists and Optometrists/ Ophthalmologists for services 
they provide to members of the public in their own 
community and to internal customers within the HSE 
and the health arena. 
Every year almost everybody in Ireland uses one or 
more of the services provided by the HSE. In 2007 over 
2.42 million persons used the services of Primary Care 
Contractors for which reimbursement was provided by 
the PCRS. In 2007 the PCRS processed in excess of 65 
million transactions with associated expenditure of more 
than €2.289 billion. 
In addition to the processing of claims and making of 
payments on a national basis to key customers, the PCRS 
captures large volumes of data from which it compiles 
statistics and trend analyses which are provided to other 
areas within the HSE, the Government, customers, 
stakeholders and to members of the public. This Statistical 
Analysis Publication reflects the many and varied Schemes 
and Payment Systems currently in operation. 
During the year the PCRS continued to play an important 
role in supporting the management of the various schemes, 
which are becoming increasingly complex, and assisted in 
rolling out new initiatives to support both the modernisation 
and the transformation agendas of the HSE.
I would like to take this opportunity to thank everybody in 
the organisation for their important individual contribution 
and commitment, and their team efforts in the delivery 
of these vital support services, which ultimately enable 
members of the public to access the health services that 
they need in their own community. I would also like to 
acknowledge the contribution of my fellow Directors and 
the support of the HSE Board throughout 2007. Once 
again the goodwill and co-operation received from all of 
our customers including General Practitioners, Pharmacists, 
Dentists and Optometrists/Ophthalmologists is very much 
appreciated.
I look forward to continuing to build on our success and 
striving to improve the services to our customers even 
further.
Liam Woods 
National Director of Finance
Introduction from the National Director of Finance
6Almost all payments for services provided in the community 
by General Practitioners, Community Pharmacies, 
Dentists and Optometrists/Ophthalmologists are made 
by the Primary Care Reimbursement Service. Payments 
in the Year 2007 were in excess of €2.289bn. Estimated 
payments by the Primary Care Reimbursement Service 
for 2008 are €2.66bn.
Claim data is processed and payments are made by the 
Primary Care Reimbursement Service under the following 
Schemes/Payment Arrangements:
General Medical Services (GMS)
Persons who are unable without undue hardship to arrange 
general practitioner medical and surgical services for 
themselves and their dependants and all persons aged 70 
years and over receive a free general medical service.
Drugs, medicines and appliances supplied under the 
Scheme are provided through Community Pharmacies. 
In most cases the Doctor gives a completed prescription 
form to a person, who takes it to any pharmacy that has an 
agreement with the Health Service Executive to dispense 
GMS prescription forms. In rural areas the Doctor may 
dispense for those persons who opt to have their medicines 
dispensed by him/her. All GMS claims are processed and 
paid by the Primary Care Reimbursement Service. 
Drugs Payment Scheme (DPS)
Under the Drugs Payment Scheme persons who are 
ordinarily resident in the State and who do not have a 
current medical card can benefit – an individual or family 
has now to pay no more than €85 in a calendar month for 
approved drugs, medicines and appliances for themselves 
or their families. In order to benefit under this Scheme a 
person must register themselves and their dependants with 
their Local Health Office. Items currently reimbursable 
under the Drugs Payment Scheme are those listed on 
the HSE Website. Other items which were reimbursable 
under the DCS and Refund of Drugs Schemes continue, in 
certain circumstances, to be reimbursable under the Drugs 
Payment Scheme. DPS claims are processed and paid by 
the Primary Care Reimbursement Service. 
Long Term Illness Scheme (LTI)
On approval by the Health Service Executive persons 
who suffer from one or more of a schedule of illnesses are 
entitled to obtain, without charge, irrespective of income, 
necessary drugs/medicines and/or appliances under the 
LTI Scheme. All LTI claims are processed and paid by the 
Primary Care Reimbursement Service.
Dental Treatment Services Scheme (DTSS)
Under the Dental Treatment Services Scheme GMS 
eligible adults have access to a range of treatments and 
clinical procedures comprised of Routine Treatments and 
Full Upper and Lower Dentures. Routine Treatments are 
now available for all eligible persons. Dentists may also 
prescribe a range of medicines to eligible persons. All claims 
under the DTSS are processed and paid by the Primary 
Care Reimbursement Service. 
European Economic Area (EEA)
Residents from one of the other states of the European 
Economic Area, with established eligibility, who require 
emergency general practitioner services while on a temporary 
visit to the State are entitled to receive from a General 
Practitioner a GMS prescription form for necessary 
medication and to have such medication dispensed in a 
Pharmacy that has entered into an agreement with the 
Health Service Executive within the State. Students, posted 
workers and their dependants are entitled to full services 
on presentation of a valid Form E128. EEA claims are paid 
by the Primary Care Reimbursement Service. 
Community Based Services – Payment Arrangements
7High Tech Drugs (HTD)
Arrangements are in place for the supply and dispensing 
of High Tech medicines through Community Pharmacies. 
Such medicines are generally only prescribed or initiated 
in hospital and would include items such as anti-rejection 
drugs for transplant patients or medicines used in 
conjunction with chemotherapy or growth hormones. The 
medicines are purchased by the Health Service Executive 
and supplied through Community Pharmacies for which 
Pharmacists are paid a patient care fee: the cost of the 
medicines and patient care fees are paid by the Primary 
Care Reimbursement Service.
Primary Childhood Immunisation Scheme
A National Primary Childhood Immunisation Scheme 
provides for immunisation of the total child population with 
the aim of eliminating, as far as possible, such conditions 
as Diphtheria, Polio, Measles, Mumps, Rubella and more 
recently Meningococcal C Meningitis. Payments under 
this Scheme to Doctors in the Midland, Mid-Western, 
Southern and Western HSE Areas are made by the Primary 
Care Reimbursement Service.
Health (Amendment) Act 1996
Under the Health (Amendment) Act 1996 certain health 
services are made available without charge to persons 
who have contracted Hepatitis C directly or indirectly 
from the use of Human Immunoglobulin – Anti D or the 
receipt within the State of another blood product or blood 
transfusion. General Practitioner services, pharmaceutical 
services, dental services and optometric/ophthalmic services 
provided under the Act are paid for by the Primary Care 
Reimbursement Service.
Methadone Treatment Scheme
Methadone is prescribed and dispensed by Doctors and 
Pharmacists for approved clients under the Methadone 
Treatment Scheme – capitation fees payable to participating 
Doctors and Community Pharmacists and claims by 
pharmacies for the ingredient cost of the Methadone 
dispensed and the associated dispensing fees are processed 
and paid by the Primary Care Reimbursement Service.
Health Services Executive Community 
Ophthalmic Services Scheme (HSE-COS)
Under the Health Service Executive Community 
Ophthalmic Services Scheme, adult medical card holders 
and their dependants are entitled, free of charge, to eye 
examinations and necessary spectacles/appliances. Claims 
by Optometrists/Ophthalmologists are paid by the Primary 
Care Reimbursement Service. Claims for spectacles provided 
under the Children’s Scheme are also paid by the Primary 
Care Reimbursement Service.
Immunisations for certain GMS Eligible Persons
Agreement was reached between the Department of Health 
& Children and the Irish Medical Organisation on fee 
rates to be applied to certain immunisations for GMS 
eligible persons. The immunisations encompassed by the 
agreement are:- Pneumococcal, Influenza, Hepatitis B 
and the combined Pneumococcal/Influenza. The Health 
Service Executive facilitated claiming for any of these 
immunisations by extending the range of codes for ‘Special 
Items of Service’.
General Practitioner Visit Card (GPVC)
Certain people in Ireland who do not qualify for a medical 
card may apply to the Health Service Executive for a GP 
Visit Card. GP Visit Cards allow individuals and families 
who qualify, to visit their General Practitioner for free. All 
GP claims are processed and paid by the Primary Care 
Reimbursement Service.
8Summary Statement of Activity During the Year
l Payments in the Year were in excess of €2,289.59m.
l Claim data is processed and payments are made by 
the PCRS under the following Schemes:
n General Medical Services (GMS);
n Drugs Payment (DP); 
n Long Term Illness (LTI);
n Dental Treatment Services (DTS);
n European Economic Area (EEA);
n High Tech Drugs (HTD);
n Primary Childhood Immunisation;
n Health (Amendment) Act 1996;
n Methadone Treatment;
n Health Service Executive Community 
Ophthalmic Services (HSE-COS).
l At year end there were more than 3.05m persons 
registered as being eligible to benefit under the General 
Medical Services, Drugs Payment, Long Term Illness, 
Dental Treatment and Health Service Executive 
Community Ophthalmic Services Schemes.
l More than 96% of eligible GMS persons availed of 
GP, Pharmaceutical, Dental or Ophthalmic services 
provided by more than 5,701 Doctors, Pharmacists, 
Dentists and Optometrists/Ophthalmologists.
l More than 60m prescription items were paid for by 
the PCRS – an increase of over 5.6m items on 2006.
l Fees and allowances paid to Doctors totalled 
€440.76m.
l Payments to Pharmacies totalled €1,508.47m:
n GMS €1,048.41m;
n DP €310.11m;
n LTI €124.46m;
n EEA €2.33m;
n Patient Care Fees under the HTD Scheme 
€11.66m;
n The Health (Amendment) Act 1996, 
Methadone Treatment Scheme, DTS 
prescriptions and Pharmacy Training Grants 
€11.50m.
l Payments to Dentists under the DTS totalled 
€58.19m.
l Payments to Optometrists/Ophthalmologists under 
the HSE-COS totalled €21.60m.
l Payments to Wholesalers under the HTD Scheme 
totalled €238.51m.
l Administration costs in the accounting period of 2007 
were €16.30m.
l Claims processed are in respect of services provided 
in the community and availed of by almost 57.07% 
of the population.
9l Fees to Doctors include an amount of €6.19m in respect 
of the Primary Childhood Immunisation Scheme, 
€0.23m in respect of the Health (Amendment) Act 
1996, €5.4m in respect of the Methadone Treatment 
Scheme.
l Allowances paid to Doctors include an amount of 
€5.93m paid as superannuation to Retired District 
Medical Officers and their dependants.
l Payments to Pharmacists include an amount of €1.74m 
in respect of drugs/medicines dispensed under the 
Health (Amendment) Act 1996, an amount of €8.74m 
in respect of the cost of Methadone dispensed under 
the Methadone Treatment Scheme and an amount of 
€0.60m in respect of DTS prescriptions.
l Payments to Dentists include an amount of €45,831 in 
respect of treatments under the Health (Amendment) 
Act 1996.
l Payments to Optometrists/Opthalmologists include 
an amount of €61,776 in respect of treatments under 
the Health (Amendment) Act 1996.
l The corresponding figures for 2006 are – 
n Total of Payments €2,075.16m.
n Doctors’ Fees €282.25m and Doctors’ 
Allowances €122.47m.
n Pharmacists’ Fees and Mark-Up €321.74m, 
Drugs and Medicines €1,032.92m.
n Payments to Dentists under the DTS Scheme 
were €55.50m.
n Payments to Optometrists/Opthalmologists €18m.
n Investment in General Practice Development 
was €10.06m.
n High Tech Drugs Scheme – Payment to 
Wholesalers €207.25m, Patient Care Fees 
€10.51m.
n Administration €14.46m.
The Year 2007
Doctors Fees  €316.24m 
 Allowances €124.52m
Pharmacists Fees and Mark-Up  €359.27m
 Drugs and Medicines €1,137.53m
Dentists   €58.19m
High Tech Drugs Scheme Payment to Wholesalers  €238.51m
Patient Care Fees paid to Pharmacists €11.66m
Optometrists/Ophthalmologists  €21.60m
Administration  €16.30m
Investment in General Practice Development  €5.77m
Total of Payments for the year €2,289.59m
0
Number of Agreements
2,347 Doctors 1,587 Pharmacists 1,243 Dentists 524 Optometrists
The number of agreements between the Health Service Executive and General Practitioners for the provision of services to GMS persons 
reflects the policy position agreed between the Department of Health & Children and the Irish Medical Organisation on entry to the GMS. 
In December 2007 there were 2,347 such agreements. 
Number of Agreements as at 31st December 2007
Health Service Executive Doctors Pharmacists Dentists Optometrists
East Coast Area 26 40 88 8
South West Area 02 24 68 7
Northern Area 25 80 2 45
Midland 46 94 68 46
Mid-Western 222 46 5 40
North Eastern 67 46 9 56
North Western 4 95 60 2
South Eastern 22 70 02 62
Southern 40 24 296 68
Western 258 6 4 66
National *2,347 #1,587 +1,243 524
Corresponding figures for 2006 2,5 ,50 ,44 552
*218 GPs who do not hold GMS agreements and who were registered as providing services under the Primary Childhood Immunisation Scheme, the Health 
(Amendment) Act 1996, Heartwatch and the Methadone Treatment Scheme at year end are included above.
#12 Pharmacies who do not hold GMS agreements and who were registered as providing services under non GMS schemes at year end are included above.
+202 Dentists who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.

Persons who are unable without undue hardship to arrange General 
Practitioner medical and surgical services plus dental and optometric 
services for themselves and their dependants are provided with 
such services free of charge under the GMS Scheme. An eligible 
person is entitled to select a Doctor of his/her choice, from among 
those Doctors who have entered into agreements with the Health 
Service Executive. Drugs, medicines and appliances prescribed by 
participating Doctors for their GMS patients are provided through 
Community Pharmacies. Dental and ophthalmic services are provided 
by Dentists and Optometrists/Ophthalmologists who have contracted 
with the Health Service Executive. GMS prescription forms may be 
dispensed in any Pharmacy that has an agreement with the Health 
Service Executive to dispense GMS prescription forms. In rural areas, 
where a Doctor has a centre of practice three miles or more from the 
nearest Community Pharmacy participating in the Scheme, the Doctor 
dispenses for those persons served from the centre who opt to have 
their medicines dispensed by him/her. The number of eligible GMS 
persons at year end included 45,836 persons who were entitled and 
had opted to have their medicines dispensed by their GPs.
Under the terms of the Drugs Payment Scheme persons who do not 
have a medical card may apply for a Drugs Payment Scheme card on 
an individual or on a family unit basis. Prescribed medicines, which are 
reimbursable under the GMS, costing in excess of a specified amount 
per month, currently €85 per family, is claimed by the Pharmacy and 
is paid by the Primary Care Reimbursement Service.
On approval by the Health Service Executive persons who suffer from 
one or more of a schedule of illnesses are entitled to obtain, without 
charge, irrespective of income, necessary drugs/medicines and/or 
appliances under the LTI Scheme. The Primary Care Reimbursement 
Service makes payments on behalf of the Health Service Executive for 
LTI claims submitted by Pharmacies.
Persons Eligible for Services
GMS 1,276,178 GPVC 75,589 DP 1,583,738 LTI 112,580
Number of Eligible Persons as at 31st December 2007
Health Service Executive GMS GPVC DP LTI
Eastern Areas 7,007 ,8 54,2 57,745
Midland 78,955 5,49 99,4 6,45
Mid-Western 6,265 5,772 64,959 7,779
North Eastern 2,2 8,725 4,754 8,7
North Western 05,465 7,090 65,40 6,52
South Eastern 54,67 ,24 66,25 ,840
Southern 90,759 5,208 260,00 7,84
Western 44,897 9,086 52,068 5,89
National 1,276,178 75,589 1,583,738 112,580
% of Population 30.10% 1.78% 37.35% 2.66%
Corresponding figures for 2006 ,22,695 5,760 ,525,657 06,07
GMS – General Medical Services Scheme. GPVC – GP Visit Card Scheme. DP – Drugs Payment Scheme. LTI – Long Term Illness Scheme.
2
Payments to Doctors
Payments to General Practitioners are categorised as fees and/or 
allowances. For the majority of GPs who operate under the 1989 
agreement the principle fee is the capitation per person which is weighted 
for gender, age and distance from Doctor’s centre of practice – capitation 
fees totalled €218,833,241 in 2007 – an increase of €23,826,230 on 2006. 
Fees totalling €1,173,286 were paid to 12 GPs who continue to provide 
services under the Fee-Per-Item of service agreements.
Apart from ‘Out-of-Hours’ fees and fees for a range of special services 
the cost of services provided in normal hours by GPs for GMS persons, 
including the prescribing of necessary medicines, is encompassed by 
the capitation fee. All GMS persons can avail of full GP services and 
in many cases they can benefit from specialist clinics provided by GPs 
for issues such as Women’s Health, Family Planning and Asthma.
In addition to a capitation fee an outside normal hours fee is payable for 
non routine consultations when an eligible GMS person is seen by their 
GP or another GP acting on his/her behalf from 5pm in the evening 
to 9am on the following morning (Monday to Friday) and all hours on 
Saturdays, Sundays and Bank Holidays. The number of ‘Out-of-Hours’ 
claims increased to 738,392 in 2007 compared with 639,573 in 2006 – and 
the cost of such claims increased to €42,120,973 from €34,717,410 in 
2006. Special fees are payable for a range of 18 services such as excisions, 
suturing, vaccinations, catheterization, family planning etc. The most 
frequent claimed special service in 2007 was Influenza Vaccination (320,634) 
followed by Excisions (81,646) and E.C.G. treatments (61,426) – there was 
a total of more than 627,986 special services provided in 2007 – special 
fees totalling €23,987,259 were paid in 2007.
Annual and Study Leave together with locum, nursing and secretarial 
support plus other practice support payments account for most of the 
€124,520,286 allowances paid in the year. The total paid in 2006 was 
€124,474,346.
Total of Payments to Doctors by Health Service Executive
Health Service Executive 2007
East Coast Area €,9,596
South West Area €50,260,699
Northern Area €4,520,02
Midland €27,99,28
Mid-Western €8,29,68
North Eastern €8,727,54
North Western €,745,597
South Eastern €5,087,87
Southern €7,08,575
Western €5,96,804
National €440,756,505
Corresponding figure for 2006 €404,728,474
The total of payments to Doctors includes payments of: €6,185,989 under the Primary Childhood Immunisation Scheme; €228,401 to Doctors who provided 
services under the Health (Amendment) Act 1996; Heartwatch €1,523,093; One-In-One Rotas €952,000 and €5,400,959 under the Methadone Treatment 
Scheme.
Total Payments accumulated by Regional Health Area
Dublin North East €82,247,86
Dublin Mid-Leinster €0,65,62
South €2,947,08
West €24,96,4
Fees €316.24m Allowances €124.52m

Volume of Claims by Doctors
Fee-Per-Item 75,990
Special Type 221,098
Special Service 627,986
Out-of-Hours 738,392
National – Number of Claims – 2007
Number of Claims in each Health Service Executive Area
Health Service Executive Fee-Per-Item Special Type Special Service Out-of-Hours
East Coast Area - 0,79 7,85 28,67
South West Area 24,099 22,065 57,584 72,758
Northern Area  9,707 8,50 54,944 47,060
Midland - 6,429 4,26 50,888
Mid-Western 2,250 28,05 5,760 55,26
North Eastern - 0,45 48,588 9,78
North Western - 2,699 54,9 6,069
South Eastern  8,558 9,276 8,59 22,528
Southern 2,76 49,66 0,76 89,54
Western - ,2 87,28 0,409
National 75,990 221,098 627,986 738,392
Corresponding figures for 2006 9,086 209,705 592,928 69,57
A majority of Doctors are paid an annual capitation fee for each eligible 
person – the rate of payment is determined by the age/gender of the 
person and distance between each person’s residence and the centre of 
practice of their Doctor-of-Choice. A minority of Doctors (12) who 
have continued to provide services under the Fee-Per-Item of Service 
agreement are paid a fee for each Doctor/Patient contact. 
A Special Type Consultation (STC) fee is payable when a GMS eligible 
person is unable to contact their registered Doctor and is seen as an 
emergency case by another. General Practitioners qualify for payment of 
‘special fees’ for the special items of service separately identified under 
the Capitation agreement and the Fee-Per-Item agreement.
4
Payments to Pharmacies 
A GMS person who is provided with a properly completed GMS 
prescription form by his/her GP can choose to have such prescription 
forms dispensed in any of the Pharmacies who have entered into 
agreements with the Health Service Executive for the provision of 
services under Section 59 of the Health Act, 1970.
In 2007 there were 14.8m prescription forms containing over 44m 
prescription items dispensed at a cost of €1,048,408,418 i.e. an average 
cost of €23.27 per dispensed item. More than 96% of all eligible GMS 
persons were prescribed for in the year. The average cost of medicines 
per GMS person in 2007 was €856.14.
Payments made to Pharmacies under the GMS and DTS Schemes are 
inclusive of the ingredient cost of medicines, dispensing fees and VAT.
Under DP, LTI and EEA Schemes Pharmacies are reimbursed the 
ingredient cost of items dispensed, dispensing fees and VAT. A mark-up 
of up to 50% on the ingredient cost of items dispensed is also paid.
The cost of the High Tech Drugs Scheme was €250.18m – at year end there 
were 41,459 persons registered under this Scheme – Patient Care Fees totalled 
€11.66m and payments for drugs and medicines totalled €238.51m.
In the year the Health Service Executive processed claims valued at 
€405.44m on drugs acting on the ‘cardiovascular system’ (GMS €250.85m, 
DP €127.82m and LTI €26.77m). The second highest cost category 
was drugs acting on the ‘nervous system’ €308.19m (GMS €215.04m, 
DP €75.11m, LTI €18.04m). The third highest amount paid was for 
drugs acting on the alimentary tract and metabolism system €269.26m 
(GMS €161.19m, DP €71.84m, LTI €36.23m).
Total of Payments to Pharmacies by Health Service Executive
Health Service Executive GMS € DP € LTI € *EEA €
East Coast Area 7,76,950 29,072,296 4,446,82 86,69
South Western Area 8,698,782 5,464,286 20,755,007 50,505
Northern Area 8,26,545 45,028,58 9,069,86 78,500
Midland 7,508,559 8,569,507 7,76,922 ,95
Mid-Western 96,226,76 24,72,97 7,995,086 257,826
North Eastern 90,488,499 25,28,04 ,24,924 49,520
North Western 67,09,52 0,8,64 7,629,750 289,648
South Eastern ,744,748 0,756,007 ,024,9 26,80
Southern 68,0,770 47,269,290 4,674,05 525,862
Western 4,565,28 24,92,044 8,472,524 49,06
National €1,048,408,418 €307,334,094 €124,458,135 €2,330,737
Corresponding figures for 2006 €940,224,576 €28,08,5 €5,46,40 €2,,9
*EEA – Payment to Pharmacies to cover the cost of GMS prescriptions dispensed for residents from the European Economic Area.
Pharmacies were also paid in respect of the drugs/medicines dispensed under: Health (Amendment) Act 1996 – €1,738,805; Methadone Treatment Scheme – €8,740,728; DTS 
Scheme – €597,452; Pharmacy Training Grant – €421,109 and Patient Care Fees totalling €11,661,846 under the High Tech Drugs Scheme (Payments to Wholesalers under the High 
Tech Drugs Scheme amounted to €238,513,378).
In 2007 The National Maternity Hospital was paid €951,712 and The Rotunda Hospital was paid €1,820,138 in respect of Fertility Treatment. These figures are not included in 
the above table.
Total Payments accumulated by Regional Health Area
GMS € DP € LTI € *EEA €
Dublin North East 208,752,044 70,266,626 0,284,0 228,020
Dublin Mid-Leinster 26,969,29 99,06,089 42,78, 49,095
South 299,855,58 78,025,297 27,698,54 787,042
West 277,8,565 59,96,082 24,097,60 966,580
GMS €1,048.41m DP €310.11m LTI €124.46m EEA €2.33m
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Volume of Claims by Pharmacies
National – Number of Items – 2007
EEA 0.10m
HTD 0.28m
Other 0.37m
LTI 2.35m
DP 13.43m
GMS 44.36m
Number of Items in each Health Service Executive Area
Health Service Executive GMS DP LTI EEA HTD *Other
East Coast Area ,085,9 ,294,8 258,592 ,852 24,8 5,592
South West Area 5,29,59 2,020,442 9,225 5,997 9,250 20,8
Northern Area 4,92,6 ,845,646 48,875 ,288 0,46 95,966
Midland 2,986,20 87,95 4,955 4,22 7,898 4,472
Mid-Western 4,78,826 ,4,580 65, 0,84 22,05 8,507
North Eastern ,89,76 ,9,949 2,765 5,984 22,22 8,589
North Western 2,822,7 478,9 44,84 ,767 9,250 6,742
South Eastern 5,565,986 ,44,7 259,8 0,408 0,77 20,552
Southern 7,4,206 2,027,08 268,447 22,90 9,780 26,664
Western 4,584,677 ,22,295 58,608 6,909 0,45 5,97
National 44,358,454 13,429,945 2,352,620 95,652 276,477 372,662
Corresponding figures for 2006 40,569,42 ,872,27 2,65,00 88,742 252,692 56,965
* This group includes: 55,012 claim items in respect of the Health (Amendment) Act 1996; 231,421 items under the Methadone Treatment Scheme and 86,229 prescription items 
under the DTS Scheme.
GMS – General Medical Services Scheme. DP – Drugs Payment Scheme. LTI – Long Term Illness Scheme. EEA – European Economic Area. HTD – High Tech Drugs Scheme.  
Other – Methadone Treatment Scheme, Health (Amendment) Act 1996 and Dental Treatment Services Scheme.
GMS prescription forms processed for payment in the year totalled 
14.8m – the total of prescribed items was more than 44.3m – these 
accounted for approximately 74% of all items paid for by the Primary 
Care Reimbursement Service in 2007.
Approximately 38.01% of GMS forms contained a single item – more 
than 19.54% contained 2 items – the average number of items per form 
was 3.00 (2006 – 2.91).
GMS dispensed items paid for by the Primary Care Reimbursement 
Service in 2007 increased by more than 3,789,112 – the increase in the 
number of DP items was more than 1,557,728 – the overall increase 
in the number of pharmacy claims processed by the Primary Care 
Reimbursement Service in the year was more than 5.6m.
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Payments to Dentists 
Dentists were paid a total of €58,145,888 in 2007, in respect of 
treatments provided for more than 258,167 GMS persons under the 
DTS Scheme.
The following treatments were available to all eligible GMS persons.
ROUTINE: Routine treatments are categorised as either ‘Above the 
Line’ or ‘Below the Line’;
 ‘Above the Line’ treatments are uncomplicated 
procedures viz. Amalgam; Extractions; 
 ‘Below the Line’ treatments are advanced procedures 
viz. Protracted Periodontal; Prosthetics.
‘Below the Line’ treatments – prior Health Service Executive approval 
for a specific course of treatment under this category is required. Full 
denture treatment is available, with prior Health Service Executive 
approval, to all edentulous GMS persons over 16 years. 
Above the line €38.68m Below the line €19.46m
Payments to Dentists in each Health Service Executive Area
Health Service Executive 2007
Eastern Areas €4,987,068
Midland €,46,09
Mid-Western €5,20,575
North Eastern €5,42,926
North Western €,754,95
South Eastern €7,2,070
Southern €0,66,400
Western €7,62,56
National €58,145,888
Corresponding figure for 2006 €55,448,42
Dentists were also paid a total of €45,831 in 2007 in respect of treatments under the Health (Amendment) Act 1996.
Total Payments accumulated by Regional Health Area
Dublin North East €0,790,978
Dublin Mid-Leinster €2,800,08
South €7,957,47
West €6,597,
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Volume of Claims by Dentists
National – Volume of Treatments – 2007
Above the Line  973,599
Below the Line 105,279
Volume of Treatments by Dentists in each Health Service Executive Area
Health Service Executive +Above the Line +Below the Line No. of persons treated 
under DTS
Eastern Areas 265,5 2,559 67,28
Midland 55,676 7,072 5,670
Mid-Western 88,58 0,569 24,890
North Eastern 82,878 0,485 22,400
North Western 66,95 5, 8,57
South Eastern 5,205 4,680 ,77
Southern 85,02 8,566 47,88
Western 4,50 5,25 0,507
National 973,599 105,279 258,167
Corresponding figures for 2006 987,49 08,770 256,26
ROUTINE – Routine treatments are categorised as either ‘Above the Line’ or ‘Below the Line’:
 ‘Above the Line’ (ATL) treatments are uncomplicated procedures;
 ‘Below the Line’ (BTL) treatments are advanced procedures.
+ The most frequently used ATL service was Amalgam Restoration, which was used by 96,763 patients followed by Oral Examination. In the BTL category the most 
frequently used service was Prosthetics followed by Protracted Periodontal and Radiographs.
8
Payments to Optometrists/Ophthalmologists
Under the Health Service Executive Community Ophthalmic Services 
Scheme, Optometric/Ophthalmic services are provided to adult medical 
card holders, which include free eye examinations and necessary 
spectacles/appliances.
Payments in respect of spectacles provided under the Children’s Scheme 
are also made by the Primary Care Reimbursement Service on behalf 
of the majority of Health Service Executive Areas.
Payments in respect of eye examinations and necessary spectacles/
appliances are provided under the Teenager’s Scheme for eligible medical 
card holders on behalf of certain Health Service Executive Areas.
In the 12-month period to the end of December 2007 claims were 
received on behalf of 210,079 GMS persons for 493,504 treatments 
costing €20,294,863. 
Eye examinations by Optometrists/Ophthalmologists totalled 203,118 – 
complete spectacles (distance, reading and bi-focals) provided under the 
Scheme totalled 290,386. The balance of treatments included replacement 
lenses and frames, tinted lenses, prisms and contact lenses. A breakdown 
of treatments and payments in each Health Service Executive Area is 
shown hereunder.
Payments to Optometrists/Ophthalmologists in each Health Service Executive Area
Health Service Executive 2007
Eastern Areas €5,788,495
Midland €,9,5
Mid-Western €,825,954
North Eastern €,599,87
North Western €,442,66
South Eastern €2,842,957
Southern €,49,52
Western €2,254,77
National €20,294,863
Corresponding figure for 2006 €6,927,04
Opticians were also paid in respect of: Health (Amendment) Act 1996 €61,776; Optical services for Teenagers €136,463; Optical services for Children 
€1,101,819.
Total Payments accumulated by Regional Health Area
Dublin North East €,40,24
Dublin Mid-Leinster €5,76,267
South €5,992,470
West €5,522,892
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Volume of Treatments by Optometrists/Ophthalmologists
National – Volume of Treatments – 2007 
Eye Exams 203,118
Appliances 290,386
Volume of Treatments by Optometrists/Opthalmologists in each Health Service Executive Area
Health Service Executive Eye Exams Appliances Volume of 
Treatments
No. of Persons 
Treated
Eastern Areas 57,642 78,84 6,48 58,576
Midland ,52 9,540 ,052 4,096
Mid-Western 7,66 27,782 44,948 8,998
North Eastern 6,48 2,804 40,52 6,474
North Western 5,475 2,045 6,520 6,57
South Eastern 27,697 42,72 70,420 0,2
Southern 2,856 4,42 76,98 ,65
Western 22,422 ,09 55,7 2,56
National 203,118 290,386 493,504 210,079
Corresponding figures for 2006 90,26 274,60 464,62 92,69
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Cost per Person
National 2007 
GMS €1,205.17
LTI €2,108.03
DP €460.23
DTS €225.23
HSE-COS €97.84
Cost per Person in each Health Service Executive Area
Health Service 
Executive
GMS LTI DP DTS HSE-COS
Doctor
Cost
€
Pharmacy
Cost
€
Total
Cost
€
Pharmacy
Cost
€
Net Cost
Per 
Claimant
€
Per 
Person
Treated
€
Per 
Adult
Treated
€
Eastern Areas 25.79 85.4 ,60.9 2,2.88 544.86 222.75 99.7
Midland 44.58 90.4 ,275.0 2,020.5 407.07 220.87 00.7
Mid-Western 4.75 877.64 ,22.9 ,88.7 407.98 209.4 97.5
North Eastern 6.94 859.24 ,22.8 2,00.7 405.62 229.59 97.20
North Western 57.26 7.6 ,070.42 2,28.84 42.04 206.76 89.46
South Eastern 47.54 866.05 ,2.59 2,022.8 440.76 2. 96.48
Southern 76.6 98.4 ,294.77 2,29.4 47.72 222. 00.05
Western 75.85 855.40 ,2.25 ,949.05 72.5 250.9 97.66
National €349.03 €856.14 €1,205.17 €2,108.03 €460.23 €225.23 €97.84
Corresponding figures for 2006 €4.85 €809.04 €,2.89 €2,75.5 €47.56 €26.7 €87.88
The Doctor cost above does not include superannuation paid to retired DMOs.
The above table shows the actual cost per person in respect of those who availed of services under each Scheme in 2007.
Medical and pharmaceutical services delivered to GMS persons increased in cost from €1,123.89 in 2006 to €1,205.17 in 2007 an increase of €81.28 
per person – the cost of medical services per person increased in cost from €314.85 in 2006 to €349.03 an increase of 10.86% – the cost per person of 
pharmaceutical services increased from €809.04 in 2006 to €856.14 in 2007 an increase of 5.8%.
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Major Therapeutic Classification of Drugs, Medicines and Appliances – General Medical Services Scheme
National 2007 
C - 23.93%
N - 20.51%
A - 15.38%
R - 8.99%
V - 7.90%
Other - 23.29%
Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 161.19 15.38
B Blood and Blood Forming Organs 46.80 4.46
C Cardiovascular System 250.85 23.93
D Dermatologicals 8.94 .8
G Genito Urinary System and Sex Hormones 8.88 .7
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 0.5 0.97
J Anti-infectives for Systemic Use 6.78 .5
L Antineoplastic and Immunomodulating Agents 9.26 0.88
M Musculo-Skeletal System 6.85 6.09
N Nervous System 215.04 20.51
P Antiparasitic Products, Insecticides and Repellents 0.79 0.08
R Respiratory System 94.29 8.99
S Sensory Organs 8.7 .78
V Clinical Nutritional Products 40.9 .85
Diagnostic Products 7.28 .65
Ostomy Appliances 0.84 .0
Urinary Appliances 5.6 0.49
Needles/Syringes/Lancets .48 0.
Other Therapeutic Products 2.8 0.2
Dressings .70 0.6
Miscellaneous .64 0.6
Total €1,048.40m 100%
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Major Therapeutic Classification of Drugs, Medicines and Appliances – Drugs Payment Scheme
Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 71.84 14.63
B Blood and Blood Forming Organs 5.64 .8
C Cardiovascular System 127.82 26.02
D Dermatologicals 9.57 .98
G Genito Urinary System and Sex Hormones 7.85 7.7
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 4.7 0.96
J Anti-infectives for Systemic Use 22.5 4.55
L Antineoplastic and Immunomodulating Agents 6.84 .9
M Musculo-Skeletal System 0.67 6.24
N Nervous System 75.11 15.29
P Antiparasitic Products, Insecticides and Repellents 2.29 0.47
R Respiratory System 54.64 11.13
S Sensory Organs 5.48 .2
V Clinical Nutritional Products 7.9 .50
Ostomy Appliances 4.74 0.97
Urinary Appliances .55 0.2
Diagnostic Products . 0.2
Dressings 0.7 0.07
Needles/Syringes/Lancets 0.26 0.05
Other Therapeutic Products 0.54 0.
Miscellaneous 0.40 0.08
Total €491.19m 100%
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by the individual or family.
National 2007 
C - 26.02%
A - 14.63%
N - 15.29%
R - 11.13%
V - 3.33%
Other - 29.60%
2
Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 36.23 29.11
B Blood and Blood Forming Organs 2.7 2.8
C Cardiovascular System 26.77 21.51
D Dermatologicals 0.7 0.4
G Genito Urinary System and Sex Hormones . .05
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 0.79 0.6
J Anti-infectives for Systemic Use 2.00 .6
L Antineoplastic and Immunomodulating Agents 0.08 0.06
M Musculo-Skeletal System 0.67 0.54
N Nervous System 18.04 14.49
P Antiparasitic Products, Insecticides and Repellents 0.00 0.00
R Respiratory System 0.6 0.5
S Sensory Organs 0.24 0.9
V Diagnostic Products 2.67 7.4
Clinical Nutritional Products 5.9 4.
Needles/Syringes/Lancets/Swabs 5.52 4.4
Urinary Appliances 0.95 0.77
Nutritional/Ancillary Devices 0.59 0.48
Dressings 0.6 0.
Ostomy Appliances 0.7 0.4
Other Therapeutic Products 0.09 0.07
Miscellaneous 0.28 0.22
Total €124.46m 100%
Major Therapeutic Classification of Drugs, Medicines and Appliances – Long Term Illness Scheme
National 2007 
V - 27.98%
A - 29.11%
C - 21.51%
N - 14.49%
Other - 6.91%
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2007 2006 2005 2004 2003
Number of Eligible Persons in December ,276,78 ,22,695 ,55,727 ,48,94 ,58,4
Doctors (000’s) (000’s) (000’s) (000’s) (000’s)
Total Payments €427,48 €9,029 €40,07 €06,250 €286,80
Doctors’ Payment per Person €49.0 €4.85 €4.5 €26.5 €247.66
Pharmacies (000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Prescriptions €,02,78 €924,995 €86,04 €747,905 €66,566
Ingredient Cost €824,2 €74,94 €65,25 €585,22 €50,578
Dispensing Fee €88,6 €6,57 €47,860 €49,08 €2,5
VAT €9,692 €7,56 €5,9 €,702 €,87
Number of Forms 4,780 ,92 ,227 2,794 2,24
Number of Items 44,58 40,569 7,428 5,00 2,24
Cost per Form €69.84 €66.9 €6.7 €58.46 €5.99
Cost per Item €2.27 €22.80 €2.8 €2.5 €9.74
Ingredient Cost per Item €8.58 €8.4 €7.45 €6.70 €5.62
Items per Form .00 2.9 2.8 2.74 2.6
(000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Stock Orders €6,2 €5,20 €5,9 €5,4 €4,096
Ingredient Cost €2,559 €,777 €,74 €,944 €0,904
Pharmacy Fees €,40 €2,944 €2,927 €2,986 €2,726
VAT €52 €509 €498 €48 €466
(000’s) (000’s) (000’s) (000’s) (000’s)
Overall Cost of Medicines €,048,408 €940,225 €8,44 €76,8 €650,662
*Pharmacy Payment per Person €856.4 €809.04 €750.04 €692.7 €595.6
(000’s) (000’s) (000’s) (000’s) (000’s)
Overall Payments €1,475,827 €1,331,254 €1,234,514 €1,069,568 €937,493
*Overall Payment per Person €1,205.17 €1,123.89 €1,093.39 €954.26 €842.82
Doctors’ payment per person is exclusive of superannuation paid to retired DMOs.
*These figures are based on the actual number of persons who availed of services.
Summary of Statistical Information relating to the GMS Scheme for each of the five years 2003-2007
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2007 2006 2005 2004 2003
LTI Scheme
Number of Eligible Persons in December 2,580 06,07 99,280 9,504 97,84
*Number of Claimants 59,040 5,082 5,006 50,526 48,05
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 2,5 2,65 ,929 ,675 ,464
Total Cost €24,458 €5,46 €00,547 €85,55 €7,48
Cost per Item €52.90 €5.2 €52.2 €5.08 €50.
*Cost per Claimant €2,08.0 €2,75.5 €,896.89 €,69.2 €,526.40
DP Scheme
Number of Eligible Persons in December ,58,78 ,525,657 ,478,650 ,469,25 ,96,8
*Number of Claimants 667,782 597,85 526,052 499,664 474,4
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items ,40 ,872 0,582 9,9 9,
Gross Cost €49,86 €442,924 €88,02 €5,44 €5,82
Net Cost €07,4 €28,08 €244,486 €22,959 €204,422
Gross Cost per Item €6.57 €7. €6.67 €5.5 €.92
*Net Cost per Claimant €460.2 €47.56 €464.76 €448.22 €40.90
*These figures are based on the actual number of persons who availed of services under each Scheme.
Summary of Statistical Information relating to the LTI/DP Schemes for each of the five years 2003-2007
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Fees and Allowances under Capitation Agreement as at 31st December 2007
Up to 3 Miles 3-5 Miles 5-7 Miles 7-10 Miles Over 10 Miles
Ages Male € Female € Male € Female € Male € Female € Male € Female € Male € Female €
Under 5 years 8.5 8.57 87.76 85.8 94.0 92. 00.9 98.0 07.85 05.94
5 – 5 50.2 50.64 5.87 52.9 54.45 55.0 56.95 57.49 60.09 60.58
6 – 44 62.89 00.8 65.7 02.65 68.54 06.00 7.84 08.76 75.89 .5
45 – 64 2.74 .8 27.20 8.85 5.26  46.89 4.20 54.87 5.09 64.70
65 – 69 28.04 42.9 4.22 57.59 65.77  80.2 87.89 202.26 25.42 229.8
70 and over 9.59 54.8 55.22 70.06 78.52  9. 20.7 26.20 229.79 244.64
Above rates inclusive of supplementary Out-of-Hours Fee.
The Capitation rate is €640 per annum for persons aged 70 years and over in the community issued with a medical card for the first time 
regardless of income. A Capitation rate of €927 per annum will apply to anyone aged 70 years and over in a private nursing home (approved by 
the Health Service Executive) for continuous periods in excess of five weeks. 
Out-of-Hours Payment
Surgery €48.20
Domiciliary
Up to  miles €48.20
 - 5 miles €64.2
5 - 7 miles €72.40
7 - 0 miles €80.6
Over 0 miles €96.47
Additional Fee €7.62
*Special Items of Service
(i) to (ix) €0.5
(x) and (xi) €45.24
(xii) €75.4
(xiii) €50.75
(xiv) €8.20
(xv) and (xvi) €40.69
(xvii) €6.0
(xviii) €46.7
+Mileage
Temporary Residents 
Surgery €48.20
Domiciliary
Up to  miles €48.20
 - 5 miles €64.2
5 - 7 miles €72.40
7 - 0 miles €80.6
Over 0 miles €96.47
Rural Dispensing Fee €4.67
Fee for Second Medical Opinion €2.6
Practice Payments for Rural Areas
Rural Practice Allowance  
Per Annum €9,74.25
Practice Support
Allowance for Practice Secretary up 
to a maximum Per Annum of €26,476.69
Allowance for Practice Nurse up to 
a maximum Per Annum of €4,606.24
Allowance for Practice Manager up 
to a maximum Per Annum of €4,04.47
Contributions to Locum Expenses
(Subject to the conditions of the Agreement)
Annual Leave
Sick Leave
Up to a maximum of 
€,678.47 per week
Study Leave
Maternity Leave
Adoptive Leave
Paternity Leave
Up to a maximum of 
€29.78 per day
Contributions to Medical  
Indemnity Insurance
Calculation of contribution is related to GMS 
panel numbers and net premium.
Asylum Seekers
A one off superannuable registration fee of 
€85.45 per relevant patient will be paid to 
Doctors in respect of each such patient on their 
GMS Scheme panels.
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging  
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting 
of a Diaphragm.
(viii) Removal of Adherent 
Foreign Bodies from the 
Conjunctival Surface of the Eye.
(ix) Removal of Lodged or Impacted 
Foreign Bodies from the Ear, Nose 
and Throat.
(x) Nebuliser Treatment  
in the case of Acute Asthmatic 
Attack. 
(xi) Bladder Catheterization.
(xii) Attendance at case conferences 
(in cases where such are 
convened by the HSE).
(xiii) Advice and Fitting  
of a Diaphragm.
(xiv) Counselling and  
Fitting of an IUCD.
(xv) Pneumococcal Vaccination.
(xvi) Influenza Vaccination.
(xvii) Pneumococcal/Influenza 
Vaccination.
(xviii) Hepatitis B Vaccination.
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Surgery Consultations
Day Normal Hours €.28
Late Outside Normal Hours other than (Night) €8.88
Night Midnight to 8.00 a.m. €7.4
Domiciliary Consultations
Day Normal Hours
Urban €9.59
Up to  miles €9.59
 - 5 miles €25.65
5 - 7 miles €4.46
7 - 0 miles €4.2
Over 0 miles €54.0
Late Outside Normal Hours
Urban €25.65
Up to  miles €25.65
 - 5 miles €.9
5 - 7 miles €4.2
7 - 0 miles €57.9
Over 0 miles €67.
Night Midnight to 8.00 a.m.
Urban €50.0
Up to  miles €50.0
 - 5 miles €64.65
5 - 7 miles €8.78
7 - 0 miles €9.25
Over 0 miles €99.07
Emergency Fee/EEA Fee (Additional to Standard Fee) €4.5
Dispensing Fee €4.5
Rural Practitioner’s Allowance
Per Annum €8,562.2
Locum and Practice Expense Allowance
Per Annum €,666.84
Sessional Rate – Homes for the Aged
Per  Hour Session  €88.97
*Special Items of Service
(i) to (vii) €27.27
(viii) and (ix) €40.69
(x) €6.0
(xi) €46.7
Immunisation Fees
(i) Registration of child with a GP €8.87
(ii) Complete course of immunisation against  
PT/DT, Hib, Polio and MMR
€29.52
(iii) 95% uptake bonus €62.8
Health (Amendment) Act 1996
Surgery Fee €7.
Domiciliary Fee €48.94
Methadone Treatment Scheme
Level  Contractor €52.26
Level 2 Contractor €67.9
Fees and Allowances under the Fee-Per-Item Agreement and Fees under the Immunisation Scheme, Health 
(Amendment) Act 1996 and Methadone Treatment Scheme as at 31st December 2007
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and 
Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging 
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting  
of a Diaphragm.
(viii) Pneumococcal Vaccination.
(ix) Influenza Vaccination.
(x) Pneumococcal/Influenza 
Vaccination.
(xi) Hepatitis B Vaccination.
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GMS Scheme €
Standard Fee-Per-Item (Note 1) .5
Extemporaneous Fee 6.76
Extemporaneous dispensing and compounding of
-   Powders
-   Ointments and Creams
20.28
.52
Controlled Drugs 5.46
Non-Dispensing – exercise of professional judgement .8
Phased Dispensing – each part of phased dispensing .8
Urgent/Late Dispensing
Additional fee for Urgent/Late dispensing other than between midnight and 8.00 a.m. (Note 2) 9.49
Additional fee for Urgent/Late dispensing between midnight and 8.00 a.m. 9.64
Note 1 €2.99 basic fee and €0.52 allowance for containers, obsolescence etc.
Note 2 Urgent fee prescriptions are those so specified by the prescriber and necessarily dispensed outside normal hours. Late fee prescriptions are  
those which, though not marked urgent, are in exceptional circumstances necessarily dispensed outside normal hours by the Pharmacist,  
having regard to the person’s requirements.
Note 3  A Standard Fee-Per-Item is also payable on prescription forms issued by Dentists under the DTS Scheme.
Note 4  A Fee-Per-Item of €4.46 is also payable on prescription forms in respect of persons aged 70 years and over issued with a medical card for  
the first time regardless of income.
Supplies to Dispensing Doctors
Pharmacies supplying Dispensing Doctors are reimbursed on the basis of the reimbursement price with the addition of 25% on cost.
DP/LTI/EEA Schemes and Health (Amendment) Act 1996
Reimbursement of ingredient cost plus 50% mark-up on ingredient cost plus Standard Fee – €3.08 (Note 1) 
20% mark-up on Incontinence products and Dressings under DP Scheme.
Extemporaneously dispensed preparations are reimbursed at current private prescription rates. In the case of the Drugs Payment Scheme  
the PCRS makes payments to Pharmacies in respect of authorised Patients whose monthly costs of prescribed drugs and medicines are  
in excess of the specified monthly amount (currently €85) payable to the Pharmacy by an individual or family.
Note 1 The standard fee is an all inclusive fee which includes container and broken bulk allowance.
High Tech Medicines Scheme 
Patient Care Fee: €59.04 per month.
Methadone Treatment Scheme 
Patient Care Fee: Up to a Maximum of €59.02 per month.
Scale of Fees Payable to Participating Pharmacists as at 31st December 2007
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Scale of Fees Payable under the Dental Treatment Services Scheme as at 31st December 2007
Treatment Type Routine 
€
Oral Examination 2.0
Prophylaxis 0.07
Restoration (Amalgam) 48.8
Restoration (Composite) 6 anterior teeth only 50.5
Exodontics (Extraction under local anaesthetic) 8.2
Surgical Extraction – Maximum  units:
Fee payable for each 5 minute unit 4.04
Maximum 02.2
st Stage Endodontic Treatment (Anterior teeth only) 55.8
Denture Repairs
st Item of Repair 44.04
Each Subsequent Item 4.2
Maximum 72.27
Apicectomy/Amputation of Roots *Dentist Estimate
Endodontics (Anterior teeth only) *Dentist Estimate
Protracted Periodontal Treatment *Dentist Estimate
Radiographs 
 Film 2.95
2 or more Films 6.20
Panoramic 40.09
Miscellaneous 
(e.g. Abcess, Haemorrhage, Dressings etc.) 2.90
Prosthetics
Full Upper or Lower Denture 00.8
(Other than Edentulous Persons)
Partial Upper or Lower Acrylic Denture 220.7
Complete Upper or Lower Reline 20.7
Complete Upper and Lower Reline 200.02
Full Upper and Lower Denture (Edentulous Persons Only) 440.52
* Dentist Estimates are subject to agreement between a Dentist and the Health Service Executive Area.
0
As at 31st December 2007 €
Examinations
Eye Examination Ophthalmic Optician 2.5
Eye Examination Ophthalmologist/
Ophthalmic Medical Practitioner 26.50
Medical Eye Examination by Ophthalmologist 5.0
Eye Examination for Contact Lenses (Grant) 70.98 (H)
Eye Examination Ophthalmic (Dilation) 46.70
Appliances
Single Vision Complete Appliances
Spectacles – Distance 42.66
Spectacles – Reading 42.66
Spectacles – Uncollected 29.84
Contact Lenses (Pair) 42.66
Contact Lenses Standard or Disposable per pair (Grant) 65.26 (H)
Single Vision Spectacles – with Glass Lenses Distance 24.48 (H)
Single Vision Spectacles – with Glass Lenses Reading 24.48 (H)
Single Vision Spectacles – with Plastic Lenses Distance .7 (H)
Single Vision Spectacles – with Plastic Lenses Reading .7 (H)
Single Vision Lenses to Own Frame
Replacement Distance Lens () to own frame 6.58
Replacement Distance Lenses (2) to own frame .5
Replacement Reading Lens () to own frame 6.58
Replacement Reading Lenses (2) to own frame .5
Single Vision Lenses to Non-Standard Frame
Single Vision Lens () (Glass) Distance 2.90 (H)
Single Vision Lenses (2) (Glass) Distance 47.82 (H)
Single Vision Lens () (Glass) Reading 2.90 (H)
Single Vision Lenses (2) (Glass) Reading 47.82 (H)
Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme
€
Single Vision Lens () (Plastic) Distance 27.20 (H)
Single Vision Lenses (2) (Plastic) Distance 54.9 (H)
Single Vision Lens () (Plastic) Reading 27.20 (H)
Single Vision Lenses (2) (Plastic) Reading 54.9 (H)
Additional Specification for Lenses to All Spectacle Types
Special grant towards additional specification for lens ()
– applies to all spectacle types 82. (H)
Special grant towards additional specification for lenses (2)
– applies to all spectacle types 64.25 (H)
Other Items – Single Vision
Lenticular Lens ( Surface) .69
Lenticular Lenses (2 Surfaces) 2.9
Lenticular Lenses ( Surfaces) 5.08
Lenticular Lenses (4 Surfaces) 46.77
Tinted Lens () 7.52
Tinted Lenses (2) 5.04
Tinted Lenses () 22.57
Tinted Lenses (4) 0.09
Prism () 6.
Prisms (2) 2.65
Prisms () 8.98
Prisms (4) 25.
Prisms (5) .64
Prisms (6) 7.97
Prisms (7) 44.0
Prisms (8) 50.6
Dioptric powers higher than 8.00 () Lens 6.5
Dioptric powers higher than 8.00 (2) Lenses 2.29
Dioptric powers higher than 8.00 () Lenses 8.44
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.

Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme continued
As at 31st December 2007 €
Dioptric powers higher than 8.00 (4) Lenses 24.59
Anti-Reflective Coating on Plastic Lens () 8.8 (H)
Anti-Reflective Coating on Plastic Lenses (2) 6.5 (H)
Dioptric powers higher than 6.00 (Plastic) () Lens 5.7
Dioptric powers higher than 6.00 (Plastic) (2) Lenses 0.7
Dioptric powers higher than 6.00 (Plastic) () Lenses 46.0
Dioptric powers higher than 6.00 (Plastic) (4) Lenses 6.47
Plastic Lens () for children as prescribed 4.69
Plastic Lenses (2) for children as prescribed 9.7
Plastic Lens () Adult 4.62 (H)
Plastic Lenses (2) Adult 9.2 (H)
Bifocals
Spectacles Bifocal Complete 85.5
Fused Bifocal Spectacles 66.5 (H)
Varifocals Spectacles – Glass or Plastic 25.67 (H)
Bifocal Lenses
Replacement Bifocal Lens () to own frame 7.86
Replacement Bifocal Lenses (2) to own frame 75.7
Bifocal Lens () To Non-Standard Frames 48.78 (H)
€
Bifocal Lenses (2) to Non-Standard Frames 97.56 (H)
Varifocal Lens () (Grant) 95.7 (H)
Varifocal Lenses (2) (Grant) 9.46 (H)
Other Items – Bifocals
Sphere over 6.00 and up to 9.00 extra charge () Lens 4.5
Sphere over 6.00 and up to 9.00 extra charge (2) Lenses 8.0
Sphere over 9.00 extra charge () Lens 9.22
Sphere over 9.00 extra charge (2) Lenses 8.44
Tinted Lens () 8.29
Tinted Lenses (2) 6.58
Prism () 8.8
Prisms (2) 7.66
Repairs
Replacement Frame to own lenses 2.46
Replacement Front to own lenses 5.8
Replacement Side () to own frame 2.45
Replacement Sides (2) to own frame 4.90
Complete New Frames 92.76 (H)
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.
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DETAILED STATISTICAL ANALYSIS 
OF CLAIMS AND PAYMENTS 2007
4
Table 1 GMS: Summary of Statistical Information for each of the Five Years 2003-2007
Year ended December:- 2007 2006 2005 2004 2003 Year ended December:- 2007 2006 2005 2004 2003
Number of Eligible  
Persons in December
,276,78 ,22,695 ,55,727 ,48,94 ,58,4 Number of Doctor 
Contracts
Number of Pharmacist 
Contracts
2,47
,587
2,5
,50
2,257
,40
2,20
,
2,8
,292
DOCTORS (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s)
Total Payments €427,418 €391,029 €403,071 €306,250 €286,830 Total Cost of Stock 
Orders
€16,231 €15,230 €15,139 €15,413 €14,096
         Ingredient Cost €2,559 €,777 €,74 €,944 €0,904
Doctors’ Payment per 
Person
€349.03 €314.85 €343.35 €261.53 €247.66          Pharmacy Fees
          VAT
€,40
€52
€2,944
€509
€2,927
€498
€2,986
€48
€2,726
€466
PHARMACIES
Total Cost of 
Prescriptions
€1,032,178 €924,995 €816,304 €747,905 €636,566 Overall Cost of 
Medicines
€1,048,408 €940,225 €831,443 €763,318 €650,662
        Ingredient Cost €824,2 €74,94 €65,25 €585,22 €50,578 *Pharmacy Payment  
per Person
€856.14 €809.04 €750.04 €692.73 €595.16
        Dispensing Fee €88,6 €6,57 €47,860 €49,08 €2,5
        VAT €9,692 €7,56 €5,9 €,702 €,87
Number of Forms 4,780 ,92 ,227 2,794 2,24
Number of Items 44,58 40,569 7,428 5,00 2,24 Overall Payments €1,475,827 €1,331,254 €1,234,514 €1,069,568 €937,493
Cost per Form €69.84 €66.9 €6.7 €58.46 €5.99 *Overall Payment  
per Person
€1,205.17 €1,123.89 €1,093.39 €954.26 €842.82
Cost per Item €2.27 €22.80 €2.8 €2.5 €9.74
Ingredient Cost per Item €8.58 €8.4 €7.45 €6.70 €5.62
Items per Form .00 2.9 2.8 2.74 2.6
Note: Doctors payment per person is exclusive of superannuation paid to retired DMOs.
*These figures are based on the actual number of persons who availed of services.
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Year ended December:- 2007 2006 2005 2004 2003 Year ended December:- 2007 2006 2005 2004 2003 
LTI Scheme
Number of Eligible  
Persons in December
2,580 06,07 99,280 9,504 97,84
DP Scheme
Number of Eligible  
Persons in December
,58,78 ,525,657 ,478,650 ,469,25 ,96,8
*Number of Claimants 59,040 5,082 5,006 50,526 48,05 *Number of Claimants 667,782 597,85 526,052 499,664 474,4
 (000’s)  (000’s)  (000’s)  (000’s)  (000’s) (000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 2,5 2,65 ,929 ,675 ,464 Number of Items ,40 ,872 0,582 9,9 9,
Total Cost €24,458 €5,46 €00,547 €85,55 €7,48 Gross Cost €49,86 €442,924 €88,02 €5,44 €5,82
Cost per Item €52.90 €5.2 €52.2 €5.08 €50. Net Cost €07,4 €28,08 €244,486 €22,959 €204,422
*Cost per Claimant €2,08.0 €2,75.5 €,896.89 €,69.2 €,526.40 Gross Cost per Item €6.57 €7. €6.67 €5.5 €.92
*Net Cost per Claimant €460.2 €47.56 €464.76 €448.22 €40.90
*These figures are based on the actual number of persons who availed of services under each Scheme.
Table 1.1 LTI/DP: Summary of Statistical Information for each of the Five Years 2003-2007
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Table 2 Number of Agreements
Health Service 
Executive
Doctors Pharmacists Dentists Optometrists
2007 2006 2007 2006 2007 2006 2007 2006
 East Coast Area 26 2 40 5 88 0 8 45
 South Western Area 02 0 24 20 68 89 7 85
 Northern Area 25 256 80 72 2 48 45 45
 Midland 46 5 94 86 68 7 46 45
 Mid-Western 222 28 46 46 5 4 40 44
 North Eastern 67 64 46 6 9 2 56 56
 North Western 4 7 95 88 60 6 2 
 South Eastern 22 225 70 65 02 29 62 54
 Southern 40 409 24 28 296  68 74
 Western 258 257 6 54 4 74 66 7
National 2,347 2,315 1,587 1,530 1,243 1,414 524 552
Note:  (i) Where doctors have panels numbers drawn from more than one HSE Area, the Area wherein the majority of such persons reside is deemed to be the doctors HSE Area.
 (ii) 218 Doctors who do not have agreements under the GMS Scheme and who provide services under the Primary Childhood Immunisation Scheme, the Health (Amendment) Act 1996, 
Heartwatch, Pallative Care and the Methadone Treatment Scheme are included in the above.
 (iii) 202 Dentists (201 - 2006) who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
 (iv) 12 Pharmacies who do not hold GMS agreements and who were registered as providing non GMS Schemes at year-end are included above.
 (v) Above figures relate to the position as at 31st December 2007.
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Table 3 GMS: Payments to Doctors
2007 2006
€ €
FEES - Item of Service Contract ,7,286 ,427,644
- Capitation 28,8,24 95,007,0
- Special Claims/Services 5,255,72 ,567,070
- Out-of-Hours 42,20,97 4,77,40
- Dispensing 2,486,967 2,567,255
- Asylum Seekers ,9,527 ,598,662
- GP Visit Cards ,888,06 ,669,850
ALLOWANCES - Annual Leave 8,642,868 8,28,80
- Locum and Practice Expenses 5,575 6,5
- Sick Leave ,88,00 ,20,00
- Maternity Leave/Paternity Leave 672,92 694,044
- Rural Practice ,78,82 ,566,52
- Secretarial/Nursing 6,860,46 55,,9
- Study Leave ,494,4 ,472,90
- Medical Indemnity Insurance 2,27,997 2,6,422
- Rostering/Out-of-Hours ,559,982 0,929,872
- Practice Development 4,54,067 4,5,85
- Practice Support Grant 2,668,954 2,67,706
- IMO Agreements:
    One-in-one rotas 952,000 64,869
    Third year Trainees - 4,92
    Trainer Grants - ,27,255
SALARIES - Former District Medical Officers ,888,474 2,55,074
- Benefits to retired DMOs and their dependants 5,926,608 6,75,56
SUPERANNUATION FUND - Contribution 22,975,769 20,5,950
TOTAL €433,344,670 €391,029,248
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Table 4 GMS: Cost of Prescriptions 
Health
Service
Executive
Ingredient Cost Dispensing Fee VAT Total
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
East Coast Area 56,26,75 52,604,778 ,869,500 2,207,696 ,90,25 ,28,9 7,496,504 66,09,59
South Western Area 94,9,7 85,9,05 2,845,274 8,962,984 2,55,506 2,6,588 8,520,49 06,28,877
Northern Area 94,744,297 84,240,528 2,06,2 8,7,09 2,27,6 ,957,6 8,045,020 04,70,75
Midland 56,79,99 5,582,6 2,848,22 ,254,647 ,56,090 ,205,29 70,944,5 64,042,57
Mid-Western 75,887,285 68,55,698 7,,75 5,0,8 ,84,452 ,66,878 95,0,490 85,200,409
North Eastern 70,86,958 64,42,026 6,275,20 4,74,9 ,725,2 ,58,627 88,862,509 80,05,046
North Western 5,956,806 46,64,9 ,664,429 0,095,7 ,77,02 ,07,007 64,798,267 57,80,
South Eastern 0,09,006 90,478,95 2,879,47 20,529,625 2,50,642 2,229,792 27,490,2 ,27,62
Southern 4,64,80 2,545,20 29,745,09 26,27,67 ,56,498 2,78,095 67,544,77 50,545,46
Western 87,82,48 78,82,20 9,64,257 6,889,727 ,977,87 ,76,22 09,442,609 97,449,78
National €824,322,416 €743,942,527 €188,163,333 €163,536,536 €19,692,184 €17,515,736 €1,032,177,933 €924,994,799
Note:  Cost of medicines supplied by pharmacies to Dispensing Doctors is given in Table 5.
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Table 5 GMS: Cost of Stock Order Forms 
Health
Service
Executive
Ingredient Cost * Pharmacy Fee VAT Total
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
East Coast Area 80,78 74,0 45,80 4,58 9,548 7,909 265,446 255,820
South Western Area 7,988 07,99 29,56 26,802 0,787 28,04 78,29 62,042
Northern Area 47,080 97,02 6,774 24,255 4,67 22,940 28,525 44,227
Midland 42,802 447,50 08,200 ,870 2,406 25,9 564,408 584,492
Mid-Western 99,48 94,7 229,786 228,68 44,292 46,40 ,9,226 ,89,54
North Eastern ,258,740 ,28,40 4,69 2,06 52,559 52,20 ,625,990 ,72,86
North Western ,749,44 ,927,446 47,50 48,86 54,560 54,84 2,24,254 2,464,50
South Eastern ,22,59 2,869,462 80,68 77,5 0,98 92,702 4,254,627 ,679,57
Southern 405,227 80,678 0,06 95,64 59,466 54,28 565,999 50,2
Western 4,025,22 ,50,08 ,006,276 882,85 9,2 94,99 5,22,79 4,507,486
National €12,558,760 €11,776,611 €3,139,717 €2,943,988 €532,008 €509,178 €16,230,485 €15,229,777
Note:  (i) Stock Order Forms are provided by HSE Areas for the use of Dispensing Doctors to obtain Medicines and Appliances from Community Pharmacies for dispensing to persons who are 
entitled to be dispensed to.
 (ii) * Pharmacies are reimbursed for stock order items on the basis of the reimbursement price, with the addition of 25% on cost.
 (iii) The above figures include needles, syringes and dressings which are available for Doctors use.
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Table 6 DTS: Payments to Dentists
Health Service Executive
Above the Line Below the Line Total
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
Eastern Areas 0,5,299 0,068,965 4,45,769 4,599,825 4,987,068 4,668,790
Midland 2,74,276 ,856,58 ,286,87 ,50,020 ,46,09 ,006,78
Mid-Western ,462,99 ,94,49 ,748,76 ,756,085 5,20,575 4,950,524
North Eastern ,5,58 ,076,7 ,827,768 ,76,4 5,42,926 4,82,847
North Western 2,60,7 2,585,220 ,5,024 ,59,695 ,754,95 ,744,95
South Eastern 4,548,750 4,290,799 2,772,20 2,689,66 7,2,070 6,980,460
Southern 7,84,797 6,806,550 ,25,60 ,5,28 0,66,400 9,957,768
Western 4,664,22 4,45,202 2,968,29 2,9,748 7,62,56 7,26,950
National €38,683,972 €36,294,066 €19,461,916 €19,154,366 €58,145,888 €55,448,432
Note:  Dentists were also paid a total €45,831 in 2007 (€51,832 in 2006) in respect of fees under Health (Amendment) Act 1996.
4
Health Service Executive
2007 2006
Doctors
€
Pharmacies
€
Total
€
Doctors
€
Pharmacies
€
Total
€
Eastern Areas 25.79 85.4 ,60.9 0.29 785.64 ,086.9
Midland 44.58 90.4 ,275.0 8.22 894.65 ,22.87
Mid-Western 4.75 877.64 ,22.9 299.82 88.20 ,8.02
North Eastern 6.94 859.24 ,22.8 24.6 80.08 ,54.7
North Western 57.26 7.6 ,070.42 299.98 674.46 974.44
South Eastern 47.54 866.05 ,2.59 8.87 87.98 ,6.85
Southern 76.6 98.4 ,294.77 40.05 862.7 ,202.76
Western 75.85 855.40 ,2.25 26.2 796.08 ,22.40
National €349.03 €856.14 €1,205.17 €314.85 €809.04 €1,123.89
Note:  The payment per person is inclusive of total payments to Doctors (Table 3) excluding superannuation benefits to retired DMOs and their dependants and total payments to pharmacies 
(Tables 4 and 5) in respect of the actual cost per person who availed of services.
Table 7 GMS: Payment per Person
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2007 (2006 in brackets)
Number of Doctors with an annual cost per eligible person of:-
Health Service 
Executive Up to €300 €301-€350 €351-€400 €401-€450 €451-€500 €501-€550 €551-€600 €601-€650 €651-€700 €701 & Over
Eastern Areas 25 (6) 6 (2) 8 () 5 (9) 0 (8) 2 (2) 2 (2) 6 (4) 7 () 508 (49)
Midland 2 (2) 4 (-)  () 2 (-)  (-)  (-) 2 (2) 2 () 2 (-) 97 (97)
Mid-Western 5 (2) - () 2 (-) 2 (-) - (2) 2 ()  (2) 2 () 5 (9) 62 (48)
North Eastern 2 (-)  (-)  ()  (2)  ()  (5) 5 (5) 4 (2) 6 (4)  (28)
North Western - - (2)  () 2 () 4 (2) 4 ()  ()  (4) 5 (9) 07 (06)
South Eastern 0 (5)  (-) 2 () -  (-)  (2) 4 (4)  (7) 4 (5) 98 (9)
Southern  (-) 4 (-) 2 ()  (-) 2 (-) 4 ()  (2) 5 () 8 (9) 25 (00)
Western 2 (-) 2 (2)  ()  (2)  (2) 5 (2) 2 () 5 (6) 6 (8) 206 (98)
National 107 (15) 18 (7) 18 (9) 16 (16) 24 (15) 32 (28) 34 (40) 40 (40) 53 (55) 1,736 (1,659)
Note:  (i) Doctors not in the GMS Scheme for the full year have been excluded from this table.
 (ii) The annual cost per eligible person is the total payment for the Doctor and the total prescribing/dispensing costs in respect of the number of persons on the panel as at December 2007.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.
Table 8 GMS: Number of Doctors in Eligible Person Cost Categories
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Table 9 GMS: Number of Eligible Persons 
Health Service 
Executive
Number of persons (including dependants)  
and % of population* eligible in Health Service 
Executive
Number of persons (including dependants)  
and % of population* eligible in
December 2007 December 2006 December 2007 December 2006
No. % No. % No. % No. %
EASTERN AREA NORTH WESTERN
Dublin 298,00 25. 289,790 24.4 Donegal 72,590 49.29 7,058 48.5
Kildare 4,656 2.4 4,6 22.0 Leitrim 2,09 42.52 ,68 40.6
Wicklow ,25 24.76 29,94 2.70 Sligo 20,566 .77 9,956 2.76
TOTAL 7,007 24.87 60,840 24.08 TOTAL 05,465 44.48 02,652 4.8
MIDLAND SOUTH EASTERN
Laois 9,44 28.99 8,7 27.2 Carlow 8,84 6.5 6,840 .7
Longford ,747 9.97 ,09 8.0 Kilkenny 2,87 24.92 20,885 2.90
Offaly 22,208 .4 20,726 29.6 Tipperary S.R. 0,242 6.4 29,50 5.0
Westmeath 2,559 29.69 22,29 28.2 Waterford 9,42 6.52 7,44 4.66
TOTAL 78,955 .7 74,9 29.56 Wexford 44,75 .97 42,679 2.4
TOTAL 54,67 .55 46,968 .92
MID-WESTERN
Clare 5,484 .98 ,556 0.29 SOUTHERN
Limerick 58,52 .70 54,242 29.50 Cork 46,072 0.5 8,720 28.85
Tipperary N.R. 22,429 .97 2,75 2.09 Kerry 44,687 .96 42,792 0.65
TOTAL 6,265 2.20 08,97 0.22 TOTAL 90,759 0.7 8,52 29.25
NORTH EASTERN WESTERN
Cavan 22,429 5.04 20,99 2.74 Galway 7,692 0.95 68,45 29.6
Louth 8,74 4.49 7,809 4.09 Mayo 50,867 4.08 48,944 9.58
Meath 4,098 20.94 2,476 9.97 Roscommon 22,8 8.0 2,285 6.26
Monaghan 7,2 0.92 6,527 29.6 TOTAL 44,897 4.98 8,680 .55
TOTAL 2,2 28.47 07,75 27.40 NATIONAL 1,276,178 30.10 1,221,695 28.85
Note: *The population figures for each county are taken from the Census of Population 2007.  The most recent Official C.S.O. estimate of national population as at October 2007 is 4,239,848.
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Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups
Health 
Service 
Executive
Age Classification
As at December 2007
Under 5 Years 5 - 11 Years 12 - 15 Years 16 - 24 Years 25 - 34 Years 35 - 44 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas ,787 4,577 28,64 9,596 20,95 40,5 8,922 9,502 8,424 6,86 0,254 27,070 2,609 ,85 5,462 20,27 4,446 4,77
Midland 2,778 2,876 5,654 4,96 4,208 8,404 2,50 2,205 4,55 ,856 2,68 6,494 4,9 2,598 6,99 4,06 ,0 7,609
Mid-Western ,72 ,88 7,550 5,55 5,820 ,55 2,845 2,874 5,79 5,82 4,424 0,26 6,62 4,277 0,900 6,229 5,052 ,28
North Eastern ,805 4,080 7,885 5,775 6,045 ,820 2,854 2,94 5,795 5,576 ,856 9,42 6,484 ,985 0,469 6,095 4,758 0,85
North Western ,259 ,542 6,80 5,089 5,56 0,652 2,767 2,945 5,72 5,862 4,442 0,04 5,795 ,887 9,682 5,922 5,062 0,984
South Eastern 4,884 5,25 0,9 7,6 7,759 4,920 ,750 ,92 7,67 7,80 5,4 ,64 8,806 5,496 4,02 8,269 6,425 4,694
Southern 5,855 6,7 2,026 8,5 8,785 6,900 4,5 4,402 8,57 8,89 6,28 4,672 0,47 6,825 7,296 9,984 8,020 8,004
Western 4,45 4,557 8,702 6,474 6,786 ,260 ,626 ,657 7,28 7,085 5,496 2,58 7,2 4,78 ,994 7,526 6,27 ,799
National 42,245 44,856 87,0 6,94 65,88 27,822 ,049 2,447 6,496 6,226 42,727 0,95 7,92 4,704 7,096 68,602 5,9 2,94
% of Eligible 
Persons .% .52% 6.8% 4.85% 5.6% 0.0% 2.4% 2.54% 4.97% 4.80% .5% 8.5% 5.75% .4% 9.8% 5.8% 4.8% 9.56%
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Health 
Service 
Executive
Age Classification
As at December 2007
45 - 54 Years 55 - 64 Years 65 - 69 Years 70 - 74 Years 75 Years and Over All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 5,50 2,6 27,662 7,775 ,860 ,65 0,795 7,77 8,566 2,60 7,970 9,600 44,527 26,469 70,996 2,229 59,778 7,007
Midland ,620 ,089 6,709 4,69 ,600 7,969 2,0 ,85 4,52 ,694 ,57 7,265 7,8 5,540 ,5 4,476 5,479 78,955
Mid-Western 5,457 4,82 0,280 6,588 5,794 2,82 ,576 ,046 6,622 5,480 5,20 0,68 ,495 7,764 9,259 6,72 52,89 6,265
North Eastern 5,044 4,40 9,474 6,055 5,246 ,0 ,9 2,58 5,774 5,25 5,024 0,277 ,58 7,65 9, 6,652 50,56 2,2
North Western 5, 4,970 0,28 6,05 5,85 ,940 2,98 2,896 5,84 ,928 ,779 7,707 9,068 6,500 5,568 56,044 49,42 05,465
South Eastern 7,45 6,52 ,965 9,02 7,828 6,90 4,989 4,277 9,266 7,47 7,0 4,428 4,845 0, 25,58 84,506 70, 54,67
Southern 9,5 8,09 7,74 ,290 9,706 20,996 6,90 5,242 ,62 9,945 9,098 9,04 20,8 ,668 4,479 04,520 86,29 90,759
Western 7, 6,790 ,90 8,24 8,02 6,275 4,460 4,095 8,555 6,0 6,86 2,76 5,207 0,622 25,829 77,420 67,477 44,897
National 58,64 50,84 09,448 69,527 59,90 29,428 8,642 ,759 70,40 6,677 58,040 2,77 5,284 88,49 22,775 704,29 57,959 ,276,78
% of Eligible 
Persons 4.60% .98% 8.58% 5.45% 4.69% 0.4% .0% 2.49% 5.52% 4.99% 4.55% 9.54% 0.60% 6.9% 7.5% 55.8% 44.82% 00.00%
Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued
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Table 9.2 GMS: Percentage of Eligible Persons by Mileage Allocation
Health Service  
Executive
Mileage Classification
As at December 2007
Up to 3 Miles 3 - 5 Miles 5 - 7 Miles 7 - 10 Miles Over 10 Miles
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 5. 8.9 89.52 .08 2.42 5.50 .75 .6 . 0.62 0.52 .4 0.40 0. 0.7
Midland 6.90 26.97 6.87 6.22 5.0 .52 2.45 0.02 22.47 .2 0.97 2.09 0.02 0.0 0.05
Mid-Western 6.84 0.6 67.47 6.4 5.40 .8 9.90 8.0 8.20 .06 0.90 .96 0.28 0.26 0.54
North Eastern 5.09 28.28 6.7 7.66 6.5 4.7 .8 9.4 20.6 0.86 0.7 .57 0.5 0. 0.28
North Western 26.66 22.96 49.62 9.2 8.9 7.62 2.29 .09 2.8 .67 .2 6.88 .0 .20 2.50
South Eastern 6.64 0.25 66.89 6.45 5.48 .9 0.02 8.7 8.9 .5 .08 2.4 0.20 0.6 0.6
Southern 5.4 28.78 64.2 6.76 5.66 2.42 9.60 8.0 7.6 .8 .6 .46 .26 . 2.9
Western 28.4 2.9 52.6 8.5 7.9 5.54 .28 0.05 2. 4.07 .77 7.84 .5 .42 2.9
National 38.88 30.68 69.56 6.03 5.14 11.17 8.12 6.88 15.00 1.62 1.43 3.05 0.64 0.58 1.22
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Health Service 
Executive
Number of persons (including dependants) 
and % of population* eligible in Health Service 
Executive
Number of persons (including dependants) 
and % of population* eligible in
December 2007 December 2006 December 2007 December 2006
No. % No. % No. % No. %
EASTERN AREA NORTH WESTERN
Dublin 9,95 0.79 5,688 0.48 Donegal 4,807 .26 ,62 2.29
Kildare 2,40 .29 ,40 0.72 Leitrim 800 2.76 540 .87
Wicklow ,522 .2 ,2 0.89 Sligo ,48 2.44 98 .62
TOTAL ,8 0.89 8,49 0.54 TOTAL 7,090 2.99 4,885 2.06
MIDLAND SOUTH EASTERN
Laois ,09 .95 ,02 .64 Carlow ,76 .4 ,2 2.62
Longford 94 2.66 677 .97 Kilkenny ,66 .85 ,264 .45
Offaly ,494 2. , .86 Tipperary S.R. 2,22 2.66 ,78 2.09
Westmeath ,42 .80 ,47 .44 Waterford 2,406 2.2 ,494 .8
TOTAL 5,49 2.05 4,29 .69 Wexford ,29 2.50 2,20 .67
TOTAL ,24 2.44 8,020 .74
MID-WESTERN
Clare ,78 .6 968 0.87 SOUTHERN
Limerick 2,764 .50 ,590 0.86 Cork 2,44 2.52 7,647 .59
Tipperary N.R. ,227 .86 7 . Kerry ,064 2.9 2,07 .48
TOTAL 5,772 .60 ,289 0.9 TOTAL 5,208 2.45 9,78 .57
NORTH EASTERN WESTERN
Cavan ,545 2.4 ,268 .98 Galway 4,70 2.0 ,597 .56
Louth 2,870 2.58 ,90 .72 Mayo 2,950 2.8 2,6 .9
Meath ,27 .99 2,02 .42 Roscommon ,45 2.44 ,52 .96
Monaghan ,07 .92 877 .57 TOTAL 9,086 2.9 7,0 .72
TOTAL 8,725 2.2 6,50 .6 NATIONAL 75,589 1.78 51,760 1.22
Note: *The population figures for each county are taken from the Census of Population 2007. The most recent Official C.S.O. estimate of national population as at October 2007 is 4,239,848.
Table 9.3 GPVC: Number of Eligible Persons 
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Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups
Health Service 
Executive
Age Classification
As at December 2007
Under 5 Years 5 - 11 Years 12 - 15 Years 16 - 24 Years 25 - 34 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 82 858 ,68 ,044 ,080 2,24 427 456 88 590 46 96 ,090 667 ,757
Midland 28 50 678 98 442 840 9 84 75 282 24 496 502 08 80
Mid-Western 8 7 69 455 447 902 26 229 445 76 269 645 525 76 90
North Eastern 580 560 ,40 658 824 ,482 295 0 596 470 8 788 780 449 ,229
North Western 26 405 7 50 579 ,09 26 267 50 440 79 89 569 89 958
South Eastern 626 672 ,298 90 876 ,777 89 99 788 699 44 ,40 ,066 675 ,74
Southern 900 956 ,856 ,4 ,65 2,06 502 524 ,026 874 575 ,449 ,420 95 2,5
Western 50 569 ,079 65 709 ,62 08 50 658 526 7 897 794 508 ,02
National 4,4 4,74 9,54 5,780 6,22 ,902 2,59 2,70 5,0 4,257 2,9 7,70 6,746 4,287 ,0
% of Eligible Persons 5.84% 6.27% 2.% 7.65% 8.0% 5.75% .4% .59% 7.0% 5.6% .85% 9.49% 8.92% 5.67% 4.60%
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Health Service 
Executive
Age Classification
As at December 2007
35 - 44 Years 45 - 54 Years 55 - 64 Years 65 - 69 Years All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas ,44 ,202 2,66 778 577 ,55 695 54 ,209 6 96 757 7,222 6,096 ,8
Midland 507 449 956 252 24 486 96 76 72 5 85 6 2,707 2,442 5,49
Mid-Western 542 505 ,047 2  654 86 88 74 5 62  2,992 2,780 5,772
North Eastern 872 8 ,685 49 404 82 67 00 667 2 8 5 4,57 4,52 8,725
North Western 640 587 ,227 469 4 880 24 25 649 68 9 87 ,629 ,46 7,090
South Eastern ,096 944 2,040 664 595 ,259 480 45 95 20 6 28 6,04 5,200 ,24
Southern ,420 ,70 2,790 926 790 ,76 69 576 ,267 92 27 46 8,066 7,42 5,208
Western 85 774 ,609 609 572 ,8 96 77 77 90 5 225 4,72 4,65 9,086
National 7,26 6,644 ,970 4,440 ,94 8,54 ,5 2,89 6,226 ,065 ,44 2,479 9,95 5,68 75,589
% of Eligible Persons 9.69% 8.79% 8.48% 5.87% 5.8% .05% 4.4% .82% 8.24% .4% .87% .28% 52.85% 47.5% 00.00%
Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups continued
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Table 10 GMS: Size of Panels of Doctors
As at December 2007 (2006 in brackets)
Health Service 
Executive
Number of Doctors with panels of:-
Up to 250 251 - 500 501 - 1,000 1,001 - 1,500 1,501 - 2,000 2,001 - 2,500
East Coast Area 5 (49) 52 (54) 6 (6) 8 (5) - -
South Western Area 47 (4) 42 (47) 92 (89) 46 (44) 0 (7) 4 ()
Northern Area 46 (4) 8 (40) 66 (69) 8 (6) 5 (9)  (2)
Midland 2 (8) 6 (8) 49 (45) 29 (27)  () -
Mid-Western 25 (29)  (4) 89 (78) 24 (20) 8 (7) -
North Eastern 0 (4) 28 (29) 90 (87) 27 (2) 4 (4) -
North Western  () 9 (2) 50 (52) 40 (4)  ()  (-)
South Eastern 26 (2) 5 (6) 5 (8) 42 (8) 0 (5) -
Southern 87 (80) 70 (77) 52 (46) 44 (4) 4 (4)  ()
Western  (7) 56 (56) 98 (02) 47 (8) 2 () -
National 355 (347) 389 (421) 862 (847) 345 (299) 65 (49) 7 (6)
5
Table 11 GMS: Payments to Doctors in each Health Service Executive Area
Health Service Executive 2007€
2006
€
East Coast Area ,07,465 28,642,65
South Western Area 47,595,005 4,78,54
Northern Area 4,768,807 8,009,490
Midland 26,48,059 24,078,44
Mid-Western 6,702,569 ,48,257
North Eastern 8,7,02 5,662,55
North Western ,58,78 ,26,24
South Eastern 52,867,749 47,70,689
Southern 68,890,46 62,870,862
Western 50,8,2 46,96,755
National €427,418,062 €391,029,248
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Health Service 
Executive
No. of Temporary 
Resident Claims
No. of EEA  
Visitor Claims
No. of  
Emergency Claims
Second Medical 
Opinion Claims
No. of Out-of-
Hours Claims
Total No. of  
Claims
2007 2006 2007 2006 2007 2006 2007 2006 2007 2006 2007 2006
East Coast Area 5,48 4,42 2,778 2,696 2,576 2,99  9 28,67 26,82 8,960 6,868
South Western 
Area ,285 8,700 5,57 4,857 5,259 5,827 4 0 72,758 65,8 94,82 85,227
Northern Area 8,505 6,707 2,200 2,5 7,79 7,94  7 47,060 49,97 65,56 65,442
Midland 2,488 0,64 2,642 2,280 ,29 ,482 8 8 50,888 42,2 67,7 58,066
Mid-Western 7,76 4,20 5,58 5,27 4,58 4,604 578 602 55,26 48,450 8,4 7,0
North Eastern* 6,79 7,78 2,66 ,029 ,69 ,668  4 9,78 8,759 20,7 20,88
North Western ,772 ,229 7,525 8,000 ,64 ,709 8 2 6,069 55,764 7,768 68,725
South Eastern 0,965 8, 5,825 5,588 2,474 ,207 2 0 22,528 9,774 4,804 08,72
Southern 0,20 ,444 4,608 ,42 4,05 5,469 87 ,57 89,54 55,70 29,50 207,96
Western 7,679 5,20 9,782 9,229 5,644 5,55 06 4 0,409 95,40 4,620 25,076
National 123,807 109,501 59,074 56,508 36,593 41,832 1,624 1,864 738,392 639,573 959,490 849,280
Note: *HSE North Eastern Area figures do not include statistics from North East Doc.
Table 12 GMS: Number of Special Type Consultations and Out-of-Hours Claims 
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Table 12.1  GMS: Payment to Doctors for Special Type Consultations and Out-of-Hours claims 
Health 
Service 
Executive
Cost of Temporary 
Resident Claims
Cost of EEA Visitor 
Claims
Cost of Emergency 
Claims
Cost of Second 
Medical Opinion 
Claims
Cost of Out-of-
Hours Claims Total Cost of Claims
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
East Coast 
Area 280,507 2,827 2,6 2,976 2,78 ,55 2 22 ,6,752 ,240,752 ,900,92 ,708,22
South 
Western Area 570,72 45,90 26,929 29,76 249,925 268,69 26 94 ,656,42 ,66,74 4,78,694 4,07,409
Northern 
Area 40,29 04,96 04,67 96,885 72,82 4,952 9 0 2,259,96 2,25,859 ,47,780 2,990,962
Midland 600,57 47,649 26,0 0,90 62,4 60,950 257 00 2,588,45 2,04,85 ,77,99 2,770,274
Mid-Western 855,75 65,98 265,56 28,662 28,505 22,026 8,246 8,2 2,77,668 2,09,40 4,29,526 ,40,4
North 
Eastern* 06,254 7,8 24,784 6,779 86,287 78,659 2 65 489,945 42,676 ,007,02 965,597
North 
Western 80,45 46,559 6,929 64,42 65,79 78,58 ,9 77 ,08,50 2,688,070 ,690,865 ,278,6
South Eastern 52,506 70,40 278,895 25,852 7,92 45,802 76 67 5,96,99 4,0,22 6,882,69 5,080,66
Southern ,60,709 ,552,499 700,00 607,849 94,59 250,0 27,592 5,25 9,52,40 7,47,8 2,056,6 9,88,75
Western 877,447 707,82 466,974 48,42 270,475 255,652 ,98 ,52 5,0,05 4,606,907 6,748,47 5,990,55
National €6,215,753 €5,170,930 €2,823,005 €2,561,800 €1,762,388 €1,918,876 €51,345 €57,550 €36,827,008 €30,460,368 €47,679,499 €40,169,524
Note: *HSE North Eastern Area figures do not include statistics from North East Doc.
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Table 13 GMS: Analysis of Special Items of Service
Type of Service Number of Claims Cost of Claims
2007 2006 2007
€
2006
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 8,646 75,248 2,422,7 2,22,742
(ii) Suturing: Cuts and Lacerations 2,04 0,48 950,2 858,09
(iii) Hydroceles: Draining of ,28 ,6 8,04 2,75
(iv) Haemorrhages: Dental/Nasal ,896 2,00 56,55 56,75
(v) Veins: Recognised treatment ,467 2,95 0,27 8,290
(vi) ECG: Tests and interpretation 6,426 56,847 ,82,780 ,604,22
(vii) Diaphragm: Instruction in the fitting of ,02 ,044 0,620 29,446
(viii) Eye: Removal of Adherent foreign body 8,975 9,209 266,7 259,796
(ix) Ear/Nose/Throat: Removal of foreign body 2,658 2,44 70,82 605,07
(x) Nebuliser: Treatment in the case of acute asthmatic attack 49,86 50,496 2,25,589 2,9,50
(xi) Bladder: Catheterization 6,295 6,022 280,06 254,955
(xii) Case Conference: Convened by HSE 227 92 6,80 ,5
(xiii) Diaphragm: Advice and fitting of 665 740 ,2 5,094
(xiv) IUCD: Counselling and fitting of 7,85 6,44 589,702 489,040
(xv) Pneumococcal: Vaccination 2,264 2,9 494,740 474,46
(xvi) Influenza: Vaccination 20,64 299,769 ,006,90 ,582,655
(xvii) Pneumococcal/Influenza: Vaccination 4,829 6,286 90,8 942,
(xviii) Hepatitis B: Vaccination 409 2 58,49 4,890
National 627,986 592,928 €23,987,260 €21,627,306
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Type of Service East Coast Area South Western Area
Number of 
Claims
Cost of 
Claims 
€
Number of 
Claims
Cost of 
Claims 
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 4,665 8,540 7,606 225,828
(ii) Suturing: Cuts and Lacerations 850 25,207 2,099 62,00
(iii) Hydroceles: Draining of 96 2,857 84 2,498
(iv) Haemorrhages: Dental/Nasal 44 ,05 228 6,82
(v) Veins: Recognised treatment 5 44 495 4,72
(vi) ECG: Tests and interpretation 2,649 78,487 4,047 20,29
(vii) Diaphragm: Instruction in the fitting of 6 47 54 0,526
(viii) Eye: Removal of Adherent foreign body 65 4,902 429 2,75
(ix) Ear/Nose/Throat: Removal of foreign body 947 28,078 2,089 6,995
(x) Nebuliser: Treatment in the case of acute asthmatic attack 985 4,805 ,67 49,820
(xi) Bladder: Catheterization 78 7,9 246 0,959
(xii) Case Conference: Convened by HSE 0 740 29 2,2
(xiii) Diaphragm: Advice and fitting of 49 2,444 0 5,07
(xiv) IUCD: Counselling and fitting of 599 47,78 827 66,064
(xv) Pneumococcal: Vaccination 72 29,7 ,08 4,676
(xvi) Influenza: Vaccination 24,55 994,724 2,92 ,4,490
(xvii) Pneumococcal/Influenza: Vaccination ,25 80,5 ,550 94,28
(xviii) Hepatitis B: Vaccination 2 279 29 4,44
Total 37,853 €1,487,606 57,584 €2,228,210
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area
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Type of Service Mid-Western North Eastern
Number of 
Claims
Cost of 
Claims  
€
Number of 
Claims
Cost of 
Claims  
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 5,554 64,609 6,08 80,95
(ii) Suturing: Cuts and Lacerations 2,476 7,420 ,985 58,98
(iii) Hydroceles: Draining of 98 2,95 8 2,466
(iv) Haemorrhages: Dental/Nasal 92 2,79 52 ,544
(v) Veins: Recognised treatment 47 4,5 75 22,06
(vi) ECG: Tests and interpretation 4,7 29,598 4,56 2,80
(vii) Diaphragm: Instruction in the fitting of 60 ,770 89 2,65
(viii) Eye: Removal of Adherent foreign body 99 ,82 59 0,65
(ix) Ear/Nose/Throat: Removal of foreign body ,566 46,504 ,69 50,254
(x) Nebuliser: Treatment in the case of acute asthmatic attack ,80 49,945 ,097 7,94
(xi) Bladder: Catheterization 440 9,598 422 8,757
(xii) Case Conference: Convened by HSE 25 ,845 24 ,780
(xiii) Diaphragm: Advice and fitting of 62 ,067 6 ,782
(xiv) IUCD: Counselling and fitting of 59 42,767 498 9,688
(xv) Pneumococcal: Vaccination , 45,692 775 ,266
(xvi) Influenza: Vaccination 0,004 ,28,065 27,08 ,094,497
(xvii) Pneumococcal/Influenza: Vaccination ,55 82,56 ,457 88,85
(xviii) Hepatitis B: Vaccination 6 8,809 26 ,686
Total 51,760 €2,010,015 48,588 €1,869,159
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area continued
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Type of Service Northern Area Midland
Number of 
Claims
Cost of 
Claims 
€
Number of 
Claims
Cost of 
Claims 
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 6,455 9,0 4, 22,2
(ii) Suturing: Cuts and Lacerations 2,29 68,07 2,575 76,84
(iii) Hydroceles: Draining of 24 77 4 ,275
(iv) Haemorrhages: Dental/Nasal 88 2,602 298 8,804
(v) Veins: Recognised treatment 7 , 70 2,094
(vi) ECG: Tests and interpretation 2,650 78,74 5,96 77,47
(vii) Diaphragm: Instruction in the fitting of 2 949 4 ,007
(viii) Eye: Removal of Adherent foreign body 89 24,804 755 22,79
(ix) Ear/Nose/Throat: Removal of foreign body 2,049 60,642 ,75 5,942
(x) Nebuliser: Treatment in the case of acute asthmatic attack ,685 75,020 4,768 22,00
(xi) Bladder: Catheterization 0 4,585 464 20,67
(xii) Case Conference: Convened by HSE 5 , 6 ,95
(xiii) Diaphragm: Advice and fitting of 0 ,50  ,564
(xiv) IUCD: Counselling and fitting of 889 7,049 589 47,28
(xv) Pneumococcal: Vaccination ,844 74,22 75 28,89
(xvi) Influenza: Vaccination 4,46 ,97,49 8,425 747,4
(xvii) Pneumococcal/Influenza: Vaccination ,406 85,66 60 7,07
(xviii) Hepatitis B: Vaccination 69 9,955 6 2,295
Total 54,944 €2,148,397 41,236 €1,561,237
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area continued
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Type of Service North Western South Eastern
Number of 
Claims
Cost of 
Claims 
€
Number of 
Claims
Cost of 
Claims 
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 7,27 26,960 9,722 288,47
(ii) Suturing: Cuts and Lacerations 2,977 88,9 5,8 57,64
(iii) Hydroceles: Draining of 8 5,55 2 ,4
(iv) Haemorrhages: Dental/Nasal 85 5,49 265 7,848
(v) Veins: Recognised treatment 2 626 84 24,769
(vi) ECG: Tests and interpretation 8,466 250,907 9,256 274,45
(vii) Diaphragm: Instruction in the fitting of 4 ,975 49 ,45
(viii) Eye: Removal of Adherent foreign body 804 2,79 777 2,07
(ix) Ear/Nose/Throat: Removal of foreign body 2,40 7,899 2,55 74,620
(x) Nebuliser: Treatment in the case of acute asthmatic attack 5,747 254,94 7,442 0,792
(xi) Bladder: Catheterization 89 9,62 994 44,242
(xii) Case Conference: Convened by HSE  824 5 2,585
(xiii) Diaphragm: Advice and fitting of 0 ,508 90 4,486
(xiv) IUCD: Counselling and fitting of 596 47,558 ,24 99,4
(xv) Pneumococcal: Vaccination 85 ,02 ,488 59,95
(xvi) Influenza: Vaccination 22,4 9,570 4,50 ,682,525
(xvii) Pneumococcal/Influenza: Vaccination ,28 78,009 ,925 7,0
(xviii) Hepatitis B: Vaccination 8 ,47 25 ,56
Total 54,339 €2,035,276 83,593 €3,200,120
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area continued
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Type of Service Southern Western
Number of 
Claims
Cost of 
Claims 
€
Number of 
Claims
Cost of 
Claims 
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 5,654 464,54 4,467 429,655
(ii) Suturing: Cuts and Lacerations 6,2 87,924 5,29 52,224
(iii) Hydroceles: Draining of 222 6,592 8 0,005
(iv) Haemorrhages: Dental/Nasal 202 5,990 442 ,0
(v) Veins: Recognised treatment 964 28,56 49 4,4
(vi) ECG: Tests and interpretation 9,48 279,984 0,40 09,524
(vii) Diaphragm: Instruction in the fitting of 77 5,244 87 2,588
(viii) Eye: Removal of Adherent foreign body 2,754 8,689 ,694 50,92
(ix) Ear/Nose/Throat: Removal of foreign body 5,22 54,706 ,406 0,8
(x) Nebuliser: Treatment in the case of acute asthmatic attack 9,5 42,578 9,86 48,298
(xi) Bladder: Catheterization ,257 55,929 ,00 57,8
(xii) Case Conference: Convened by HSE 45 , 7 ,260
(xiii) Diaphragm: Advice and fitting of 47 7,8 89 4,450
(xiv) IUCD: Counselling and fitting of ,25 00,06 54 28,288
(xv) Pneumococcal: Vaccination ,992 80,9 ,700 68,762
(xvi) Influenza: Vaccination 5,08 2,6,92 6,049 ,46,56
(xvii) Pneumococcal/Influenza: Vaccination 2,4 0,26 ,775 08,060
(xviii) Hepatitis B: Vaccination 2 8,860 4 5,75
Total 110,761 €4,198,074 87,328 €3,249,165
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area continued
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NATIONAL
2007 (2006 in brackets)
Doctors with 
panels of:-
Visiting Rate:-*
6 - 6.9 7 - 7.9 8 - 8.9 9 - 9.9 10 - 10.9 11 - 11.9 12 and Over
00-249 -  (-)  () - () - - - ()
250-499 - - - (2)  (-) - -  ()
500-999 - () - () 2 (-) - - - -
,000-,499 -  (-) - - - -  ()
Over ,500 - -  (-) - - () - -
TOTAL - (1) 2 (1) 4 (3) 1 (1) - (1) - 2 (3)
Note:  (i) The overall visiting rate in 2007 of the Doctors who continued on a Fee-Per-Item of service contract was 9.66 (Surgery: 9.24 Domiciliary: 0.42), (2006 – Total: 10.59 Surgery: 9.88 Domiciliary: 0.71).
 (ii) Only Doctors with panels of 100 persons or over are included in the above table.
 (iii) * Visiting Rate is the total number of consultations divided by the total number of persons on panel.
Table 14 GMS: Visiting Rate Categories for Doctors on Fee-Per-Item of Service
6
Health 
Service 
Executive
Age Classification
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Eastern Areas 84.96 99. 92.2 65.47 78.95 72.4 76.7 75.47 76.07 249.64 28.72 27.9 0.0 88. 49.69 484.59 494.04 488.52 
Midland 99. 08.46 0.96 86.57 82.0 84.0 78.2 95.74 87.04 289. 267.46 280.2 92.9 496.6 4. 587.7 579.85 584.0 
Mid-Western 26.97 26.04 26.50 86.59 5.2 0.27 0.87 29.8 6.69 272.20 272.6 272.27 9.7 47. 409.20 544.52 58.7 562.08 
North Eastern 9.9 98.94 95.20 70.00 92.94 8.7 9.7 92.70 92.9 245.87 22.76 26.8 42. 406.9 66.6 479.00 470.2 475. 
North Western 65.55 88.24 77.7 6.02 7.88 68.69 69. 8.9 75.82 85.85 66.0 77.42 275.97 26.0 270.89 9.94 62.29 79.5 
South Eastern 05.65 7.2 .6 70.28 89.6 80.0 89.7 2.48 06.80 256.40 244.08 25.4 7.04 424.46 70.6 542.94 564.0 552.5 
Southern 06.96 0.65 9.2 00.6 .9 07. 5.90 26.00 2. 290.72 0.85 296.4 96.85 475.0 427.70 575.7 627.67 598.67 
Western 0. 07.87 09.05 72.2 78.54 75.50 72.68 9.27 8.02 28.48 25.0 26.97 66.62 457.46 402.84 496.4 54.6 5.79 
National
% of National 
Average
€96.6 €08.47 €02.72 €74.85 €88.96 €82.2 €86.4 €98.4 €92.56 €25.02 €240.07 €247.70 €50.6 €45.69 €74.62 €509.7 €526.50 €57.07
.76% .20% 2.50% 9.% 0.8% 0.00% 0.52% .98% .27% 0.80% 29.22% 0.5% 42.62% 50.60% 45.60% 62.05% 64.09% 62.94%
Table 15 GMS: Cost of Medicines by Gender within Age Groups 
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Table 15 GMS: Cost of Medicines by Gender within Age Groups continued
Health 
Service 
Executive
Age Classification
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years & Over Total
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Eastern Areas 909.58 86.44 889.29 ,259.6 ,26.27 ,260.5 ,46.66 ,542.7 ,496.76 ,42.42 ,46.24 ,87.0 ,72.76 ,669.4 ,709.4 868.0 789.50 84.55
Midland ,06.97 946.47 984.5 ,92.72 ,45.0 ,4.82 ,52.98 ,62.7 ,57.44 ,656.98 ,595.22 ,626.62 ,976.65 ,99.76 ,95.04 94.84 907.76 927.6
Mid-Western 892.4 86.9 866.00 ,2.66 ,225. ,229.67 ,72.78 ,5.00 ,6.68 ,409.86 ,55. ,8.0 ,657.47 ,670.75 ,662.8 844.9 809.57 828.44
North Eastern 797.67 80.75 80.79 ,8.7 ,62.27 ,8.75 ,04.58 ,69.85 ,.76 ,406.0 ,42.4 ,74.80 ,664.46 ,664.45 ,664.45 795.5 76.4 78.05
North Western 604.8 604.55 604.6 950.47 97.44 94. ,6.69 ,04.0 ,4.07 ,222.0 ,206. ,24.2 ,507.4 ,475.90 ,494.26 65.9 62.44 64.47
South Eastern 89.46 88.20 887.6 ,22.4 ,25.5 ,28.52 ,49.6 ,4.20 ,424.82 ,40.6 ,97.65 ,44.46 ,746.80 ,70.2 ,728.94 854.4 824.7 840.79
Southern 962.78 97.92 95.4 ,289.09 ,288.26 ,288.7 ,44.77 ,477.2 ,457.70 ,476.47 ,42.42 ,450.7 ,654.5 ,62.24 ,64.90 97.80 874.86 898.9
Western 792.44 7.80 762.8 ,08.7 ,02.9 ,029.79 ,204.70 ,25.80 ,29.59 ,6.88 ,260.22 ,298.8 ,570.0 ,504.48 ,54.07 790.02 747.80 770.6
National €869.09 €82.7 €852.20 €,99.6 €,92.2 €,96.8 €,84.20 €,409.78 €,95.74 €,42.75 €,6.4 €,92.99 €,690.69 €,647.57 €,67.64 €844.4 €79. €82.52
% of National 
Average
05.79% 0.6% 0.7% 46.02% 45.2% 45.6% 68.49% 7.6% 69.90% 7.06% 65.72% 69.56% 205.80% 200.55% 20.72% 02.79% 96.57% 00.00%
6
Health Service Executive
Number of Forms Number of Items Items per Form
2007 2006 2007 2006 2007 2006
East Coast Area 974,28 955,567 ,085,9 2,92,08 .7 .06
South Western Area ,77,457 ,66, 5,29,59 4,770,974 .05 2.95
Northern Area ,565,80 ,47,22 4,92,6 4,4,096 .4 .0
Midland 976,72 97,7 2,986,20 2,747,55 .06 2.99
Mid-Western ,75,475 ,29,45 4,78,826 ,80,272 .04 2.95
North Eastern ,284,945 ,209,68 ,89,76 ,59,48 2.99 2.9
North Western ,048,2 980,06 2,822,7 2,570,902 2.69 2.62
South Eastern ,86,45 ,746,598 5,565,986 5,055,269 2.99 2.89
Southern 2,92,54 2,262,96 7,4,206 6,564,57 2.99 2.90
Western ,582,06 ,479, 4,584,677 4,78,4 2.90 2.82
National 14,780,410 13,932,341 44,358,454 40,569,342 3.00 2.91
Table 16 GMS: Number of Prescription Forms and Items 
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Table 16.1  GMS: Payment to Pharmacists in Respect of Prescriptions
Health Service 
Executive
Cost Cost per Form Cost per Item Ingredient Cost per Item
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
2007
€
2006
€
East Coast Area 7,496,504 66,09,59 7.9 69.7 2.7 22.62 8.22 8.0
South Western Area 8,520,49 06,28,877 69.0 65.72 22.62 22.26 8.00 7.85
Northern Area 8,045,020 04,70,75 75.9 70.85 24.0 2.55 9.29 9.0
Midland 70,944,5 64,042,57 72.68 69.8 2.76 2. 9.00 8.78
Mid-Western 95,0,490 85,200,409 69.09 65.97 22.74 22.6 8.6 7.99
North Eastern 88,862,509 80,05,046 69.6 66.6 2.4 22.74 8.45 8.28
North Western 64,798,267 57,80, 6.8 58.96 22.96 22.48 8.4 8.4
South Eastern 27,490,2 ,27,62 68.42 64.8 22.9 22.40 8.7 7.90
Southern 67,544,77 50,545,46 70.0 66.5 2.46 22.9 8.85 8.52
Western 09,442,609 97,449,78 69.8 65.88 2.87 2.2 9.6 8.86
National €1,032,177,933 €924,994,799 €69.84 €66.39 €23.27 €22.80 €18.58 €18.34
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Prescription forms having:-
2007 2006
No. of Forms % of Total No. of Forms % of Total
One Item 5,628,759 8.0 5,42,68 8.2
Two Items 2,892,452 9.54 2,766,47 9.84
Three Items ,669,247 .27 ,602,99 .49
Four Items ,56,77 7.8 ,4,28 7.99
Five Items 927,549 6.26 89,95 6.4
Six Items 84,0 5.70 805,925 5.78
Seven Items 95,547 6.2 89,042 6.9
Eight or more Items 75,509 5.09 527,20 .78
Table 16.2  GMS: Number of Items on Prescription Forms
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Table 16.3  DP: Number of Items on Claim Forms 
Claim forms having:-
2007 2006
No. of Forms % of Total No. of Forms % of Total
One Item 2,47,060 44.72 2,084,274 4.78
Two Items ,62,02 2.2 ,0,609 2.25
Three Items 670,205 2.0 599,84 2.59
Four Items 40,406 7.90 9,966 8.2
Five Items 28,489 5.7 255,97 5.8
Six Items 78,625 .28 62,2 .4
Seven Items ,702 2.05 00,00 2.0
Eight or more Items 77,68 .26 54,906 .25
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Table 16.4  LTI: Number of Items on Claim Forms 
Claim forms having:-
2007 2006
No. of Forms % of Total No. of Forms % of Total
One Item 29,64 6.5 288,808 7.66
Two Items 48,890 8.55 46,459 9.0
Three Items 99,05 2.5 96,048 2.5
Four Items 79,722 9.94 74,748 9.75
Five Items 64,506 8.04 58,4 7.60
Six Items 47,60 5.88 4,592 5.42
Seven Items ,28 .89 27,58 .59
Eight or more Items 40,02 5.00 ,22 4.5
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Table 17 GMS: Number of Dispensing Doctors* and Persons for whom they Dispense
Health Service Executive 2007 2006
No. of Doctors No. of Persons No. of Doctors No. of Persons
Eastern Areas - - - -
Midland 8 4,75 9 4,58
Mid-Western 0 , 2 2,840
North Eastern 5 ,47 5 ,4
North Western  ,25 6 6,588
South Eastern 2 7,95 2 8,742
Southern  ,459  ,6
Western  4,58 5 9,025
National 117 45,836 129 54,257
Note: *In rural areas where a Doctor has a centre of practice 3 miles or more from the nearest Community Pharmacy the Doctor dispenses for persons served from that centre who opt to 
be dispensed to. The Doctor is paid a dispensing fee for each such person. A Doctor’s medicine requirements are obtained on a Stock Order from a Community Pharmacy – the stock 
ordered is approved in advance by a HSE Area.
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Table 18 GMS: Advance Payments to Pharmacists 
Health Service Executive
Amount Advanced to Pharmacists as at 31st December:-
2007
€
2006
€
Eastern Areas ,557,665 ,728,97
Midland 850,584 87,07
Mid-Western ,5,95 ,87,858
North Eastern ,444,002 ,496,578
North Western ,87,407 ,74,5
South Eastern ,845,28 ,902,969
Southern 2,029,54 2,,547
Western ,754,02 ,87,466
National €13,783,567 €14,313,785
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Table 19 GMS: Notes on Some of the More Commonly Prescribed Products
AMOXICILLIN 
AMOXICILLIN AND 
ENZYME INHIBITOR
FUROSEMIDE 
FUROSEMIDE WITH 
POTASSIUM SPARING 
DIURETICS
SALBUTAMOL
DICLOFENAC
ATORVASTATIN AND 
PRAVASTATIN
Amoxicillin, alone or potentiated by 
an inhibitor of bacterial enzymes is a 
broad spectrum Penicillin antibiotic 
indicated for the treatment of a wide 
range of infections. 
Salbutamol is a beta-adrenergic 
stimulant used mainly in the 
treatment of chronic asthma and 
chronic bronchitis.
Diclofenac is a Non-Steroidal Anti-
inflammatory Drug (NSAID) mainly 
used to treat pain and inflammation 
associated with muscular conditions 
and rheumatoid arthritis.
Atorvastatin and Pravastatin are 
indicated, in combination with dietary 
measures, for lowering cholesterol 
levels.
The diuretic Furosemide, alone or 
in combination with potassium – 
sparing diuretics, is used to treat 
hypertension.
OMEPRAZOLE
LANSOPRAZOLE
BECLOMETASONE
AMLODIPINE
ACETYLSALICYLIC ACID 
- ASPIRIN
ATENOLOL
Beclometasone is a potent steroid 
having an anti-inflammatory action 
within the lungs. It is used mainly 
by inhalation for the treatment of 
bronchial asthma.
Amlodipine is a calcium – channel 
blocker (similar to nifedipine) with 
peripheral and coronary vasodilator 
properties. It is given by mouth in the 
management of hypertension and of 
angina pectoris.
Acetylsalicylic Acid – Aspirin has 
anti-inflammatory and additionally 
analgesic and antipyretic (body 
temperature lowering) action. 
Acetylsalicylic Acid – Aspirin also has 
action against thrombosis or clot 
formation by inhibition of platelet cell 
aggregation in the blood.
Atenolol is a beta blocker. Members 
of this class of drugs are used in the 
treatment of hypertension, angina 
pectoris and cardiac arrythmias.
Omeprazole and Lansoprazole are 
proton pump inhibitors which prevent 
secretion of gastric acid. They are 
used in the treatment of reflux 
oesophagitis and peptic ulceration.
7
Table 19.1  GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing 
Frequency
% of Scheme Total Ingredient Cost € % of Scheme Total
 Acetylsalicylic Acid-Aspirin (Antithrombotic) 2,05,894 5.8 4,752,276 0.57
2 Atorvastatin ,46,264 .2 57,654,48 6.89
 Levothyroxine Sodium 78,578 .76 ,566,52 0.9
4 Calcium, Combinations 697,94 .57 5,607,695 0.67
5 Amlodipine 67,5 .5 ,44,4 .6
6 Bisoprolol 66,42 .49 6,52,2 0.74
7 Salbutamol (Inhaled) 655,26 .47 ,588,206 0.4
8 Paracetamol 650,774 .46 887,88 0.
9 Amoxicillin and Enzyme Inhibitor 628,645 .4 5,728,5 0.68
0 Ramipril 65,200 .8 8,25,964 0.99
 Warfarin 588,426 .2 ,540,844 0.8
2 Furosemide 579,64 .0 654,00 0.08
 Lansoprazole 570,084 .28 2,494,04 2.57
4 Pravastatin 567,48 .28 20,05,904 2.40
5 Omeprazole 558,600 .26 24,654,899 2.95
6 Atenolol 52,248 .20 2,748,954 0.
7 Clinical Nutritional Products 55,92 .6 7,965,622 4.54
8 Diclofenac (Systemic) 52,8 .5 5,876,578 0.70
9 Esomeprazole 485,006 .09 20,845,50 2.49
20 Diazepam 455,52 .02 86,45 0.05
2 Prednisolone (Systemic) 427,542 0.96 ,469,679 0.7
22 Bendroflumethiazide 409,745 0.92 642,24 0.08
2 Zopiclone 402,22 0.90 ,58,84 0.4
24 Perindopril 95,072 0.89 7,86,842 0.94
25 Metformin 86,246 0.87 ,06,042 0.6
26 Amoxicillin 70,987 0.8 ,75,402 0.2
27 Diagnostic Products 52,627 0.79 2,798,482 .5
28 Salmeterol and other drugs for obstructive airway diseases 46,645 0.78 24,62,96 2.94
29 Alprazolam 46,0 0.78 ,46,9 0.4
0 Pantoprazole 8,644 0.76 ,540,450 .8
 Clopidogrel 5,986 0.76 8,27,2 2.8
2 Paracetamol, Combs. excl. Psycholeptics 27,56 0.74 ,975,845 0.24
 Codeine, Combs. excl. Psycholeptics 7,29 0.7 2,762,2 0.
4 Alendronic Acid 07,228 0.69 0,550,979 .26
5 Tramadol 298, 0.67 4,96,078 0.50
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Table 19.1  GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing 
Frequency
% of Scheme Total Ingredient Cost € % of Scheme Total
6 Zolpidem 298,06 0.67 ,77,70 0.2
7 Carbocisteine 289,92 0.65 ,82,4 0.6
8 Lactulose 288,94 0.65 ,522,725 0.8
9 Digoxin 286,256 0.64 242,68 0.0
40 Rosuvastatin 280,596 0.6 8,28,67 0.98
4 Doxazosin 280,405 0.6 8,788,06 .05
42 Salbutamol and other drugs for obstructive airway diseases 278,80 0.6 7,97,78 0.95
4 Gliclazide 276,689 0.62 2,92,5 0.5
44 Diclofenac (Topical) 270,596 0.6 ,7,777 0.20
45 Alginic Acid 267,26 0.60 ,488,88 0.8
46 Beclometasone (Inhaled) 258,209 0.58 4,885,85 0.58
47 Citalopram 255,90 0.58 5,80,529 0.69
48 Artificial tears and other indifferent preparations 255,28 0.57 ,280,827 0.5
49 Folic Acid 25,97 0.57 248,45 0.0
50 Ferrous Fumarate 246,805 0.55 445,228 0.05
5 Escitalopram 245,787 0.55 7,492,600 0.90
52 Venlafaxine 24,24 0.55 0,52,47 .26
5 Bendroflumethiazide and Potassium 240,820 0.54 502,508 0.06
54 Lisinopril 240,27 0.54 ,4,824 0.40
55 Domperidone 26,228 0.5 ,27,444 0.
56 Clarithromycin 22,8 0.52 4,4,442 0.52
57 Isosorbide Mononitrate 229,29 0.52 ,090,548 0.7
58 Furosemide and Potassium-Sparing Agents 227,87 0.5 ,07,679 0.
59 Temazepam 28,625 0.49 447,29 0.05
60 Tiotropium Bromide 200,54 0.45 9,905,765 .8
6 Glucosamine 88,878 0.42 5,6,4 0.67
62 Ibuprofen 8,449 0.4 647,59 0.08
6 Flurazepam 79,965 0.40 ,027,88 0.2
64 Needles/Syringes/Lancets 7,582 0.9 2,208,44 0.26
65 Olanzapine 65,875 0.7 9,200,66 2.29
66 Allopurinol 65,602 0.7 ,049,459 0.
67 Mefenamic Acid 6,402 0.7 79,897 0.09
68 Risedronic Acid 59,08 0.6 5,78,077 0.69
69 Metoprolol 58,88 0.6 48,08 0.05
70 Tamsulosin 57,09 0.5 4,498,764 0.54
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Table 19.1  GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
7 Simvastatin 56,744 0.5 4,749,0 0.57
72 Valsartan 56,055 0.5 ,706,59 0.44
7 Glyceryl Trinitrate 54,4 0.5 ,579,056 0.9
74 Other Osmotically Acting Laxatives 54,05 0.5 2,47,466 0.0
75 Tolterodine 52,264 0.4 7,2,74 0.85
76 Losartan 5,257 0.4 4,45,67 0.50
77 Drospirenone and Estrogen 49,644 0.4 ,042,698 0.2
78 Rabeprazole 47,52 0. 4,6,42 0.55
79 Flucloxacillin 46,029 0. ,,557 0.6
80 Betamethasone (Topical) 45,78 0. 665,677 0.08
8 Betahistine 45,542 0. ,970,7 0.2
82 Nimesulide 4,06 0.2 2,224,02 0.27
8 Cefaclor 4,04 0.2 ,22,025 0.
84 Amitriptyline 9,467 0. 29,58 0.02
85 Latanoprost 6,875 0. ,28,928 0.9
86 Valproic Acid 6,596 0. ,469,97 0.8
87 Mirtazapine 5,77 0. ,595,9 0.4
88 Carbamazepine 0,508 0.29 924,27 0.
89 Fluoxetine 29,76 0.29 ,52,885 0.42
90 Risperidone 28,249 0.29 8,775,596 .05
9 Diltiazem 25,67 0.28 ,805,799 0.22
92 Prochlorperazine 22,6 0.28 ,79 0.04
9 Formoterol and other drugs for obstructive airway diseases 2,996 0.27 7,05,42 0.84
94 Bromazepam 20,86 0.27 657,405 0.08
95 Levonorgestrel and Estrogen (Fixed Comb. Contraceptives) 8,02 0.27 454,970 0.05
96 Meloxicam 6,4 0.26 ,445,405 0.7
97 Sertraline 6,27 0.26 4,700,077 0.56
98 Paroxetine 5,798 0.26 ,8,470 0.8
99 Ispaghula (Psylla Seeds) 4,057 0.26 488,259 0.06
00 Other Emollients and Protectives 06,687 0.24 259,864 0.0
Total 31,985,162 71.89% €556,884,352 66.54%
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Table 19.2  GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost 
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total 
 Atorvastatin 57,654,48 6.89 ,46,264 .2
2 Clinical Nutritional Products 7,965,622 4.54 55,92 .6
 Omeprazole 24,654,899 2.95 558,600 .26
4 Salmeterol and other drugs for obstructive airway diseases 24,62,96 2.94 46,645 0.78
5 Lansoprazole 2,494,04 2.57 570,084 .28
6 Esomeprazole 20,845,50 2.49 485,006 .09
7 Pravastatin 20,05,904 2.40 567,48 .28
8 Olanzapine 9,200,66 2.29 65,875 0.7
9 Clopidogrel 8,27,2 2.8 5,986 0.76
0 Diagnostic Products 2,798,482 .5 52,627 0.79
 Donepezil ,550,952 .8 96,824 0.22
2 Pantoprazole ,540,450 .8 8,644 0.76
 Amlodipine ,44,4 .6 67,5 .5
4 Alendronic acid 0,550,979 .26 07,228 0.69
5 Venlafaxine 0,52,47 .26 24,24 0.55
6 Ostomy Appliances 0,4,07 .24 97,72 0.22
7 Tiotropium Bromide 9,905,765 .8 200,54 0.45
8 Doxazosin 8,788,06 .05 280,405 0.6
9 Risperidone 8,775,596 .05 28,249 0.29
20 Pregabalin 8,586,066 .0 92,056 0.20
2 Ramipril 8,25,964 0.99 65,200 .8
22 Rosuvastatin 8,28,67 0.98 280,596 0.6
2 Salbutamol and other drugs for obstructive airway diseases 7,97,78 0.95 278,80 0.6
24 Perindopril 7,86,842 0.94 95,072 0.89
25 Escitalopram 7,492,600 0.90 245,787 0.55
26 Tolterodine 7,2,74 0.85 52,264 0.4
27 Formoterol and other drugs for obstructive airway diseases 7,05,42 0.85 2,996 0.27
28 Fentanyl 6,58,60 0.78 44,06 0.0
29 Bisoprolol 6,52,2 0.74 66,42 .49
0 Quetiapine 6,05,588 0.7 00,846 0.2
 Diclofenac (Systemic) 5,876,578 0.70 52,8 .5
2 Citalopram 5,80,529 0.69 255,90 0.58
 Risedronic acid 5,78,077 0.69 59,08 0.6
4 Amoxicillin and Enzyme Inhibitor 5,728,5 0.68 628,645 .4
5 Budesonide (Inhaled) 5,68,4 0.68 7,772 0.7
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Table 19.2  GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total 
6 Glucosamine 5,6,4 0.67 88,878 0.42
7 Calcium, Combinations 5,607,695 0.67 697,94 .57
8 Lamotrigine 5,052,588 0.60 88,50 0.20
9 Beclometasone (Inhaled) 4,885,85 0.58 258,209 0.58
40 Urinary Appliances 4,820,2 0.58 57,57 0.
4 Acetylsalicylic Acid-Aspirin (Antithrombotic) 4,752,276 0.57 2,05,894 5.8
42 Simvastatin 4,749,0 0.57 56,744 0.5
4 Sertraline 4,700,077 0.56 6,27 0.26
44 Rabeprazole 4,6,42 0.55 47,52 0.
45 Tamsulosin 4,498,764 0.54 57,09 0.5
46 Clarithromycin 4,4,442 0.52 22,8 0.52
47 Tramadol 4,96,078 0.50 298, 0.67
48 Losartan 4,45,67 0.50 5,257 0.4
49 Anastrozole 4,007,706 0.48 7,505 0.08
50 Gabapentin 4,00,452 0.48 78,928 0.8
5 Valsartan ,706,59 0.44 56,055 0.5
52 Montelukast ,65,655 0.44 94,26 0.2
5 Mirtazapine ,595,9 0.4 5,77 0.
54 Salbutamol (Inhaled) ,588,206 0.4 655,26 .47
55 Zopiclone ,58,84 0.4 402,22 0.90
56 Fluoxetine ,52,885 0.42 29,76 0.29
57 Lisinopril ,4,824 0.40 240,27 0.54
58 Nicotine (Replacement Therapy) ,282,024 0.9 0,607 0.2
59 Latanoprost ,28,928 0.9 6,875 0.
60 Paroxetine ,8,470 0.8 5,798 0.26
6 Isosorbide Mononitrate ,090,548 0.7 229,29 0.52
62 Levetiracetam ,067,828 0.7 2,520 0.07
6 Simvastatin, Combinations ,047,8 0.6 56,759 0.
64 Gliclazide 2,92,5 0.5 276,689 0.62
65 Fluticasone (Inhaled) 2,927,68 0.5 49,054 0.
66 Buprenorphine 2,820,624 0.4 44,072 0.0
67 Insulin Glargine, Long Acting 2,8,779 0.4 7,85 0.08
68 Codeine, Combs. excl. Psycholeptics 2,762,2 0. 7,29 0.7
69 Atenolol 2,748,954 0. 52,248 .20
70 Valsartan and Diuretics 2,585,05 0. 99,65 0.22
76
Table 19.2  GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total 
7 Mesalazine 2,52,95 0.0 40,477 0.09
72 Etoricoxib 2,54,027 0.0 77,58 0.7
7 Other Osmotically Acting Laxatives 2,47,466 0.0 54,05 0.5
74 Alendronic Acid Combinations 2,455,958 0.29 69,7 0.6
75 Ezetimibe 2,99,07 0.29 58,522 0.
76 Sildenafil 2,86,065 0.29 74,26 0.7
77 Ranitidine 2,297,52 0.27 99,48 0.22
78 Candesartan 2,267,476 0.27 96,89 0.2
79 Nimesulide 2,224,02 0.27 4,06 0.2
80 Needles/Syringes/Lancets 2,208,44 0.26 7,582 0.9
8 Insulin Aspart, Fast Acting 2,20,965 0.26 7,206 0.08
82 Aripiprazole 2,88,75 0.26 2,90 0.0
8 Memantine 2,8,784 0.26 22,24 0.05
84 Oxycodone 2,75,487 0.26 57,44 0.
85 Orlistat 2,2,24 0.25 2,97 0.07
86 Alfuzosin 2,04,429 0.25 70,074 0.6
87 Telmisartan 2,087,46 0.25 82,685 0.9
88 Rosiglitazone 2,056,946 0.25 7,96 0.08
89 Insulin Detemir, Long Acting 2,02,08 0.24 24,67 0.06
90 Paracetamol, Combs. excl. Psycholeptics ,975,845 0.24 27,56 0.74
9 Betahistine ,970,7 0.2 45,542 0.
92 Sevelamer ,880,55 0.22 0,727 0.02
9 Ondansetron ,85,68 0.22 2,57 0.0
94 Ciprofloxacin ,85,74 0.22 04,650 0.24
95 Duloxetine ,848,564 0.22 48,48 0.
96 Diltiazem ,805,799 0.22 25,67 0.28
97 Timolol, Combinations ,805,427 0.22 65,79 0.5
98 Tinzaparin ,799,25 0.2 7,974 0.02
99 Calcipotriol, Combinations ,777,500 0.2 9,590 0.04
00 Perindopril ,77,748 0.2 74,88 0.7
Total €658,001,885 78.63% 23,439,768 52.68%
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Table 19.3  DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
 Acetylsalicylic Acid-Aspirin (Antithrombotic) 642,60 4.78 ,9,284 0.47
2 Atorvastatin 60,7 4.48 25,67,98 8.54
 Levothyroxine Sodium 5,799 2.5 669,686 0.2
4 Salbutamol (Inhaled) 292,648 2.8 ,448,685 0.49
5 Amoxicillin and Enzyme Inhibitor 24,022 .8 2,276,07 0.77
6 Diclofenac (Systemic) 240,682 .79 2,806,62 0.95
7 Esomeprazole 29,055 .6 9,875,85 .5
8 Calcium, Combinations 22,278 .58 ,850,042 0.6
9 Bisoprolol 20,86 .57 2,04,607 0.68
0 Amlodipine 20,08 .5 ,52,7 .20
 Omeprazole 86,868 .9 8,999,785 .05
2 Rosuvastatin 78,47 . 5,47,4 .8
 Salmeterol and other drugs for obstructive airway diseases 7,9 .29 ,875,40 4.0
4 Atenolol 69,8 .26 902,04 0.
5 Pravastatin 68,07 .25 6,298,75 2.4
6 Lansoprazole 64,4 .22 6,77,79 2.29
7 Ramipril 6,89 .20 2,274,00 0.77
8 Prednisolone (Systemic) 5,224 .4 66,62 0.2
9 Clarithromycin 26,40 0.94 2,50,54 0.85
20 Venlafaxine 20,979 0.90 5,57,880 .87
2 Perindopril 20,4 0.90 2,58,85 0.85
22 Clinical Nutritional Products 2,4 0.84 4,7,44 .60
2 Escitalopram 07,62 0.80 ,55,892 .2
24 Bendroflumethiazide 02,60 0.77 60,826 0.05
25 Amoxicillin 00,562 0.75 548,754 0.9
26 Warfarin 00,007 0.75 282,92 0.09
27 Alprazolam 98,70 0.7 28,492 0.
28 Pantoprazole 98,255 0.7 ,59,76 .9
29 Clopidogrel 95,856 0.7 5,25,804 .80
0 Zopiclone 95,652 0.7 899,947 0.
 Beclometasone (Inhaled) 89,925 0.67 ,68,92 0.55
2 Zolpidem 87,646 0.65 549,7 0.9
 Formoterol and other drugs for obstructive airway diseases 85,27 0.6 5,007,265 .70
4 Paracetamol, Combs. excl. Psycholeptics 84,50 0.6 542,265 0.8
5 Alendronic Acid 84,59 0.6 2,946,7 .00
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Table 19.3  DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
6 Diazepam 82,699 0.62 54,97 0.02
7 Doxazosin 82,54 0.6 2,67,670 0.9
8 Codeine, Combs. excl. Psycholeptics 8,64 0.6 672,889 0.2
9 Montelukast 8,80 0.6 ,224,7 .09
40 Citalopram 80,675 0.60 2,009,425 0.68
4 Glucosamine 77,977 0.58 2,68,69 0.80
42 Tramadol 75,28 0.56 ,079,460 0.7
4 Folic Acid 72,47 0.54 74,66 0.0
44 Drospirenone and Estrogen 69,272 0.52 489,955 0.7
45 Lisinopril 67,904 0.5 972,99 0.
46 Paracetamol 67,09 0.50 97,08 0.0
47 Valsartan 66,40 0.49 ,588,60 0.54
48 Domperidone 6,57 0.48 06,20 0.0
49 Allopurinol 6,05 0.46 442,545 0.5
50 Mefenamic Acid 58,667 0.44 252,85 0.09
5 Alginic Acid 58,087 0.4 62,506 0.2
52 Diclofenac (Topical) 57,758 0.4 87,28 0.
5 Carbocisteine 57,686 0.4 286,686 0.0
54 Nimesulide 56,757 0.42 842,855 0.29
55 Losartan 56,26 0.42 ,572,5 0.5
56 Bendroflumethiazide and Potassium 56,2 0.42 7,5 0.04
57 Fluticasone (Nasal) 55,649 0.4 766,759 0.26
58 Nebivolol 54,264 0.40 820,5 0.28
59 Mometasone 5,5 0.40 846,428 0.29
60 Valsartan and Diuretics 5,044 0.9 ,9,875 0.47
6 Fluoxetine 52,5 0.9 ,604,79 0.54
62 Cetirizine 5,4 0.8 442,090 0.5
6 Cefaclor 50,99 0.8 44,52 0.4
64 Risedronic Acid 50,746 0.8 ,846,740 0.6
65 Estradiol 50,556 0.8 474,69 0.6
66 Simvastatin 50,280 0.7 ,65,900 0.55
67 Sertraline 49,29 0.7 2,9,56 0.7
68 Betamethasone (Topical) 47,977 0.6 24,446 0.08
69 Artificial Tears and other indifferent preparations 47,424 0.6 6,997 0.
70 Furosemide 47,070 0.5 6,492 0.02
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Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
7 Paroxetine 46,587 0.5 ,4,84 0.45
72 Methotrexate 44,559 0. 254,05 0.09
7 Simvastatin, Combinations 4,67 0.2 2,85,28 0.8
74 Amitriptyline 4,04 0.2 5,056 0.02
75 Flucloxacillin 4,859 0. 86,7 0.
76 Levonorgestrel and Estrogen (Fixed Comb. Contraceptives) 4,8 0. 69,774 0.06
77 Mesalazine 40,867 0.0 ,098,985 .05
78 Candesartan 40,679 0.0 96,956 0.
79 Telmisartan 40,479 0.0 ,028,6 0.5
80 Metoprolol 40,07 0.0 6,07 0.04
8 Lithium 9,99 0.0 9,57 0.0
82 Ezetimibe 9,894 0.0 ,645,67 0.56
8 Salbutamol and other drugs for obstructive airway diseases 9,452 0.29 689,54 0.2
84 Olanzapine 9,7 0.29 ,756,800 .27
85 Etoricoxib 9,220 0.29 ,28,522 0.4
86 Desloratadine 8,0 0.28 427,827 0.4
87 Bromazepam 7,442 0.28 20,2 0.07
88 Tadalafil 7,67 0.28 ,26,98 0.8
89 Cyproterone and Estrogen 7,077 0.28 25,824 0.08
90 Ibuprofen 6,26 0.27 56,62 0.05
9 Ciprofloxacin 6,080 0.27 74,68 0.24
92 Tiotropium Bromide 6,057 0.27 ,790,69 0.6
9 Fluticasone (Inhaled) 5,978 0.27 ,45,64 0.48
94 Olmesartan Medoxomil 5,44 0.26 768,66 0.26
95 Sildenafil 4,799 0.26 ,0,747 0.7
96 Rabeprazole 4,78 0.26 ,27,742 0.8
97 Fluconazole 4,46 0.26 58,89 0.20
98 Antifungal Combs. (Topical) ,778 0.25 7,287 0.04
99 Terbinafine (Systemic) ,50 0.25 ,68,06 0.57
00 Doxycycline ,502 0.25 2,74 0.
Total 9,548,284 71.10% €196,505,253 66.65%
Table 19.3  DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
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Table 19.4  DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total 
 Atorvastatin 25,67,98 8.54 60,7 4.48
2 Salmeterol and other drugs for obstructive airway diseases ,875,40 4.0 7,9 .29
 Esomeprazole 9,875,85 .5 29,055 .6
4 Omeprazole 8,999,785 .05 86,868 .9
5 Follitropin Beta 7,024,69 2.8 7,997 0.06
6 Lansoprazole 6,77,79 2.29 64,4 .22
7 Pravastatin 6,298,75 2.4 68,07 .25
8 Venlafaxine 5,57,880 .87 20,979 0.90
9 Rosuvastatin 5,47,4 .8 78,47 .
0 Clopidogrel 5,25,804 .8 95,856 0.7
 Formoterol and other drugs for obstructive airway diseases 5,007,265 .70 85,27 0.6
2 Clinical Nutritional Products 4,595,29 .56 09,58 0.82
 Olanzapine ,756,800 .27 9,7 0.29
4 Escitalopram ,55,892 .2 07,62 0.80
5 Amlodipine ,52,7 .20 20,08 .5
6 Pantoprazole ,59,76 .9 98,255 0.7
7 Montelukast ,224,7 .09 8,80 0.6
8 Mesalazine ,098,985 .05 40,867 0.0
9 Ostomy Appliances ,077,548 .04 2,0 0.24
20 Alendronic Acid 2,946,7 .00 84,59 0.6
2 Pregabalin 2,899,6 0.98 0,26 0.2
22 Diclofenac (Systemic) 2,806,62 0.95 240,682 .79
2 Doxazosin 2,67,670 0.9 82,54 0.6
24 Perindopril 2,58,85 0.85 20,4 0.90
25 Clarithromycin 2,50,54 0.85 26,40 0.94
26 Simvastatin, Combinations 2,85,28 0.8 4,67 0.2
27 Glucosamine 2,68,69 0.80 77,977 0.58
28 Amoxicillin and Enzyme Inhibitor 2,276,07 0.77 24,022 .8
29 Ramipril 2,274,00 0.77 6,89 .20
0 Calcipotriol, Combinations 2,5,49 0.7 20,998 0.6
 Sertraline 2,9,56 0.7 49,29 0.7
2 Bisoprolol 2,04,607 0.68 20,86 .57
 Citalopram 2,009,425 0.68 80,675 0.60
4 IUCD with Progestogen ,894,272 0.64 4,925 0.
5 Calcium, Combinations ,850,042 0.6 22,278 .58
8
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total 
6 Risedronic acid ,846,740 0.6 50,746 0.8
7 Tiotropium Bromide ,790,69 0.6 6,057 0.27
8 Terbinafine (Systemic) ,68,06 0.57 ,50 0.25
9 Ezetimibe ,645,67 0.56 9,894 0.0
40 Beclometasone (Inhaled) ,68,92 0.55 89,925 0.67
4 Simvastatin ,65,900 0.55 50,280 0.7
42 Fluoxetine ,604,79 0.54 52,5 0.9
4 Valsartan ,588,60 0.54 66,40 0.49
44 Losartan ,572,5 0.5 56,26 0.42
45 Anastrozole ,55,560 0.5 4,2 0.
46 Orlistat ,466,062 0.50 2,984 0.6
47 Salbutamol (Inhaled) ,448,685 0.49 292,648 2.8
48 Fluticasone (Inhaled) ,45,64 0.48 5,978 0.27
49 Valsartan and Diuretics ,9,875 0.47 5,044 0.9
50 Acetylsalicylic Acid-Aspirin (Antithrombotic) ,9,284 0.47 642,60 4.78
5 Varenicline ,78,267 0.47 25,98 0.9
52 Paroxetine ,4,84 0.45 46,587 0.5
5 Isotretinoin ,287,27 0.44 9,7 0.4
54 Etoricoxib ,28,522 0.4 9,220 0.29
55 Proguanil, Combinations ,268,749 0.4 7,464 0.
56 Sibutramine ,248,582 0.42 9,5 0.5
57 Fentanyl ,227,569 0.42 5,8 0.04
58 Quetiapine ,225,970 0.42 8,728 0.4
59 Sumatriptan ,2,02 0.4 2,555 0.6
60 Gabapentin ,22, 0.4 2,7 0.6
6 Tolterodine ,87,625 0.40 24,799 0.9
62 Budesonide (Inhaled) ,52,4 0.9 26,590 0.20
6 Lamotrigine ,44,78 0.9 25,0 0.9
64 Famciclovir ,2,27 0.8 8,40 0.06
65 Rabeprazole ,27,742 0.8 4,78 0.26
66 Tadalafil ,26,98 0.8 7,67 0.28
67 Sildenafil ,0,747 0.7 4,799 0.26
68 Tramadol ,079,460 0.7 75,28 0.56
69 Duloxetine ,070,2 0.6 26,620 0.20
70 Risperidone ,069,04 0.6 7,55 0.
Table 19.4  DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
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Table 19.4  DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total 
7 Telmisartan ,028,6 0.5 40,479 0.0
72 Azathioprine ,02,56 0.4 27,290 0.20
7 Urinary Appliances 977,058 0. 7,942 0.06
74 Lisinopril 972,99 0. 67,904 0.5
75 Rimonabant 962,88 0. ,975 0.09
76 Candesartan 96,956 0. 40,679 0.0
77 Atenolol 902,04 0. 69,8 .27
78 Zopiclone 899,947 0. 95,652 0.7
79 Progesterone 892,264 0.0 7,749 0.06
80 Alendronic Acid, Combinations 866,227 0.29 24,969 0.9
8 Tamsulosin 844,70 0.29 28,88 0.22
82 Nimesulide 842,855 0.29 56,757 0.42
8 Omega--triglycerides 8,729 0.28 28,605 0.2
84 Nebivolol 820,5 0.28 54,264 0.40
85 Losartan and Diuretics 805,6 0.27 27,654 0.2
86 Strontium Ranelate 797,966 0.27 6,860 0.
87 Zolmitriptan 788,09 0.27 8,22 0.4
88 Olmesartan Medoxomil 768,66 0.26 5,44 0.26
89 Fluticasone (Nasal) 766,759 0.26 55,649 0.4
90 Raloxifene 79,524 0.25 24,25 0.8
9 Calcipotriol 72,992 0.25 7,99 0.
92 Mirtazapine 70,896 0.25 26,570 0.20
9 Mometasone 724,284 0.25 4,48 0.
94 Perindopril and Diuretics 72,98 0.25 0,58 0.2
95 Ciprofloxacin 74,672 0.24 6,079 0.27
96 Ibandronic acid 72,644 0.24 2,80 0.6
97 Aciclovir (Systemic ) 696,452 0.24 7,608 0.06
98 Salbutamol and other drugs for obstructive airway diseases 689,54 0.2 9,452 0.29
99 Tacrolimus (Topical) 68,988 0.2 0,2 0.08
00 Tinzaparin 679,45 0.2 ,878 0.0
Total €235,297,100 79.81% 7,672,569 57.13%
8
Table 19.5  LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
 Diagnostic Products 25,994 0.7 ,46,00 5.94
2 Acetylsalicylic Acid-Aspirin (Antithrombotic) 20,407 8.56 442,502 0.62
 Metformin 8,69 7.72 672,568 0.94
4 Atorvastatin 46,950 6.25 6,078,58 8.46
5 Needles/Syringes/Lancets ,6 5.60 2,788,75 .88
6 Gliclazide 05,8 4.47 ,20,52 .67
7 Insulin Aspart, Fast Acting 72,447 .08 4,62,0 6.07
8 Ramipril 69,79 2.97 ,009,066 .40
9 Valproic Acid 46,58 .96 576,69 0.80
0 Carbamazepine 44,025 .87 94,9 0.55
 Insulin Glargine, Long Acting 42,976 .8 ,24,76 4.62
2 Perindopril 42,9 .80 965,7 .4
 Amlodipine 4,947 .78 776,746 .08
4 Lamotrigine 9,596 .68 2,757,666 .84
5 Pravastatin 0,826 . ,78,70 .64
6 Insulin Detemir, Long Acting 0,224 .28 2,487,650 .46
7 Clinical Nutritional Products 0,79 .28 ,50,66 4.9
8 Bisoprolol 26,900 .4 266,848 0.7
9 Rosuvastatin 26,062 . 789,429 .0
20 Atenolol 22,947 0.98 0,29 0.8
2 Phenytoin 22,6 0.96 46,0 0.20
22 Lisinopril 22,250 0.95 42,95 0.48
2 Doxazosin 2,78 0.92 764,24 .06
24 Rosiglitazone 9,54 0.82 ,07,085 .54
25 Metformin and Rosiglitazone 8,4 0.77 990,57 .8
26 Levetiracetam 7,245 0.7 ,727,09 2.40
27 Levothyroxine Sodium 5,5 0.66 6,72 0.05
28 Losartan 4,554 0.62 426,724 0.59
29 Insulin (Human), Comb. Intermediate/Fast Acting 4,2 0.60 745,478 .04
0 Clopidogrel ,955 0.59 776,50 .08
 Folic Acid ,062 0.56 4,295 0.02
2 Valsartan 2,49 0.5 07,495 0.4
 Glimepiride 2,094 0.52 2,808 0.7
4 Bendroflumethiazide ,477 0.49 7,59 0.0
5 Furosemide 0,87 0.46 5,56 0.02
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
6 Insulin (Human), Intermediate Acting 0,94 0.44 77,8 0.52
7 Simvastatin 0,07 0.4 29,892 0.46
8 Insulin Aspart, Comb. Intermediate/Fast Acting 9,65 0.4 672,22 0.9
9 Insulin Lispro, Fast Acting 9,8 0.40 54,556 0.76
40 Phenobarbital 9,24 0.9 27,54 0.04
4 Pancreatic Enzymes 7,8 0. 874,44 .22
42 Candesartan 7,777 0. 90,80 0.26
4 Nebivolol 7,62 0. 2,982 0.7
44 Topiramate 7,50 0.2 562,764 0.78
45 Warfarin 7,20 0. 20,42 0.0
46 Glucagon 6,95 0.29 20,847 0.28
47 Sildenafil 6,62 0.28 2,5 0.29
48 Levodopa and Decarboxylase Inhibitor 6,62 0.28 27,0 0.8
49 Telmisartan 6,575 0.28 7,570 0.24
50 Valsartan and Diuretics 6,476 0.28 74,649 0.24
5 Perindopril and Diuretics 6,085 0.26 54,892 0.22
52 Metoprolol 6,09 0.26 9,256 0.0
5 Omeprazole 5,728 0.24 259,06 0.6
54 Tadalafil 5,497 0.2 66,58 0.2
55 Urinary Appliances 5,29 0.2 609,4 0.85
56 Irbesartan 5,085 0.22 5,976 0.9
57 Lercanidipine 4,94 0.2 77,560 0.
58 Bendroflumethiazide and Potassium 4,95 0.2 0,44 0.0
59 Olmesartan Medoxomil 4,92 0.2 09,272 0.5
60 Insulin (Human), Fast Acting 4,897 0.2 7,84 0.9
6 Enalapril 4,84 0.2 76,874 0.
62 Gabapentin 4,800 0.20 2,090 0.45
6 Ezetimibe 4,765 0.20 96,765 0.27
64 Glibenclamide 4,76 0.20 8,406 0.05
65 Indapamide 4,75 0.20 7,670 0.05
66 Lisinopril and Diuretics 4,55 0.9 77,42 0.
67 Simvastatin, Combinations 4,52 0.9 25,06 0.5
68 Baclofen 4,406 0.9 67,266 0.09
69 Calcium, Combinations 4,296 0.8 8,050 0.05
70 Lansoprazole 4,257 0.8 76,05 0.24
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
7 Salbutamol (Inhaled) 4,088 0.7 ,44 0.05
72 Diltiazem 4,079 0.7 66,02 0.09
7 Quinapril ,8 0.6 54,98 0.08
74 Captopril ,762 0.6 77,764 0.
75 Evening Primrose Oil (Naudicelle) ,726 0.6 0,02 0.4
76 Vitamin A and D in Combination ,722 0.6 8,05 0.
77 Selegiline ,65 0.6 26,26 0.8
78 Oxcarbazepine ,547 0.5 5,249 0.6
79 Esomeprazole ,499 0.5 54,829 0.22
80 Pramipexole ,47 0.5 608,86 0.85
8 Isosorbide Mononitrate ,455 0.5 46,87 0.06
82 Omega--Triglycerides ,84 0.4 96,489 0.
8 Acetylsalicylic Acid-Aspirin (Anti-inflammatory) ,6 0.4 4,74 0.0
84 Fenofibrate ,8 0.4 72,69 0.0
85 Nifedipine ,27 0.4 50,58 0.07
86 Amoxicillin and Enzyme Inhibitor ,24 0.4 42,0 0.06
87 Pregabalin ,27 0.4 26,440 0.45
88 Rimonabant ,0 0. 250,2 0.5
89 Atenolol and other Diuretics ,066 0. 28,08 0.04
90 Losartan and Diuretics ,04 0. 94,866 0.
9 Diazepam 2,8 0.2 9,526 0.0
92 Paracetamol 2,85 0.2 9,960 0.0
9 Clobazam 2,804 0.2 6,8 0.02
94 Clonazepam 2,79 0.2 7,245 0.05
95 Allopurinol 2,786 0.2 2,929 0.0
96 Tolterodine 2,59 0. 27,8 0.8
97 Furosemide and Potassium-Sparing Agents 2,59 0. ,078 0.02
98 Dressings 2,547 0. 84,58 0.2
99 Amitriptyline 2,456 0.0 ,626 0.0
00 Glyceryl Trinitrate 2,447 0.0 8,54 0.0
Total 2,140,479 90.98% €63,080,159 87.74%
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Table 19.6  LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
 Diagnostic Products ,46,00 5.94 25,994 0.7
2 Atorvastatin 6,078,58 8.46 46,950 6.25
 Insulin Aspart, Fast Acting 4,62,0 6.07 72,447 .08
4 Clinical Nutritional Products ,50,66 4.9 0,79 .28
5 Insulin Glargine, Long Acting ,24,76 4.62 42,976 .8
6 Needles/Syringes/Lancets 2,788,75 .88 ,6 5.60
7 Lamotrigine 2,757,666 .84 9,596 .68
8 Insulin Detemir, Long Acting 2,487,650 .46 0,224 .28
9 Levetiracetam ,727,09 2.40 7,245 0.7
0 Gliclazide ,20,52 .67 05,8 4.47
 Pravastatin ,78,70 .64 0,826 .
2 Rosiglitazone ,07,085 .54 9,54 0.82
 Ramipril ,009,066 .40 69,79 2.97
4 Metformin and Rosiglitazone 990,57 .8 8,4 0.77
5 Perindopril 965,7 .4 42,9 .80
6 Apomorphine 95,988 .0 ,0 0.05
7 Pancreatic Enzymes 874,44 .22 7,8 0.
8 Rosuvastatin 789,429 .0 26,062 .
9 Amlodipine 776,746 .08 4,947 .78
20 Clopidogrel 776,50 .08 ,955 0.59
2 Doxazosin 764,24 .06 2,78 0.92
22 Insulin (Human), Comb. Intermediate/Fast Acting 745,478 .04 4,2 0.60
2 Metformin 672,568 0.94 8,69 7.72
24 Insulin Aspart, Comb. Intermediate/Fast Acting 672,22 0.9 9,65 0.4
25 Urinary Appliances 609,4 0.85 5,29 0.2
26 Pramipexole 608,86 0.85 ,47 0.5
27 Valproic Acid 576,68 0.80 46,58 .96
28 Topiramate 562,764 0.78 7,50 0.2
29 Insulin Lispro, Fast Acting 54,556 0.76 9,8 0.40
0 Acetylsalicylic Acid-Aspirin (Antithrombotic) 442,502 0.62 20,407 8.56
 Losartan 426,724 0.59 4,554 0.62
2 Carbamazepine 94,9 0.55 44,025 .87
 Insulin (Human), Intermediate Acting 77,8 0.52 0,94 0.44
4 Lisinopril 42,95 0.48 22,250 0.95
5 Nutritional/Ancillary Devices 40,956 0.47 ,90 0.08
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Table 19.6  LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
6 Colistin (Parenteral) 2,00 0.46 2,27 0.0
7 Simvastatin 29,892 0.46 0,07 0.4
8 Pregabalin 26,440 0.45 ,27 0.4
9 Gabapentin 2,090 0.45 4,800 0.20
40 Valsartan 07,495 0.4 2,49 0.5
4 Metamfetamine 05,084 0.42 2,78 0.0
42 Ropinirole 285,45 0.40 2,05 0.09
4 Bisoprolol 266,848 0.7 26,900 .4
44 Omeprazole 259,06 0.6 5,728 0.24
45 Simvastatin, Combinations 25,06 0.5 4,52 0.9
46 Rimonabant 250,2 0.5 ,0 0.
47 Sildenafil 2,5 0.29 6,62 0.28
48 Zonisamide 202,5 0.28 ,877 0.08
49 Glucagon 20,847 0.28 6,95 0.29
50 Ezetimibe 96,765 0.27 4,765 0.20
5 Rotigotine 96,78 0.27 ,052 0.04
52 Candesartan 90,80 0.26 7,777 0.
5 Meropenem 84,966 0.26 5 0.00
54 Alimentary Tract/Metabolism, Various Products 84,642 0.26 ,557 0.07
55 Lansoprazole 76,05 0.24 4,257 0.8
56 Valsartan and Diuretics 74,649 0.24 6,476 0.28
57 Telmisartan 7,570 0.24 6,575 0.28
58 Tadalafil 66,582 0.2 5,497 0.2
59 Perindopril and Diuretics 54,892 0.22 6,085 0.26
60 Esomeprazole 54,829 0.22 ,499 0.5
6 Azithromycin 5,09 0.2 2,96 0.09
62 Phenytoin 46,0 0.20 22,6 0.96
6 Tizanidine 40,990 0.20 ,488 0.06
64 Insulin (Human), Fast Acting 7,84 0.9 4,897 0.2
65 Irbesartan 5,976 0.9 5,085 0.22
66 Orlistat ,954 0.9 2,026 0.09
67 Atenolol 0,29 0.8 22,947 0.98
68 Tolterodine 27,8 0.8 2,59 0.
69 Levodopa and Decarboxylase Inhibitor 27,0 0.8 6,62 0.28
70 Desmopressin 26,85 0.8 ,926 0.08
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Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
7 Selegiline 26,26 0.8 ,65 0.5
72 Nebivolol 2,982 0.7 7,62 0.2
7 Glimepiride 2,808 0.7 2,094 0.5
74 Salmeterol and other drugs for obstructive airway diseases 8,695 0.7 ,552 0.07
75 Oxcarbazepine 5,248 0.6 ,547 0.5
76 Ostomy Appliances 0,04 0.5 ,25 0.05
77 Olmesartan Medoxomil 09,272 0.5 4,92 0.2
78 Modafinil 04,900 0.5 627 0.0
79 Evening Primrose Oil (Naudicelle) 0,02 0.4 ,726 0.6
80 Omega--Triglycerides 96,489 0. ,84 0.4
8 Insulin Glulisine, Fast Acting 95,5 0. ,78 0.07
82 Losartan and Diuretics 94,866 0. ,04 0.
8 Rasagiline 90,06 0. 80 0.0
84 Dressings 84,58 0.2 2,547 0.
85 Vitamin A and D in Combination 8,05 0. ,722 0.6
86 Pioglitazone 78,426 0. ,424 0.06
87 Captopril 77,764 0. ,762 0.6
88 Lercanidipine 77,560 0. 4,94 0.2
89 Lisinopril and Diuretics 77,42 0. 4,55 0.9
90 Enalapril 76,874 0. 4,84 0.2
9 Pantoprazole 75,696 0. 2,27 0.0
92 Ciprofloxacin 74,809 0.0 ,608 0.07
9 Insulin Combinations, Intermediate/Fast Acting 7, 0.0 ,96 0.05
94 Fenofibrate 72,69 0.0 ,8 0.4
95 Levocarnitine 70,79 0.0 67 0.0
96 Baclofen 67,266 0.09 4,406 0.9
97 Melatonin 67,69 0.09 656 0.0
98 Risperidone 66,4 0.09 ,50 0.05
99 Diltiazem 66,02 0.09 4,079 0.7
00 Entacapone 64,4 0.09 670 0.0
Total €67,023,986 93.23% 2,039,460 86.67%
Table 19.6  LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
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Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
 Etanercept 22,8 8.09 25,985,5 .08
2 Bicalutamide 22,204 7.87 4,02,7 2.07
 Tacrolimus 20,08 7. 5,855,6 2.95
4 Ciclosporin 9,507 6.9 2,467,94 .24
5 Adalimumab 9,29 6.8 25,0,540 2.64
6 Mycophenolic Acid 8,790 6.66 4,2,9 2.2
7 Erythropoietin 6,529 5.86 2,80,6 6.45
8 Darbepoetin alfa 5,487 5.49 7,692,454 .87
9 Interferon beta-a 2,544 4.44 4,7,808 7.42
0 Triptorelin ,055 .92 ,745,240 .89
 Leuprorelin 0,840 .84 5,40,22 2.59
2 Interferon beta-b 8,27 2.88 9,508,52 4.79
 Pegfilgrastim 7,900 2.80 0,8,988 5.09
4 Somatropin 7,48 2.65 5,279,824 2.66
5 Teriparatide 7,96 2.62 ,92,985 .7
6 Goserelin 6,082 2.5 2,070, .04
7 Capecitabine 5,26 .85 ,20,854 0.66
8 Filgrastim 4,72 .55 2,956,048 .49
9 Dornase alfa ,849 .6 ,68,5 .85
20 Cinacalcet ,59 .25 ,78,5 0.59
2 Glatiramer Acetate ,506 .24 4,264,552 2.5
22 Imatinib 2,40 0.86 6,858,292 .45
2 Octreotide 2,026 0.72 2,242,560 .
24 Riluzole ,864 0.66 609,89 0.
25 Sildenafil ,746 0.62 ,26,568 0.57
26 Ribavirin ,588 0.56 ,29,0 0.57
27 Temozolomide ,542 0.55 ,498,507 0.75
28 Peginterferon alfa-2a ,527 0.54 ,54, 0.77
29 Tobramycin ,50 0.5 4,285,465 2.6
0 Bosentan ,294 0.46 4,00,085 2.0
 Palivizumab ,287 0.46 ,52,448 0.68
2 Fulvestrant ,245 0.44 647,54 0.
 Ibandronic Acid ,98 0.42 47,76 0.7
4 Linezolid ,5 0.40 ,76,070 0.89
5 Sirolimus ,2 0.40 4,6 0.7
6 Interferon alfa-2b ,007 0.6 608,258 0.
7 Erlotinib 990 0.5 2,249,762 .
8 Lamivudine 984 0.5 95,947 0.05
Table 19.7  HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 19.7  HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
9 Peginterferon alfa-2b 955 0.4 487,6 0.24
40 Nafarelin 90 0.2 45,546 0.07
4 Voriconazole 84 0.0 ,974,55 0.99
42 Anagrelide 822 0.29 46,42 0.22
4 Clodronic Acid 69 0.25 89,58 0.0
44 Efalizumab 668 0.24 770,59 0.9
45 Valganciclovir 64 0.2 ,00,58 0.5
46 Lanreotide 625 0.22 665,25 0.
47 Adefovir Dipivoxil 600 0.2 0,46 0.7
48 Flutamide 57 0.20 79,040 0.04
49 Sunitinib 508 0.8 2,9,95 .08
50 Interferon alfa-2a 47 0.5 69,80 0.09
5 Etoposide 46 0.5 44,778 0.02
52 Deferasirox 79 0. 77,28 0.9
5 Anakinra 265 0.09 27,96 0.4
54 Vancomycin 200 0.07 4,0 0.02
55 Sorafenib 9 0.07 76,985 0.8
56 Fludarabine 86 0.07 6,00 0.08
57 Risedronic Acid 7 0.06 7,5 0.02
58 Pegvisomant 57 0.06 545,205 0.27
59 Lenograstim 8 0.05 2,47 0.06
60 Idarubicin 26 0.04 50,594 0.0
6 Bexarotene 5 0.04 278,844 0.4
62 Buserelin 4 0.04 25,4 0.0
6 Sitaxentan 75 0.0 90,54 0.0
64 Dasatinib 7 0.0 286,65 0.4
65 Aldesleukin 72 0.0 70,988 0.04
66 Iloprost 65 0.02 50,65 0.8
67 Entecavir 57 0.02 8,44 0.02
68 Hydroxybutyric Acid 2 0.0 24,408 0.0
69 Epoprostenol 5 0.0 79,697 0.04
70 Lenalidomide 4 0.00 00,875 0.05
7 Becaplermin  0.00 7,82 0.00
72 Parathyroid hormone 7 0.00 2,907 0.00
7 Interferon gamma 4 0.00 2,6 0.00
74 Posaconazole 4 0.00 4,279 0.0
Total 282,273 100.00% €198,628,605 100.00%
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
9
Table 19.8  HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost 
Name Ingredient Cost €  % of Scheme Total Prescribing Frequency  % of Scheme Total 
 Etanercept 25,985,5 .08 22,8 8.09
2 Adalimumab 25,0,540 2.64 9,29 6.8
 Interferon beta-a 4,7,808 7.42 2,544 4.44
4 Erythropoietin 2,80,6 6.45 6,529 5.86
5 Pegfilgrastim 0,8,988 5.09 7,900 2.80
6 Interferon beta-b 9,508,52 4.79 8,27 2.88
7 Darbepoetin alfa 7,692,454 .87 5,487 5.49
8 Imatinib 6,858,292 .45 2,40 0.86
9 Tacrolimus 5,855,6 2.95 20,08 7.
0 Somatropin 5,279,824 2.66 7,48 2.65
 Leuprorelin 5,40,22 2.59 0,840 .84
2 Tobramycin 4,285,465 2.6 ,50 0.5
 Glatiramer Acetate 4,264,552 2.5 ,506 .24
4 Mycophenolic Acid 4,2,9 2.2 8,790 6.66
5 Bicalutamide 4,02,7 2.07 22,204 7.87
6 Bosentan 4,00,085 2.0 ,294 0.46
7 Triptorelin ,745,240 .89 ,055 .92
8 Dornase alfa ,68,5 .85 ,849 .6
9 Teriparatide ,92,985 .7 7,96 2.62
20 Filgrastim 2,956,048 .49 4,72 .55
2 Ciclosporin 2,467,94 .24 9,507 6.9
22 Erlotinib 2,249,762 . 990 0.5
2 Octreotide 2,242,560 . 2,026 0.72
24 Sunitinib 2,9,95 .08 508 0.8
25 Goserelin 2,070, .04 6,082 2.5
26 Voriconazole ,974,55 0.99 84 0.0
27 Linezolid ,76,070 0.89 ,5 0.40
28 Peginterferon alfa-2a ,54, 0.77 ,527 0.54
29 Temozolomide ,498,507 0.75 ,542 0.55
0 Palivizumab ,52,448 0.68 ,287 0.46
 Capecitabine ,20,854 0.66 5,26 .85
2 Cinacalcet ,78,5 0.59 ,59 .25
 Ribavirin ,29,0 0.57 ,588 0.56
4 Sildenafil ,26,568 0.57 ,746 0.62
5 Valganciclovir ,00,58 0.5 64 0.2
6 Efalizumab 770,59 0.9 668 0.24
7 Sorafenib 76,985 0.8 9 0.07
8 Lanreotide 665,25 0. 625 0.22
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Name Ingredient Cost €  % of Scheme Total Prescribing Frequency  % of Scheme Total 
9 Fulvestrant 647,54 0. ,245 0.44
40 Riluzole 609,89 0. ,864 0.66
4 Interferon alfa-2b 608,258 0. ,007 0.6
42 Pegvisomant 545,205 0.27 57 0.06
4 Peginterferon alfa-2b 487,6 0.24 955 0.4
44 Anagrelide 46,42 0.22 822 0.29
45 Deferasirox 77,28 0.9 79 0.
46 Iloprost 50,65 0.8 65 0.02
47 Ibandronic Acid 47,76 0.7 ,98 0.42
48 Sirolimus 4,6 0.7 ,2 0.40
49 Adefovir Dipivoxil 0,46 0.7 600 0.2
50 Dasatinib 286,65 0.4 7 0.0
5 Bexarotene 278,844 0.4 5 0.04
52 Anakinra 27,96 0.4 265 0.09
5 Sitaxentan 90,54 0.0 75 0.0
54 Clodronic Acid 89,58 0.0 69 0.25
55 Interferon alfa-2a 69,80 0.09 47 0.5
56 Fludarabine 6,00 0.08 86 0.07
57 Nafarelin 45,546 0.07 90 0.2
58 Lenograstim 2,47 0.06 8 0.05
59 Lenalidomide 00,875 0.05 4 0.00
60 Lamivudine 95,947 0.05 984 0.5
6 Epoprostenol 79,697 0.04 5 0.0
62 Flutamide 79,040 0.04 57 0.20
6 Aldesleukin 70,988 0.04 72 0.0
64 Idarubicin 50,594 0.0 26 0.04
65 Etoposide 44,778 0.02 46 0.5
66 Vancomycin 4,0 0.02 200 0.07
67 Entecavir 8,44 0.02 57 0.02
68 Risedronic Acid 7,5 0.02 7 0.06
69 Buserelin 25,4 0.0 4 0.04
70 Hydroxybutyric Acid 24,408 0.0 2 0.0
7 Posaconazole 4,279 0.0 4 0.00
72 Becaplermin 7,82 0.00  0.00
7 Parathyroid hormone 2,907 0.00 7 0.00
74 Interferon gamma 2,6 0.00 4 0.00
Total €198,628,605 100.00% 282,273 100.00%
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
Table 19.8  HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost continued
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Table 20  GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 5,749,910 12.92 133,810,644 16.00
A01 Stomatological Preparations 94,0 0.2 47,94 0.04
A02 Drugs for Acid Related Disorders 2,546,94 5.7 87,7,52 0.48
A03 Drugs for Functional Gastrointestinal Disorders 44,65 0.9 2,09,229 0.28
A04 Anti-emetics and Anti-nauseants 20,562 0.05 2,500,25 0.0
A05 Bile and Liver Therapy ,558 0.0 587,827 0.07
A06 Laxatives 602,067 .5 5,46,207 0.62
A07 Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 22,796 0.50 ,95,708 0.47
A08 Anti-obesity Preparations, excl. Diet Products 64,065 0.4 4,29,560 0.5
A09 Digestives, incl. Enzymes 0,860 0.02 ,0,425 0.2
A10 Drugs used in Diabetes 949,06 2. 9,0,97 2.
A11 Vitamins 62,87 0.4 724,49 0.09
A12 Mineral Supplements 752,46 .69 5,966,08 0.7
A14 Anabolic Agents for Systemic Use 4 0.00 6 0.00
B Blood and Blood Forming Organs 3,950,005 8.88 29,156,201 3.48
B01 Antithrombotic Agents ,298,89 7.4 27,626,94 .0
B02 Antihemorrhagics ,08 0.0 7,70 0.02
B03 Anti-anemic Preparations 640,06 .44 ,9,506 0.6
B05 Blood Substitutes and Perfusion Solutions 5 0.00 84 0.00
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Table 20  GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
C Cardiovascular System 11,087,484 24.92 201,873,833 24.12
C01 Cardiac Therapy 86,057 .88 8,9,208 0.98
C02 Antihypertensives 06,274 0.69 8,975,86 .07
C03 Diuretics ,765,764 .97 5,06,85 0.60
C04 Peripheral Vasodilators 56,400 0. 909,44 0.
C05 Vasoprotectives 07,44 0.24 669,787 0.08
C07 Beta Blocking Agents ,742,696 .92 ,650,20 .6
C08 Calcium Channel Blockers ,0,59 2.47 7,67,694 2.05
C09 Agents Acting on the Renin-Angiotensin System 2,50,87 5.62 48,4,90 5.77
C10 Lipid Modifying Agents 2,668,5 6.00 98,957,92 .8
D Dermatologicals 1,204,004 2.71 11,439,920 1.37
D01 Antifungals for Dermatological Use 280,766 0.6 ,92,95 0.8
D02 Emollients and Protectives 55,08 0.5 4,077 0.05
D03 Preparations for Treatment of Wounds and Ulcers ,240 0.00 42,665 0.0
D05 Antipsoriatics 55,94 0.2 2,82,60 0.4
D06 Antibiotics and Chemotherapeutics for Dermatological Use ,600 0.0 ,7,84 0.
D07 Corticosteroids, Dermatological Preparations 527,57 .9 2,592,665 0.
D10 Anti-Acne Preparations 8,48 0.09 647,46 0.08
D11 Other Dermatological Preparations ,49 0.0 592,600 0.07
G Genito Urinary System and Sex Hormones 1,535,171 3.45 31,883,590 3.81
G01 Gynecological Anti-infectives and Antiseptics 22,8 0.05 24,868 0.0
G02 Other Gynecologicals 6,80 0.04 ,297,406 0.6
G03 Sex Hormones and Modulators of the Genital System 84,47 .8 6,98,99 0.8
G04 Urologicals 68,92 .5 2,52,7 2.8
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Table 20  GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones 
and Insulins 
1,364,579 3.07 4,544,634 0.54
H01 Pituitary, Hypothalamic Hormones and Analogues ,577 0.0 75,28 0.09
H02 Corticosteroids for Systemic Use 506,0 .4 ,9,276 0.2
H03 Thyroid Therapy 89,458 .89 ,689,668 0.20
H04 Pancreatic Hormones 5,20 0.0 62,686 0.02
H05 Calcium Homeostasis 2 0.00 9,72 0.00
J Anti-infectives for Systemic Use 2,347,777 5.28 26,500,598 3.17
J01 Antibacterials for Systemic Use 2,255,2 5.07 22,442,98 2.68
J02 Antimycotics for Systemic Use 6,658 0.4 ,22,708 0.6
J04 Antimycobacterials ,005 0.0 76,95 0.0
J05 Antivirals for Systemic Use 25,952 0.06 2,659,097 0.2
J07 Vaccines 9 0.00 400 0.00
L Antineoplastic and Immunomodulating Agents 214,396 0.48 8,290,829 0.99
L01 Antineoplastic Agents 6,52 0.04 45,646 0.04
L02 Endocrine Therapy 85,605 0.9 6,0,795 0.75
L04 Immunosuppressive Agents 2,49 0.25 ,64,88 0.20
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Table 20  GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 2,873,822 6.46 50,918,786 6.08
M01 Anti-inflammatory and Antirheumatic Products ,576,099 .54 22,584,856 2.70
M02 Topical Products for Joint and Muscular Pain 468,429 .05 ,658,287 0.44
M03 Muscle Relaxants 8,060 0.09 ,257,56 0.5
M04 Antigout Preparations 65,602 0.7 ,049,459 0.2
M05 Drugs for treatment of Bone Diseases 625,092 .4 22,289,09 2.66
M09 Other Drugs for Disorders of the Musculo-Skeletal System 540 0.00 79,989 0.0
N Nervous System 8,302,934 18.66 174,134,049 20.81
N01 Anesthetics 2,48 0.0 4,7 0.00
N02 Analgesics ,962,40 4.4 2,962,4 2.86
N03 Anti-epileptics 726,92 .6 25,470,48 .04
N04 Anti-Parkinson Drugs 207,72 0.46 4,967,7 0.60
N05 Psycholeptics ,2,26 7.27 49,78,8 5.94
N06 Psychoanaleptics ,85,777 4.6 62,,98 7.45
N07 Other Nervous System Drugs 9,025 0.72 7,669,4 0.92
P Antiparasitic Products, Insecticides and Repellents 67,905 0.15 516,122 0.06
P01 Antiprotozoals 47,09 0.0 80,99 0.05
P02 Anthelmintics 7,859 0.02 2,969 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 2,97 0.0 ,754 0.0
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Table 20  GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
R  Respiratory System 3,239,879 7.28 80,591,553 9.63
R01  Nasal Preparations 22,7 0.52 2,67,242 0.2
R02  Throat Preparations 9,564 0.02 2,778 0.00
R03  Drugs for Obstructive Airway Diseases 2,86,606 5.7 7,822,405 8.82
R05  Cough and Cold Preparations 26,26 0.7 ,566,29 0.9
R06  Antihistamines for Systemic Use 284,52 0.64 2,49,47 0.0
R07  Other Respiratory System Products 74 0.00 8,64 0.00
S  Sensory Organs 1,100,178 2.47 11,073,616 1.32
S01  Ophthalmologicals ,0,247 2.27 0,766,667 .28
S02  Otologicals 8,70 0.09 74,647 0.02
S03  Ophthalmological and Otological Preparations 50,228 0. 2,02 0.02
V  Various 1,453,892 3.27 72,146,801 8.62
V03  Other Therapeutic Products ,59 0.0 2,02,2 0.27
V04  Diagnostic Products 52,627 0.79 2,798,482 .5
V06  Clinical Nutritional Products 55,92 .6 7,965,622 4.54
V07  All Other Non-Therapeutic Products 572,4 .29 9,080,464 2.28
        Needles/Syringes/Lancets 7,582 0.9 2,208,44 0.26
        Ostomy Requisites 97,72 0.22 0,4,07 .24
        Urinary Requisites 57,57 0. 4,820,2 0.58
        Dressings 25,959 0.06 ,,0 0.
        Miscellaneous 27,544 0.49 597,785 0.07
 TOTAL 44,491,936 100.00% €836,881,176 100.00%
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Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A  Alimentary Tract and Metabolism 1,492,265 11.11 44,850,571 15.21
A01  Stomatological Preparations 27,460 0.2 0,006 0.04
A02  Drugs for Acid Related Disorders 804,770 5.99 ,45,62 0.67
A03  Drugs for Functional Gastrointestinal Disorders 22,5 0.9 76,026 0.26
A04  Anti-emetics and Antinauseants 9,857 0.07 926,057 0.
A05  Bile and Liver Therapy 6,98 0.05 86,056 0.
A06  Laxatives 7,48 0.5 62,87 0.2
A07  Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 09,0 0.8 ,970,87 .5
A08  Anti-obesity Preparations, excl. Diet Products 5,492 0.40 ,677,528 .25
A09  Digestives, incl. Enzymes ,775 0.0 94,407 0.0
A10  Drugs used in Diabetes 45,267 0.4 628,069 0.2
A11  Vitamins 6,40 0.2 278,007 0.09
A12  Mineral Supplements 224,7 .67 ,945,0 0.66
A14  Anabolic Agents for Systemic Use 9 0.00 5 0.00
A16  Other Alimentary Tract/Metabolism Products 22 0.00 ,656 0.00
B  Blood and Blood Forming Organs 967,160 7.20 8,352,299 2.83
B01  Antithrombotic Agents 849,877 6. 7,998,98 2.7
B02  Antihemorrhagics 5,46 0.04 66,654 0.02
B03  Anti-anemic Preparations 2,2 0.8 285,99 0.0
B05  Blood Substitutes and Perfusion Solutions 4 0.00 74 0.00
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by an individual or family.
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ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme Total Ingredient Cost € % of Scheme Total
C Cardiovascular System 3,442,214 25.63 78,487,576 26.62
C01  Cardiac Therapy 0,50 0.77 ,52,064 0.52
C02  Antihypertensives 86,49 0.64 2,729,52 0.9
C03  Diuretics 285,765 2. ,069,77 0.6
C04  Peripheral Vasodilators ,689 0.0 66,82 0.02
C05  Vasoprotectives 45,628 0.4 266,565 0.09
C07  Beta Blocking Agents 568,646 4.2 4,80,470 .6
C08  Calcium Channel Blockers 08,52 2.0 5,046,704 .7
C09  Agents Acting on the Renin-Angiotensin System 898,75 6.69 8,897,56 6.4
C10  Lipid Modifying Agents ,4,98 8.50 44,076,746 4.95
D  Dermatologicals 514,877 3.84 10,400,890 3.53
D01  Antifungals for Dermatological Use ,46 0.99 2,69,702 0.89
D02  Emollients and Protectives 0,40 0.2 00,906 0.0
D03  Preparations for Treatment of Wounds and Ulcers 899 0.0 90,050 0.0
D04  Antipruritics including Antihistamines, Anesthetics, etc. ,089 0.0 68,780 0.02
D05  Antipsoriatics 47,75 0.6 ,,45 .
D06  Antibiotics and Chemotherapeutics for Dermatological Use 46,5 0.5 640,052 0.22
D07  Corticosteroids Dermatological Preparations 89,45 .4 ,055,647 0.6
D08  Antiseptics and Disinfectants 5 0.00 7 0.00
D10  Anti-Acne Preparations 52,78 0.9 ,7,7 0.58
D11  Other Dermatological Preparations 2,698 0.09 779,254 0.27
G  Genito Urinary System and Sex Hormones 655,843 4.88 21,420,548 7.27
G01  Gynecological Anti-infectives and Antiseptics 8,40 0.06 50,0 0.02
G02  Other Gynecologicals 20,40 0.5 2,052,294 0.70
G03  Sex Hormones and Modulators of the Genital System 44,497 .29 2,857,68 4.6
G04  Urologicals 85,5 .8 6,460,270 2.9
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by an individual or family.
Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
00
Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient 
Cost €
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 516,951 3.85 2,108,590 0.71
H01 Pituitary, Hypothalamic Hormones and Analogues 8,56 0.06 68,602 0.2
H02 Corticosteroids for Systemic Use 79,729 .4 77,05 0.26
H03 Thyroid Therapy 28,87 2.45 70,946 0.24
H04 Pancreatic Hormones 7 0.00 5,07 0.00
H05 Calcium Homeostasis 78 0.00 2,972 0.00
J Anti-infectives for Systemic Use 901,424 6.71 13,163,763 4.47
J01 Antibacterials for Systemic Use 86,447 6.2 9,720,92 .0
J02 Antimycotics for Systemic Use 40,44 0.0 962,57 0.
J04 Antimycobacterials ,944 0.0 69,750 0.02
J05 Antivirals for Systemic Use 22,670 0.7 2,40,574 0.82
J07 Vaccines 9 0.00 6 0.00
L Antineoplastic and Immunomodulating Agents 108,887 0.81 4,254,662 1.44
L01 Antineoplastic Agents 6,90 0.05 28,956 0.08
L02 Endocrine Therapy 29,67 0.22 2,544,564 0.86
L04 Immunosuppressive Agents 7,0 0.54 ,47,42 0.50
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by an individual or family.
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Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 981,792 7.30 18,344,866 6.22
M01 Anti-inflammatory and Antirheumatic Products 64,94 4.57 9,50,945 .22
M02 Topical Products for Joint and Muscular Pain 95,895 0.7 770,660 0.26
M03 Muscle Relaxants 4,706 0.04 40,260 0.05
M04 Antigout Preparations 62,45 0.46 458,86 0.6
M05 Drugs for treatment of Bone Diseases 204,90 .52 7,400,774 2.5
M09 Other Drugs for Disorders of the Musculo-Skeletal System 462 0.00 72,84 0.02
N Nervous System 1,969,674 14.67 45,940,718 15.58
N01 Anesthetics ,06 0.0 25,48 0.08
N02 Analgesics 49,067 .2 6,90,880 2.5
N03 Anti-epileptics 8,859 .0 6,26,7 2.2
N04 Anti-Parkinson Drugs 8,572 0.4 597,47 0.20
N05 Psycholeptics 69,659 5.7 9,602,580 .26
N06 Psychoanaleptics 64,85 4.7 20,220,9 6.86
N07 Other Nervous System Drugs 6,58 0.47 2,09,00 0.7
P Antiparasitic Products, Insecticides and Repellents 47,969 0.36 1,427,532 0.49
P01 Antiprotozoals 45, 0.4 ,405,765 0.48
P02 Anthelmintics ,205 0.0 5, 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents ,45 0.0 6,454 0.0
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by an individual or family.
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Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
R Respiratory System 1,335,221 9.94 33,368,619 11.32
R01 Nasal Preparations 6,744 .22 2,20,224 0.72
R02 Throat Preparations ,509 0.0 7,87 0.00
R03 Drugs for Obstructive Airway Diseases 954,072 7.0 29,462,482 9.99
R05 Cough and Cold Preparations 67,2 0.50 8,785 0.2
R06 Antihistamines for Systemic Use 46,605 .09 ,48,09 0.49
R07 Other Respiratory System Products 58 0.00 ,272 0.00
S Sensory Organs 267,908 2.00 2,513,169 0.85
S01 Ophthalmologicals 22,654 .65 2,65,85 0.80
S02 Otologicals 5,900 0.2 75,75 0.0
S03 Ophthalmological and Otological Preparations 0,54 0.2 72,4 0.02
V Various 227,760 1.70 10,192,720 3.46
V03 Other Therapeutic Products 2,76 0.02 5,007 0.2
V04 Diagnostic Products 6,6 0.2 579,65 0.20
V06 Clinical Nutritional Products 2,4 0.84 4,7,45 .60
V07 All Other Non-Therapeutic Products 97,27 0.72 4,546,75 .54
       Ostomy Appliances 2,454 0.24 ,087,779 .05
       Needles/Syringes/Lancets 20,904 0.5 0,25 0.0
       Dressings 7,59 0.06 22,040 0.08
       Urinary Appliances 7,96 0.06 977,474 0.
       Miscellaneous 28,269 0.2 48,5 0.05
TOTAL 13,429,945 100.00% €294,826,523 100.00%
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by an individual or family.
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Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A  Alimentary Tract and Metabolism 613,152 26.06 20,189,013 28.08
A01  Stomatological Preparations 775 0.0 ,85 0.0
A02  Drugs for Acid Related Disorders 8,448 0.78 722,897 .0
A03  Drugs for Functional Gastrointestinal Disorders 2,8 0.09 40,66 0.05
A04  Anti-emetics and Antinauseants ,8 0.05 40,02 0.05
A05  Bile and Liver Therapy 87 0.0 47,570 0.07
A06  Laxatives 7,299 0. 7,47 0.0
A07  Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents ,59 0.05 ,570 0.05
A08  Anti-obesity Preparations, excl. Diet Products 5,765 0.25 426,407 0.59
A09  Digestives, incl. Enzymes 7,857 0. 884,49 .2
A10  Drugs Used in Diabetes 546,27 2.22 7,290,87 24.05
A11  Vitamins 4,048 0.60 25,486 0.5
A12  Mineral Supplements 5,575 0.24 5,09 0.07
A14  Anabolic Agents for Systemic Use 22 0.00 8 0.00
A16  Other Alimentary Tract and Metabolism Products ,824 0.08 2,2 0.45
B  Blood and Blood Forming Organs 240,484 10.22 1,337,139 1.86
B01  Antithrombotic Agents 22,965 9.52 ,279,952 .78
B02  Antihemorrhagics 246 0.0 ,069 0.00
B03  Anti-anemic Preparations 5,878 0.67 26,8 0.04
B05  Blood Substitutes and Perfusion Solutions 95 0.02 28,000 0.04
04
Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
C Cardiovascular System 667,618 28.38 16,570,210 23.05
C01 Cardiac Therapy 0,775 0.46 0,99 0.8
C02 Antihypertensives 22,477 0.96 79,70 .0
C03 Diuretics 8,759 .65 74, 0.24
C04 Peripheral Vasodilators 74 0.0 8,025 0.0
C05 Vasoprotectives 27 0.0 ,56 0.00
C07 Beta Blocking Agents 72,86 .0 649,72 0.9
C08 Calcium Channel Blockers 57,00 2.42 ,007,888 .40
C09 Agents Acting on the Renin-Angiotensin System 20,209 9.78 4,674,258 6.50
C10 Lipid Modifying Agents 24,60 9.97 9,20,60 2.69
D Dermatologicals 7,552 0.32 85,211 0.12
D01 Antifungals for Dermatological Use 2,7 0.0 2,06 0.05
D02 Emollients and Protectives ,75 0.08 ,64 0.02
D03 Preparations for Treatment of Wounds and Ulcers 9 0.00 74 0.00
D04 Antipruritics, incl. Antihistamines, Anesthetics, etc. 6 0.00 ,908 0.00
D05 Antipsoriatics 29 0.0 4,060 0.02
D06 Antibiotics and Chemotherapeutics for Dermatological Use 540 0.02 4,275 0.0
D07 Corticosteroids, Dermatological Preparations ,497 0.06 8,222 0.0
D08 Antiseptics and Disinfectants 509 0.02 ,20 0.00
D10 Anti-Acne Preparations 68 0.0 ,54 0.00
D11 Other Dermatological Preparations 4 0.02 5,9 0.0
G Genito Urinary System and Sex Hormones 24,552 1.04 816,758 1.14
G01 Gynecological Anti-infectives and Antiseptics 2 0.0 ,795 0.02
G02 Other Gynecologicals 6 0.00 ,080 0.02
G03 Sex Hormones and Modulators of the Genital System 2,87 0.09 5,54 0.05
G04 Urologicals 22,26 0.94 754,42 .05
05
Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient 
Cost €
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 28,412 1.21 413,849 0.58
H01 Pituitary, Hypothalamic Hormones and Analogues ,96 0.08 4,542 0.20
H02 Corticosteroids for Systemic Use ,458 0.5 27,55 0.04
H03 Thyroid Therapy 6,080 0.68 8,689 0.06
H04 Pancreatic Hormones 6,95 0.0 20,847 0.28
H05 Calcium Homeostasis 2 0.00 2,28 0.00
J Anti-infectives for Systemic Use 19,909 0.85 1,151,528 1.60
J01 Antibacterials for Systemic Use 8,82 0.80 ,08,269 .5
J02 Antimycotics for Systemic Use 654 0.0 2,70 0.05
J04 Antimycobacterials 9 0.0 9,60 0.0
J05 Antivirals for Systemic Use 266 0.0 25,400 0.0
J07 Vaccines 8 0.00 546 0.00
L Antineoplastic and Immunomodulating Agents 1,339 0.06 49,834 0.07
L01 Antineoplastic Agents 26 0.0 2,96 0.0
L02 Endocrine Therapy 25 0.0 9,75 0.0
L04 Immunosuppressive Agents 95 0.04 9,06 0.0
06
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 17,954 0.76 413,780 0.58
M01 Anti-inflammatory and Antirheumatic Products 5,74 0.24 87,959 0.2
M02 Topical Products for Joint and Muscular Pain 640 0.0 4,950 0.0
M03 Muscle Relaxants 6,06 0.26 22,868 0.0
M04 Antigout Preparations 2,844 0.2 24,29 0.04
M05 Drugs for treatment of Bone Diseases 2,24 0.09 80,985 0.
M09 Other Drugs for Disorders of the Musculo-Skeletal System 459 0.02 2,725 0.00
N Nervous System 275,308 11.70 11,239,505 15.63
N01 Anesthetics 09 0.0 ,927 0.04
N02 Analgesics 0,09 0.4 88,549 0.2
N03 Anti-epileptics 206,7 8.79 7,48, 0.22
N04 Anti-Parkinson Drugs 2,276 0.98 2,520,57 .5
N05 Psycholeptics 7,40 0.7 55,6 0.49
N06 Psychoanaleptics 6,7 0.69 809,84 .
N07 Other Nervous System Drugs ,586 0.07 85,659 0.2
P Antiparasitic Products, Insecticides and Repellents 187 0.01 1,625 0.00
P01 Antiprotozoals 64 0.0 ,455 0.00
P02 Anthelmintics 0 0.00 6 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents  0.00 4 0.00
Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
07
Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
R Respiratory System 14,771 0.63 386,751 0.54
R01 Nasal Preparations ,600 0.07 20,27 0.0
R02 Throat Preparations 7 0.00 89 0.00
R03 Drugs for Obstructive Airway Diseases 0,668 0.45 44,56 0.48
R05 Cough and Cold Preparations 69 0.0 4,579 0.0
R06 Antihistamines for Systemic Use ,77 0.08 7,249 0.02
S Sensory Organs 7,749 0.33 116,637 0.16
S01 Ophthalmologicals 7,448 0.2 5,665 0.6
S02 Otologicals 00 0.00 454 0.00
S03 Ophthalmological and Otological Preparations 20 0.0 58 0.00
V Various 433,633 18.43 19,119,480 26.59
V03 Other Therapeutic Products 87 0.02 57,656 0.08
V04 Diagnostic Products 25,994 0.7 ,46,00 5.94
V06 Clinical Nutritional Products 0,79 .28 ,50,66 4.9
V07 All Other Non-Therapeutic Products 5,07 6.42 4,070,648 5.66
      Needles/Syringes/Lancets/Swabs ,6 5.60 2,788,75 .88
      Urinary Appliances 5,29 0.2 609,4 0.85
      Dressings 2,547 0. 84,58 0.2
      Nutritional/Ancillary Devices ,90 0.08 40,956 0.48
      Ostomy Appliances ,25 0.05 0,04 0.5
      Miscellaneous 8,540 0.5 7,075 0.8
TOTAL 2,352,620 100.00% €71,891,320 100.00%
08
Table 20.3  HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 200 0.07 43,310 0.02
A07A Intestinal Anti-infectives 200 0.07 4,0 0.02
B Blood and Blood Forming Organs 32,096 11.37 20,926,102 10.54
B0 Antithrombotic Agents 80 0.0 40,2 0.22
B0 Anti-anemic Preparations 2,06 .4 20,495,770 0.2
C Cardiovascular System 3,115 1.10 5,347,007 2.69
C02 Antihypertensives ,5 .0 5,47,007 2.69
D Dermatologicals 13 0.00 7,821 0.00
D0A Cicatrizants  0.00 7,82 0.00
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
09
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient 
Cost €
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 22,116 7.84 13,452,614 6.77
H0 Pituitary and Hypothalamic Hormones and Analogues ,94 .97 8,878,87 4.47
H05 Calcium Homeostasis 0,922 .87 4,574,227 2.0
J  Anti-infectives for Systemic Use 8,640 3.06 11,994,370 6.04
J0 Antibacterials for Systemic Use 2,68 0.9 6,048,55 .05
J02 Antimycotics for Systemic Use 845 0.0 ,988,84 .00
J05 Antivirals for Systemic Use ,870 .7 2,604,57 .
J06 Immune Sera and Immunoglobulins ,287 0.46 ,52,448 0.68
L Antineoplastic and Immunomodulating Agents 207,909 73.66 141,587,820 71.28
L0 Antineoplastic Agents 2,65 4.48 6,090,667 8.0
L02 Endocrine Therapy 52, 8.46 5,80,84 7.96
L0 Immunostimulants 40,589 4.8 44,576,69 22.44
L04 Immunosuppressive Agents 02,574 6.4 65,0,400 2.78
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
Table 20.3  HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
0
ATC 
Class
Product Category Prescribing 
Frequency 
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 2,060 0.73 574,605 0.29
M05 Drugs for treatment of Bone Diseases 2,060 0.7 574,605 0.29
N Nervous System 1,896 0.67 634,227 0.32
N07XX Other Nervous System Drugs ,896 0.67 64,227 0.2
R Respiratory System 3,849 1.36 3,683,511 1.86
R05CB Mucolytics (Inhaled) ,849 .6 ,68,5 .86
V Various 379 0.14 377,218 0.19
V0AC Iron Chelating Agents 79 0.4 77,28 0.9
 TOTAL 282,273 100% €198,628,605 100%
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
Table 20.3  HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

Health Service 
Executive
Average Panel Ranges in 2007
0-100 101-250 251-500 501-1,000 1,001-1,500 1,501-2,000 2,001 and 
Over
€ € € € € € €
East Coast Area 2,04 (24) 94,84 (6) 75,79 (5) 262,664 (6) 9,04 (8) - -
South Western Area 25,70 (40) 60,97 (2) 28,994 (4) 224,290 (86) ,927 (46) 47,50 (0) 4,050 (4)
Northern Area 20,575 () 69,22 (24) 22,949 (5) 240,0 (65) 22,06 (8) 46,574 (5) 692,290 ()
Midland 6,5 (0) 4,788 (2) 26,625 (6) 25,86 (49) 72,4 (29) 92,24 () -
Mid-Western 6,7 (22) 8,246 (5) ,766 () 2,848 (87) 4,884 (24) 45,99 (8) -
North Eastern 4,947 () 9,48 (5) 22,7 (26) 29,878 (88) ,22 (28) 42,0 (4) -
North Western 8,569 (5) 60,027 (6) 44,60 (8) 224,606 (49) 44,45 (40) 49, () 406,47 ()
South Eastern 9,464 (9) 54,70 (0) 5,20 (4) 2,489 (2) 26,290 (4) 46,9 (0) -
Southern 4,574 (59) 66,49 (45) 4,490 (69) 245,880 (50) 64,4 (45) 552,208 (4) 54,509 ()
Western 4,82 (27) 62,58 (8) ,402 (5) 245,90 (96) 62,009 (47) 467, (2) -
National 2007 €17,547 (232) €69,062 (194) €140,165 (376) €237,617 (843) €342,082 (348) €445,510 (65) €481,735 (7)
National 2006 €2,529 (88) €65,29 (97) €29,02 (45) €220,09 (86) €7,0 (295) €404,27 (49) €454,698 (6)
Note:  (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) The number of doctors in each range is shown in brackets.
 (iii) The average payment to doctors in each panel range is the gross payments divided by the number of doctors in that range.
 (iv) Doctors payment is exclusive of superannuation paid to retired DMOs. 
Table 21 GMS: Average Payment to Doctors in Panel Ranges 
2
Table 21.1  GMS: Number of Doctors in Payment Ranges
2007 (2006 in brackets)
Health 
Service 
Executive
Up to 
€30,000
€30,001 - 
€60,000
 €60,001 -
€90,000
€90,001-
€120,000
€120,001 -
€150,000
€150,001 -
€180,000
€180,001-
€210,000
€210,001-
€240,000
€240,001-
€270,000
€270,001-
€370,000
€370,001-
€470,000
€470,001 
and Over
East Coast 
Area 7 (2) 8 () 9 (2) 22 (2) 6 (5) 20 (6)  (7) 4 (0) 8 (8) 5 (22) 6 (4) 2 (-)
South Western 
Area 0 () 20 (28) 6 (22) 24 () 4 (29) 8 (8) 6 (2) 9 (27) 7 () 49 (40) 20 (4) 6 () 
Northern Area 28 (5) 9 (5) 27 (7) 8 (2) 9 (2) 4 () 4 (5) 6 (27)  () 9 () 5 (8)  (5) 
Midland  (6) 8 (5) 4 ()  (6) 5 (5) 9 (8) 5 ()  ()  (5) 0 (26) 4 (5) 2 (-)
Mid-Western 2 (8) 7 (7) 0 (5) 2 (6) 9 (24) 9 (7) 9 (6) 7 (5) 4 (4) 7 (0) 2 (7)  () 
North Eastern 5 ()  (8) 9 (9) 8 (9)  (6) 4 (6) 2 (25) 9 (9) 7 (8) 7 (2) 4 (5) 2 () 
North 
Western 5 (4)  () 4 (5) 6 (0) 8 (8)  () 8 () 0 () 4 (8) 40 (5)  (8) 6 () 
South Eastern 0 (9) 5 (7) 6 (9) 0 (0) 4 (7) 24 () 22 (2) 26 (25) 26 (28) 58 (42)  () 6 () 
Southern 48 (2) 28 (28) 27 (0) 22 (2) 22 (6)  (7) 4 (6) 5 (2) 4 () 64 (47) 9 (2) 8 () 
Western 22 (9) 8 (6)  (2) 2 (20) 2 (7) 22 (5) 2 (20) 2 () 20 (0) 54 (52) 9 (8) 7 () 
National 199 (77) 109 (128) 133 (156) 136 (149) 142 (170) 184 (182) 166 (188) 190 (210) 172 (178) 443 (346) 133 (82) 53 (20) 
Note:  (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) Above table relates to the payments listed in Table 3.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.

Table 22 GMS: Number of Pharmacists in Dispensing Fee Ranges
2007 (2006 in brackets)
Health 
Service 
Executive
Up to 
€20,000
€20,001-
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast 
Area 8 (4) 0 ()  () 7 (20) 8 (9)  (6) 0 (4) 6 (8) 7 (2)  (8) 2 (-)  () 7 (4)
South Western 
Area 2 (2) 2 (7) 20 (2) 25 (25) 2 (9) 6 (6) 6 (2)  (0)  (9) 6 (6) 2 (0) 0 (7)  (4)
Northern Area 2 () 5 (2) 6 (9) 8 (9) 4 (9) 7 (9) 8 (0) 8 (9) 8 (6) 5 (4) 6 (5) 6 (4) 8 (4)
Midland  (2) 8 (5)  (7) 8 (6) 7 (5) 4 (6) 7 (2) 2 (6)  (8) 0 (6) 4 () 6 (2) 8 (0)
Mid-Western 5 (7) 9 (0) 8 (4) 2 () 7 (25) 8 () 4 (0)  () 0 (8) 4 (0) 0 () 6 (2) 6 (6)
North Eastern 0 (6) 8 (8)  (8) 0 (4)  (6) 9 (9) 7 (4) 9 (7) 0 (9) 6 (5) 2 () 4 (5) 2 (5)
North 
Western 4 (6) 4 () 5 (8) 7 (7) 8 (9) 4 (7) 4 (7) 0 (5) 5 ()  (5)  () 5 () 0 (0)
South Eastern 7 (5) 7 (8) 6 () 2 (20) 2 (4)  (4) 6 (6) 7 (2) 0 (9) 9 (8)  (0) 4 (5) 2 (5)
Southern 6 (6) 7 (20) 5 (22) 29 (0) 24 (27) 2 (26) 27 (8) 6 (20)  (2) 4 (0) 6 (8) 9 (5) 2 ()
Western 8 (7) 0 (9) 2 (9) 5 (9) 2 (4) 5 (20) 2 ()  (7) 6 (9) 8 (0)  (9) 9 () 5 (8)
National 82 (77) 111 (103) 109 (132) 153 (171) 155 (167) 148 (146) 141 (124) 111 (97) 81 (75) 66 (72) 59 (52) 62 (39) 133 (89)
Note:  Pharmacies that entered or left the Scheme during the year are not included in the above table.
4
Table 23 DP: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Health Service 
Executive
*Number 
of Persons 
Covered
 Unique 
Number of 
Claimants
Number of 
Items
Cost per Item 
€
Gross Cost
€
Net Cost per 
Claimant 
€
Paid by HSE 
€
Eastern Areas 54,2 20,452 5,60,469 7.74 94,756,409 544.86 25,565,65 
Midland 99,4 45,67 87,95 4.59 0,2,80 407.07 8,569,507 
Mid-Western 64,959 60,57 ,4,580 5.6 40,425,896 407.98 24,72,97 
North Eastern 4,754 62,22 ,9,949 4.8 4,50,8 405.62 25,28,04 
North Western 65,40 25,604 478,9 6.64 7,527,789 42.04 0,8,64 
South Eastern 66,25 69,780 ,44,7 4.86 50,247,5 440.76 0,756,007 
Southern 260,00 07,99 2,027,08 7.8 75,78,79 47.72 47,269,290 
Western 52,068 65,544 ,22,295 6.27 40,705,86 72.5 24,92,044 
National 2007 1,583,738 667,782 13,429,945 €36.57 €491,186,086 €460.23 €307,334,094
National 2006 ,525,657 597,85 ,872,27 €7. €442,92,858 €47.56 €28,08,5
Note:  * As at 31st December 2007.
5
Table 23.1  DP: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
2007 (2006 in brackets)
Health 
Service 
Executive
Up to 
€20,000
€20,001 -
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast Area 2 (9) 5 (5) 2 (24) 9 (7)  (6) 0 (0) 8 (0) 4 (2) 4 (2)  () 2 (2) 5 (2)  (2)
South Western 
Area 22 (2) 45 (6) 2 (2) 25 (22) 8 (20) 2 () 0 () 9 (6) 0 () 5 (8) 7 (2)  (2) 8 (9)
Northern Area 9 (6) 26 (24) 28 (2) 0 () 5 (6) 7 (8)  (4) 0 (9) 5 () 2 (2) 6 () 4 (4) 8 (8)
Midland 8 (8) 2 (4) 5 (6) 6 (2) 5 (7) 6 (5) 6 (6) 5 (4) 2 () 4 (-) - () 2 (2) -
Mid-Western 9 (20) 24 (25) 26 (26) 2 (2) 6 (6) 8 (8) 5 (4) 2 (5)  (2) 2 (2) 2 () - -
North Eastern 20 () 9 (25) 2 (0) 20 (5) 7 (0) 8 (7) 9 (7) 6 (4) 4 (5) 4 () 2 () - ()  ()
North Western 9 (7) 8 (7) 8 ()  (4) 4 () 5 ()  (2)  (-) - - - ()  (-) -
South Eastern 20 (2) 26 (24) 2 (0) 24 (27) 20 (7)  (8) 4 () 0 () 2 (4) - 2 (-) - 2 (2)
Southern 7 (4) 44 (52) 45 (5) 6 (26) 25 (28) 8 (7) 9 (0) 8 (5) 7 ()  () 2 (4) 2 () 5 (4)
Western 2 (26) 4 (9) 2 (25) 7 (7) 4 (9) 0 (5) 5 (9) 4 (4) 5 (-) - () - - ()  (-)
National 179 (167) 272 (271) 263 (261) 201 (186) 137 (142) 107 (92) 70 (84) 59 (42) 42 (33) 19 (18) 23 (15) 17 (13) 26 (26)
Note: (i) Pharmacies that entered or left the Scheme during the year are not included in the above table.
 (ii) The above figures do not include the monthly co-payment of €85 paid by an individual or family to the pharmacist.
6
Table 24 LTI: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Health Service Executive *Number of 
Eligible Persons
Unique 
Number of 
Claimants
Number of 
Items
Cost per Item
€
Total Cost
€
Cost per 
Claimant 
€
Eastern Areas 57,745 24,56 998,692 54.4 54,270,775 2,2.88
Midland 6,45 ,552 4,955 49.86 7,76,922 2,020.5
Mid-Western 7,779 4,49 65, 48.42 7,995,086 ,88.7
North Eastern 8,7 5,40 2,765 52.46 ,24,924 2,00.7
North Western 6,52 ,584 44,84 52.68 7,629,750 2,28.84
South Eastern ,840 6,440 259,8 50.25 ,024,9 2,022.8
Southern 7,84 6,892 268,447 54.66 4,674,05 2,29.4
Western 5,89 4,47 58,608 5.42 8,472,524 ,949.05
National 2007 112,580 59,040 2,352,620 €52.90 €124,458,135 €2,108.03
National 2006 06,07 5,082 2,65,00 €5.2 €5,46,40 €2,75.5
Note:  * As at 31st December 2007. 
7
Table 24.1  LTI: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
2007 (2006 in brackets)
Health Service Executive Up to €10,000
€10,001 - 
€20,000
€20,001- 
€30,000
€30,001- 
€40,000
€40,001- 
€50,000
€50,001 - 
€60,000
€60,001 and 
over
East Coast Area  () 2 (28) 26 () 4 (8) 0 (2) 9 () 2 (20)
South Western Area 29 (25) 42 (9) 5 (26) 20 (25) 6 (2) 6 (5) 6 (0)
Northern Area 4 (2) 7 (25) 26 () 9 (7) 2 (6) 7 (6) 5 (25)
Midland  (0) 26 (25) 2 (2) 2 (4) 8 (7) 5 (2) 7 (8)
Mid-Western 2 (4) 44 (45) 0 (29) 2 (9) 6 (6)  (4)  ()
North Eastern 28 (22) 27 (28) 26 (25) 6 (4) 6 (2)  (6) 5 (2)
North Western 5 (4)  (7) 5 () 4 (7) 9 (9)  (4) 8 (7)
South Eastern 29 (28) 4 ()  (5) 29 (24) 6 (5) 9 (6) 7 (8)
Southern 47 (54) 68 (7) 55 (47) 2 (6) 8 (4) 6 (6) 9 (5)
Western 48 (47) 42 (4) 27 (2) 2 (2) 0 (5) 2 ()  (2)
National 266 (266) 356 (344) 283 (252) 171 (166) 122 (117) 63 (73) 144 (120)
Note: Pharmacies that entered or left the Scheme during the year are not included in the above table.
8
Table 25 EEA: Number and Cost of Pharmacists Claims
Health Service Executive Number of Items Cost per Item€
Total Cost
€
East Coast Area ,852 22.49 86,69
South Western Area 5,997 25.0 50,505
Northern Area ,288 2.87 78,500
Midland 4,22 26.5 ,95
Mid-Western 0,84 2.80 257,826
North Eastern 5,984 24.99 49,520
North Western ,767 24.62 289,648
South Eastern 0,408 25.09 26,80
Southern 22,90 2.49 525,862
Western 6,909 24.79 49,06
National 2007 95,652 €24.37 €2,330,737
National 2006 88,742 €2.82 €2,,9
9
Table 26 DTS: Number of Treatments
Health Service Executive Above the Line Below the Line Total
Eastern Areas 265,5 2,559 288,694
Midland 55,676 7,072 62,748
Mid-Western 88,58 0,569 99,52
North Eastern 82,878 0,485 9,6
North Western 66,95 5, 72,064
South Eastern 5,205 4,680 29,885
Southern 85,02 8,566 20,587
Western 4,50 5,25 29,85
National 2007 973,599 105,279 1,078,878
National 2006 987,49 08,770 ,095,99
20
Table 26.1  DTS: Number of Dentists in Payment Ranges
2007 (2006 in brackets)
Health 
Service 
Executive
Up to 
€10,000
€10,001-
€20,000
€20,001-
€30,000
€30,001-
€40,000
€40,001-
€50,000
€50,001-
€60,000
€60,001-
€70,000
€70,001-
€80,000
€80,001-
€90,000
€90,001-
€100,000
€100,001-
€110,000
€110,001-
€120,000
€120,001 
and over
Eastern Areas 29 (0) 27 (9) 27 (2) 20 (26) 22 (24) 9 (9) 6 (5) 5 (9) 9 (20) 7 () 9 (7)  (5) 2 ()
Midland 5 (5) 5 (2) 9 ()  () 0 (6) 5 (4) 8 (6) 7 (4)  ()  (-)  (4)  () 8 ()
Mid-Western 4 (6)  (9)  (6)  ()  (4) 4 () 7 (7)  (4) 5 () 2 () 2 () 4 (4) 5 (6)
North Eastern 8 ()  (6) 5 (6) 0 (0) 8 (8) 6 (6) 5 (7) 2 (5) 4 ()  ()  (4) 2 (2)  (6)
North Western  () 2 (-) 2 (5)  (2)  (2)  (2) 2 (2) 4 (2)  (4)  () 6 (5) 2 () 6 (6)
South Eastern  (7) 2 () 7 (0)  () 9 (0) 8 (8) 4 () 7 (5) 0 (0)  (8) 7 () 4 (2) 8 (9)
Southern 24 (2) 26 ()  (40) 22 (25) 25 (25)  (4) 4 (24) 8 (4)  (2) 7 (5) 5 (2)  () 8 (6)
Western 2 (9) 9 (0)  (7) 5 (4) 2 (7) 6 (7) 9 (0) 6 (7) 7 (7) 4 (5) 5 (2)  (7) 5 (2)
National 107 (106) 77 (102) 95 (107) 77 (106) 80 (96) 52 (71) 65 (84) 62 (60) 64 (60) 30 (38) 38 (28) 22 (27) 82 (61)
Note:  Dentists who entered or left the Scheme during the year are not included in the above table.
2
Health Service Executive Number of Treatments Cost of Claims €
Eastern Areas 6,48 5,788,495
Midland ,052 ,9,5
Mid-Western 44,948 ,825,954
North Eastern 40,52 ,599,87
North Western 6,520 ,442,66
South Eastern 70,420 2,842,957
Southern 76,98 ,49,52
Western 55,7 2,254,77
National 2007 493,504 €20,294,863
National 2006 464,62 €6,927,04
Note:  Optometrists/Ophthalmologists were also paid in respect of: Health (Amendment) Act 1996 €61,776; Optical services for Teenagers €136,463; Optical services for Children €1,101,819.
Table 27 HSE-COS: Number of Treatments and Cost of Claims 
22
Table 27.1  HSE-COS: Number of Optometrists/Ophthalmologists in Payment Ranges
2007 (2006 in brackets)
Health 
Service 
Executive
 Up to 
€10,000 
 €10,001-
€20,000 
 €20,001-
€30,000 
 €30,001-
€40,000 
 €40,001-
€50,000 
 €50,001-
€60,000 
 €60,001-
€70,000 
 €70,001-
€80,000 
 €80,001-
€90,000 
 €90,001-
€100,000 
€100,001-
€110,000 
€110,001-
€120,000 
 €120,001 
and over 
Eastern Areas 44 (45)  (7) 4 (6) 5 (4) 6 (6) 4 ()  (5) 2 ()  (-) - ()  () - 5 ()
Midland  (4) 5 (5)  () 6 (5) 5 () 2 () -  (-) - () - - -  ()
Mid-Western 2 (5) 4 (7) 7 (4)  () 2 () - (2)  (-) - - - - () -  (2)
North Eastern 9 (7) 8 () 6 (4) 4 (2)  ()  ()  () - - ()  (-) - - -
North Western 5 (5) 4 (5) 5 (4) 4 (7) 4 ()  ()  () - - - - () -  (-)
South Eastern 8 (2)  () 6 () 2 () 2 () 8 (7)  (2)  () - - ()  () - 2 ()
Southern  (5) 5 (2) 5 (5) 2 (9) 4 (6) 4 (2)  () - - - - () -  (2)
Western 0 (2)  (8) 9 (7) 2 (6) 2 () - - - () - -  (-) -  ()
National 122 (144) 91 (117) 53 (46) 58 (47) 28 (24) 22 (19) 10 (10) 6 (5) 3 (2) 1 (2) 3 (5) - 16 (10)
Note:  Optometrists/Ophthalmologists who entered or left the Scheme during the year are not included in the above table.
2
Health Service Executive 2007
€
2006
€
Eastern Areas ,976,872 2,8,46
Midland 20,796 86,585
Mid-Western 47,94 400,42
North Eastern 502,79 527,24
*North Western - 2,492,60
South Eastern 95,790 ,9,556
Southern 76,767 888,24
Western 957,898 ,94,506
National €5,801,783 €10,062,393
Note: The above are payments from the Indicative Drug Target Savings. 
 *No funds available to draw down in 2007.
Table 28  GMS: Investment in General Practice Development
